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Pluripotent stem cells, because of their ability to differentiate into any cell type, have 
been widely advocated as a means of producing a nearly unlimited source of new insulin-
producing β cells for the treatment of diabetic diseases. However, while there has been 
remarkable progress in learning how to direct the differentiation of human embryonic stem 
(hES) cells towards pancreatic endocrine cell fates, insulin-expressing cells made in this 
manner are often polyhormonal and lack a normal response to glucose, thereby suggesting a 
need for a deeper understanding of the gene regulatory networks that are established in a 
stepwise manner during pancreas development.  
My thesis studies explored three main topics, each of which holds potential for the 
development of improved hES cell directed pancreatic differentiation protocols and the 
discovery of genes that may specifically affect β cell development. First, we used mice that 
contained a fluorescent reporter allele and fluorescence-activated cell sorting (FACS) to 
isolate several discrete pancreatic cell populations which were then analyzed using whole 
transcriptome sequencing (RNA-Seq). By doing so, we were able to examine the genetic 
requirement and temporal changes of cells expressing pancreas specific transcription factor 
1a (Ptf1a), a marker of the pancreatic multipotent progenitor cells (MPCs) and of acinar-
specified cells, during pancreas development. By comparing the transcriptional profiles, we 
identified five gene clusters, each of which provides insights into the dynamics of gene 
expression during specific aspects of pancreas development. Second, my studies revealed that 
Nephrocan, an inhibitor of the TGFβ signaling pathway, was expressed in pancreatic MPCs. 
Thus, to explore the role of Nepn further, we generated mice containing a single copy 
insertion of a Nepn-Cherry transgene. Finally, to facilitate the combinatorial sorting of Pdx1- 
and Ptf1a-expressing cells during early pancreas development, we generated a mouse line 
expressing a cyan fluorescent protein under control of the endogenous pancreatic and 
duodenal homeobox 1 (Pdx1) gene.  
The research that I have performed is part of a larger project focused on generating 
and characterizing a series of high quality transcriptional profiles representing key stages in 
the generation of pancreatic endocrine cells that occur naturally in the mouse. We anticipate 
that further analysis of the datasets I have generated for specific developmental stages, in 
combination with similarly generated datasets at other developmental stages, will facilitate 
identification of signaling pathways and gene clusters essential for formation of functional 
pancreatic β cells in the mouse, thereby stimulating new hypotheses for identifying pro-β cell 
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Pancreas development, morphology and function 
The pancreas is a dual-function organ located directly adjacent to the stomach and is 
an integral part of the digestive system (Figure 1.1). The exocrine cells comprise 
approximately 98% of the organ mass and produce digestive enzymes that are secreted into 
the small intestine through a system of ducts. Conversely, the endocrine cells, which are 
organized into the islets of Langerhans, comprise only 1 – 2% of the entire organ and 
produce a variety of hormones that regulate levels of glucose in the bloodstream. While the 
cellular architecture of the Islets of Langerhans differs among species, in the mouse 
pancreatic islets are primarily comprised of five hormone-secreting cell types arranged in a 
stereotypical manner: insulin-producing β cells lie in the core of the islet (comprising 60 – 
80% of the islet), and glucagon-producing α cells, somatostatin-producing δ cells, pancreatic 
polypeptide-producing PP cells, and ghrelin-producing ε cells lie in the periphery.  
One of the critical roles of the pancreas is to maintain blood glucose levels within a 
narrow range. Primarily, insulin and glucagon secreted by the β cells and α cells, 
respectively, are responsible for regulating glucose homeostasis. Glucagon, a catabolic 
hormone, is produced and secreted in response to a low blood glucose concentration and acts 
upon the liver to release stored glycogen, thus increasing circulating glucose. Conversely, 
insulin, an anabolic hormone, is secreted in response to high levels of blood glucose. Once 
secreted, insulin stimulates glucose uptake by adipose and muscle tissue and acts on the liver 
to increase glycogen synthesis and inhibit gluconeogenesis (Berne and Levy, 1993), thereby 






Figure 1.1  Pancreas anatomy and histology. A) The pancreas is located in the upper 
abdomen adjacent to the stomach. B) The exocrine acinar cells and the duct cells comprise 
98% of the pancreatic mass. The acinar cells produce digestive enzymes that are carried to 
the small intestine through a system of ducts. C) The endocrine cells are organized into the 
pancreatic islets, termed the Islets of Langerhans, which contain five hormone-secreting cell 
types. D) In the mouse, the insulin-producing β cells (dark purple) primarily lie in the core of 
the islet and comprise 60 – 80% of the islet, while the glucagon-producing α cells lie in the 
periphery and comprise 15 – 20% of the islet. E) Representative H&E stain of the pancreas. 
The endocrine cells (lighter staining) lie within the dense network of acini (darker staining) 
and form cell clusters that are highly vascularized. F) Representative immunolabeling of a 
murine pancreatic islet. The β cells and α cells are labeled by insulin (red) and glucagon 
(blue), respectively. The digestive enzyme amylase (green) identifies the acinar cells 
surrounding the islet. Pancreas schematics adapted from: www.youtube.com-Dual Role of 
the Pancreas; Pancreas histology adapted from: http://education.vetmed.vt.edu/. 
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Diabetes mellitus and β-cell dysfunction  
The regulation of glucose is of particular medical importance as diabetes mellitus is 
one of the most common metabolic diseases worldwide. The World Health Organization 
estimates more than 180 million people are afflicted with diabetes worldwide, an estimate 
likely to double by 2030. In addition to hyperglycemia, a condition in which excessive 
amounts of glucose circulate in the blood plasma, diabetes is associated with a number of 
other conditions such as diabetic retinopathy, neuropathy, kidney failure, cardiovascular 
disease and stroke. As a result, the efforts of numerous investigators focus on elucidating the 
disease and discovering promising treatments.  
Diabetes mellitus can be classified as type 1, type 2, or maturity onset diabetes of the 
young (MODY) which accounts for a number of hereditary forms of diabetes caused by 
genetic mutations. Type 1 diabetes, also referred to as juvenile or insulin-dependent diabetes, 
is a result of an autoimmune destruction of β cells which leads to a loss of insulin production. 
Alternatively, type 2 diabetes, termed insulin-independent, is the most common form of 
diabetes, comprising 90 – 95% of those diagnosed. This type is caused by a combination of 
genetic predisposition and environmental pressures that result in the progressive 
desensitization of peripheral tissues to insulin (Berne and Levy, 1993). This reduction in 
sensitivity triggers the existing β cells to produce more insulin, leading to increased 
desensitization of the β cells, and this cycle ultimately leads to decreased β cell function and 
β cell death, which results in hyperglycemia.  
 
Current treatments and limitations of islet transplantation 
A wide variety of pharmacological agents, includuing sulfonylureas, meglitinides, 
biguanides, thiazolidinediones, and alpha-glucosidase inhibitors, are marketed towards type 2 
diabetics. These current treatments are fairly effective for maintaining normal blood glucose 
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levels and controlling acute and chronic complications, such as diabetic ketoacidosis, 
retinopathy, and neuropathies. Alternatively, exogenous insulin injections are an obligatory 
requirement for type 1 patients; thus, islet transplantation has been viewed as a promising 
treatment that can lead to euglycemia in type 1 diabetics (Ryan et al., 2001; Ryan et al., 2005; 
Shapiro et al., 2000).  
The transplantation of pancreatic islets as a treatment for diabetes first gained interest 
in the early 1970s when Paul Lacy and colleagues revealed that hyperglycemia in diabetic 
rats could be alleviated by the transplantation of donor islets (Ballinger and Lacy, 1972). In 
1990 that work led to the first successful islet cell transplant in humans (Scharp et al., 1990) 
in which endocrine islets isolated from cadaveric donors were transplanted into the portal 
vein of type 1 diabetic patients. Throughout the 1990s, successful transplants were 
documented; however, the Islet Transplant Registry estimated that approximately only six 
percent of these transplantations were successful (Hering et al., 1996). A significant advance 
came in 2000, when Shapiro and colleagues reported sustained insulin independence of seven 
patients with type 1 diabetes following transplantation of donor islets (Shapiro et al., 2000), 
demonstrating that islet transplantation can reproducibly lead to insulin independence for at 
least one year.  
While the use of islet transplantation may hold promise, there are a number of 
limitations and complications that arise from this treatment. First, the efficacy of the 
treatment is dependent upon the survival of engrafted islets which can be affected by both the 
donor’s age and health. However, due to the shortage of organ donors, and thus 
transplantable pancreatic islets, the ability to discriminate based on donor qualifications is 
limited. Second, to prevent a host-immune response and reduce transplant rejection, patients 
are subjected to life-long immunosuppressive therapy. These immunosuppressants can cause 
a variety of complications, including mouth ulcers, hypertension, diarrhea, anemia, weight 
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loss, ovarian cysts, and insulin resistance (Hirshberg et al., 2003). These complications 
highlight the need to assess the risks that diabetic patients face and whether the benefits of a 
cell therapy outweigh the given risks. Third, in Shapiro’s report, the diabetic recipients 
required islets from at least two donor pancreata to achieve insulin independence (Shapiro et 
al., 2000). Once again, due to the low rate of organ donation, the shortage of human 
cadaveric donor islets presents a major limitation, and overcoming the supply and demand 
issue is a significant determinant concerning the accessibility of this therapy. Lastly, in a later 
report by Shapiro and colleagues, it was reported that less than ten percent of patients 
receiving islet transplants remained insulin independent after five years (Ryan et al., 2005). 
These results, taken with other limitations and complications, highlight the need for 
improvements if islet transplantation will prove to be an effective therapeutic treatment. 
 
Emerging therapies for diabetes: Human embryonic stem (hES) cells as a source of 
insulin-producing cells 
Due to the limitations and complications of islet transplantation from human 
cadaveric donors, especially as pertains to the limited supply of donor tissue, there has been 
much interest in alternative methods for generating insulin-producing β cells. There are 
numerous alternatives for potential sources of pancreatic insulin-producing cells, including 
but not limited to self-replication of existing β cells, direct transdifferentiation of committed 
cells types, and the differentiation of hES cells towards pancreatic fates. Given the ability of 
human ES cells to differentiate into any cell type and their unlimited supply, the generation 
of insulin-producing cells from hES cells has been viewed as an appealing alternative.  
Human ES cells were first isolated in 1998 by James Thomson at the University of 
Wisconsin-Madison (Thomson et al., 1998). ES cells are derived from the inner cell mass of 
a developing blastocyst and are characterized by both their ability to self-renew and their 
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pluripotency. ES cells can develop into any derivative of the three primary germ layers: 
ectoderm, endoderm and mesoderm, and because this plasticity, hES cells have become an 
attractive alternative for regenerative medicine and tissue replacement following disease or 
injury. Following the initial report regarding their isolation, numerous hES cell lines have 
been generated and used in a variety of studies. While there has been much enthusiasm 
concerning the potential use of hES cells in therapeutic applications, there has also been 
equal opposition arising from the ethical issues introduced by the usage and destruction of 
fertilized human embryos (Jain, 2005; Robertson, 2010). In spite of this opposition, 
significant progress has been made in understanding the characteristics of hES cells and the 
mechanisms by which they can differentiate to various cell types.  
Recently, there has been remarkable progress in the directed differentiation of human 
ES cells towards pancreatic hormone-producing cell fates (D'Amour et al., 2006; Kubo et al., 
2004; Phillips et al., 2007). Most notably, Baetge and colleagues at Novocell Inc. reported a 
five-stage protocol to direct hES cells through a process that mimics normal pancreatic 
development, taking into account numerous years of research in vertebrate endoderm 
development and pancreatic differentiation (Figure 1.2). The induction protocol led to the 
production of a number of hormone-expressing endocrine cells, with approximately 7% of 
final endocrine-specified cells expressing insulin. However, there were some significant 
deficiencies in these insulin-expressing endocrine cells, such as the lack of glucose-
stimulated insulin secretion and improper maturation of the β-like cells. Therefore, in a later 
publication, the authors chose to assess whether the hES cell-derived pancreatic progenitors, 
apparent during the fourth stage of the induction, are competent to mature in vivo into 
endocrine cells (Kroon et al., 2008). The gene expression pattern and functionality of the hES 
cell-derived insulin-positive cells were consistent with mature, functional Insulin-expressing 









Figure 1.2  Schematic of developmental intermediates in vivo and corresponding 
derivation of endocrine cells from ES cells in vitro. The key in vivo developmental 
intermediates of pancreatic endocrine development are shown in the upper panel. To 
efficiently direct the differentiation of ES cells towards the endocrine lineage, investigators 
have shown that it is advantageous to mimic normal developmental events. The lower panel 
depicts the stepwise differentiation of ES cells towards hormone-producing cell fates. Figure 
from Jean-Philippe Cartailler. 
8 
 
stem cell research in treatments for diabetes and highlight the potential that hES cells hold in 
generating an abundant and renewable source of glucose-responsive, insulin-producing cells.  
 
Embryonic stem (ES) cells, adult stem cells and progenitor cells 
 While stem and progenitor cells both possess the ability to differentiate into various 
specialized cell types that are committed to given fates, they differ in some of their functional 
characteristics. ES cells are isolated from the inner cell mass of a developing blastocyst and 
are characterized by their ability to self-renew while maintaining their undifferentiated state, 
as well as producing daughter cells that can differentiate into committed cell types 
(McCulloch and Till, 2005). The capacity for stem cells to differentiate into specialized cell 
types requires them to be pluripotent, in which the cell can give rise to derivatives of the 
three germ layers but does not contribute to the extraembryonic lineage (Beddington and 
Robertson, 1989).  
 While ES cells are characterized by their pluripotency, adult stem cells can only 
differentiate into a limited number of cell types. Similar to ES cells, adult stem cells possess 
the ability to self-renew; however, they are typically multipotent or unipotent and can give 
rise to only a particular lineage or a family of closely related cells. These adult stem cells are 
evident in the hematopoietic system where multipotent adult stem cells give rise to cells that 
can replace damaged and aging blood cells or replenish low volumes (Ema and Nakauchi, 
2003). Additionally, multipotent adult stem cells in the liver possess the ability to regenerate 
the majority of the liver’s mass following injury or disease (Fausto, 2000; Stanger et al., 
2007).  
 Similar to adult stem cells, progenitor cells are also characterized by their 
multipotency or unipotency; however, in comparison to a stem cell’s ability to self-renew, 
progenitor cells can divide only a limited number of times before exiting the cell cycle and 
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committing to a terminal fate (Fuchs et al., 2004; Li and Xie, 2005; Scheres, 2007). Within 
the context of embryogenesis, numerous organs contain multipotent progenitor cells that are 
capable to respond to developmental cues and inductive signals which dictate their 
commitment towards particular fates. While the majority of these tissue-specific progenitor 
cells are specified during embryogenesis, some progenitor cells persist in adult tissues, such 
as the epidermal transient amplifying cell population (Clayton et al., 2007). 
 
Signaling pathways and genetic regulatory factors directing pancreas development 
During a process termed gastrulation, the pluripotent epiblast cells become specified 
to three principal germ layers: the ectoderm, mesoderm, and endoderm. As the epiblast cells 
migrate through the anterior region of the primitive streak and the node, they undergo an 
epithelial-to-mesenchymal transition (EMT) and subsequently become either mesoderm or 
definitive endoderm. The definitive endoderm emerges from this primitive streak and forms a 
single epithelial sheet, resembling a cup, of approximately 500 – 1,000 cells (Kwon et al., 
2008; Wells and Melton, 2000). It has been postulated that the mesoderm and definitive 
endoderm arise from a bi-potent mesendoderm precursor (Kimelman and Griffin, 2000; 
Rodaway and Patient, 2001) which is typically characterized by the expression of Goosecoid 
(Gsc) or Brachyury (T). As the cells migrate through the primitive streak, members of the 
Nodal family of proteins, a subclass of the TGFβ superfamily, play a critical role inducing 
and patterning the endoderm and mesoderm.  
There are many known transcription factors involved in vertebrate endoderm 
development, such as factors in the Gata, Sox and Forkhead families. Sox genes encode  
transcriptional regulators, belonging to a superfamily of proteins characterized by a high 
mobility group (HMG) DNA-binding domain. Of these factors, Sox17 was first identified in 
endoderm formation from work in Xenopus in which Sox17 was shown to mediate activin-
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induced endoderm differentiation in animal caps (Hudson et al., 1997). Later studies 
characterized the role of Sox17 in mouse endoderm development and revealed its expression 
in the visceral endoderm as well as the definitive endoderm (Kanai-Azuma et al., 2002). 
Further confirming its essential role in endoderm formation, Sox17 mutant embryos are 
deficient of gut endoderm (Kanai-Azuma et al., 2002). In addition to factors belonging to the 
Sox family, Forkhead genes have been extensively implicated in endoderm formation. 
Specifically, Foxa1/HNF3α, Foxa2/HNF3β, and Foxa3/HNF3γ are expressed during 
endoderm development (Ang et al., 1993; Monaghan et al., 1993).  
As development continues, the single epithelial layer of the endoderm forms into a 
primitive gut tube which runs along the anterior-posterior axis of the developing embryo, and 
numerous organs including the pharynx, thyroid, lungs, liver, stomach, pancreas and intestine 
(Wells and Melton, 1999) are established along an anterior-posterior patterned gut tube 
endoderm (Figure 1.3). The anterior-posterior patterning of the gut endoderm is modulated 
by numerous signaling pathways, including FGF, Wnt, and retinoic acid. High concentrations 
of Fgf4 from the overlying mesoderm have a posteriorizing effect on the definitive endoderm 
(Dessimoz et al., 2006; Wells and Melton, 2000). Similarly, Wnt/β-catenin signaling and 
retinoic acid from the overlying mesoderm play critical roles in anterior-posterior patterning 
and serve to posteriorize the gut tube endoderm (Bayha et al., 2009; Kinkel et al., 2009; Li et 
al., 2008; Martin et al., 2005; McLin et al., 2007; Molotkov et al., 2005; Stafford et al., 
2004).  
Along the gut tube, the pancreas originates from the posterior foregut endoderm as 
dorsal and ventral buds which are characterized by their expression of pancreatic and 
duodenal homeobox 1 (Pdx1) and pancreas specific transcription factor 1a (Ptf1a) (Figures 
1.3 and 1.4). The cells in the early pancreatic buds also express Mnx1/Hlxb9 (Harrison et al., 





Figure 1.3  Pancreatic organogenesis: endoderm patterning and branching 
morphogenesis. A) Along the gut tube endoderm, the dorsal and ventral pancreatic 
endoderm are specified. By E9.0, the endoderm evaginates to form the dorsal and ventral 
pancreatic buds (only dorsal bud depicted), and rapid growth and proliferation cause the 
epithelium to expand. The pancreatic epithelium consists of multipotent progenitor cells 
(MPCs, yellow) with periodic endocrine progenitors (grey). B) During early stages of 
development (8 – 10 somites, E8.5), Sonic hedgehog (Shh) expression (blue) is repressed in 
the dorsal pancreatic epithelium (yellow) by signals from the overlying notochord (green), 
thereby permitting expression of Ipf1/Pdx1. C) By the 20 somite stage (E9.5), the dorsal aorta 
comes into contact with the dorsal pancreatic epithelium and continues Shh repression. 
Signals from the septum transversum and cardiogenic mesoderm induce Shh expression in 
the endoderm adjacent to the ventral pancreatic endoderm, thus permitting the specification 
of the ventral endoderm to the pancreatic lineage. D) By E12.5, the dorsal and ventral 
pancreas fuse and begin to undergo branching morphogenesis and epithelial elongation. 
Endocrine cell clusters (grey) begin to delaminate from the pancreatic epithelium. E) During 
the secondary transition (~E13.5), committed cell types begin to form with pancreatic islets 
(cluster of green, blue, and purple cells) delaminating from the ductal epithelium (yellow) 
which contains endocrine progenitor cells (light green) while the tips of the branching 




1997), and Sox9 (Seymour et al., 2007) which all play critical roles in pancreas formation. 
The pre-pancreatic endoderm receives a variety of instructive and permissive cues from the 
various mesodermally-derived tissues that it contacts, with the dorsal pancreatic endoderm 
being in contact with the notochord and dorsal aortae and the ventral endoderm making 
contact with the cardiac mesoderm, septum transversum mesenchyme, and later, the vitelline 
veins (Figure 1.3) (Deutsch et al., 2001; Kim et al., 1997; Rossi et al., 2001). The notochord 
secretes a variety of signaling molecules, including the TGFβ family member, Activin βB, 
and Fgf2, both of which activate pancreatic gene expression in the dorsal pre-pancreatic 
epithelium by repressing the expression of Sonic hedgehog (Shh) (Hebrok et al., 1998). 
Additionally, signals from endothelial cells in the dorsal aorta and the vitelline veins promote 
the specification of the pre-pancreatic endoderm, as evident in Flk-/- mice, which lack 
endothelial cells, where Ptf1a fails to be expressed in the dorsal pancreatic epithelium 
(Yoshitomi and Zaret, 2004). Conversely, the ventral pre-pancreatic endoderm diverges from 
a bipotential progenitor in the ventral foregut that can give rise to both the liver and ventral 
pancreatic fates (Deutsch et al., 2001). Signals from the cardiogenic mesenchyme, including 
BMPs produced by the septum transversum and FGFs from the cardiac mesoderm, induce 
hepatic and pancreatic developmental programs (Jung et al., 1999; Kumar et al., 2003; Rossi 
et al., 2001). A proper balance of signaling is required, with strong signaling inducing hepatic 
differentiation and lower levels of signaling from the cardiogenic mesenchyme inducing a 
pancreatic fate (Deutsch et al., 2001).  
Following pancreatic bud formation, the cells further proliferate and branch in 
response to signals from the adjacent mesenchyme (Figure 1.3). While at this point the cells 
are specified to a pancreatic fate, they are not fully and irreversibly committed to this fate. 
The majority of the cells within the pancreatic epithelium undergo a primary transition where 





Figure 1.4  Ptf1a and Pdx1 expression during pancreas development. A – C) Whole 
mount X-gal histochemistry of Pdx1lacZ/+ embryos. Figure adapted from Offield et al. (1996). 
A) At E9.5, Pdx1lacZ expression is evident in the dorsal (d) and ventral (v) endoderm. B) By 
E11.5, the pancreatic epithelium has expanded and Pdx1lacZ expression is evident in the antral 
stomach (a), duodenum (du), dorsal (d) and ventral (v) pancreas, and common bile duct (c). 
C) By E16.5, Pdx1lacZ expression is evident in the pancreatic epithelium (p), as well as the 
stomach (s) and duodenum (du). D – E) Whole mount X-gal histochemistry following Ptf1a 
lineage tracing. Figure adapted from Kawaguchi et al. (2002). D) The progenitor cells 
contained in the pancreatic epithelium are derived from Ptf1a-expressing cells as evident by 
the lineage label. As compared to Pdx1, Ptf1a expression is restricted to the dorsal (d) and 
ventral (v) pancreatic buds within the developing midgut. E) At E18.5, whole mount X-gal 




enzymes and the detection of early differentiated hormone-expressing endocrine cells. Some 
uncertainty surrounds the exact function and fate of these early endocrine cells with studies 
both supporting and refuting that these “first wave” endocrine cells can contribute to the 
mature endocrine pancreas (Gu et al., 2002; Herrera, 2000; Herrera et al., 1994; Lee et al., 
1999; Pang et al., 1994; Wilson et al., 2002).  
After initial specification and commitment of the pancreatic epithelium, endocrine 
cell specification begins with the inhibition of Notch signaling in a population of cells, which 
subsequently express the pro-endocrine gene Neurogenin 3 (Neurog3) (Gradwohl et al., 
2000; Jensen et al., 2000; Schwitzgebel et al., 2000). Notch signaling is an evolutionarily 
conserved pathway and is known principally for its regulation of cell fate decisions; a process 
termed “lateral specification.” In this pathway, a cell-surface Notch receptor is activated by 
binding a ligand (e.g. Delta or Jagged) produced by a neighboring cell under the direction of 
the transcriptional regulator Neurog3. This process leads to the proteolytic release of the 
intracellular domain of the Notch receptor (NICD) which subsequently binds to Rbpj and 
thus causes transactivation of target genes, such as Hes1 or related members of the 
Hairy/Enhancer of Split family which serve as transcriptional repressors that inhibit the 
expression of pro-endocrine factors. The process of “lateral inhibition” via the Notch 
signaling pathway is essential for maintaining the undifferentiated state of the pancreatic 
MPC population, and the inhibition of this signaling mechanism is critical for the widespread 
commitment of cells to specific cell fates.  
The next stage of organogenesis, termed the “secondary transition,” results in the 
commitment of acinar, ductal and a “second wave” of endocrine cells from the 
protodifferentiated pancreatic epithelium (Figure 1.3). During this transition, Neurog3-
expressing cells are scattered throughout the epithelial cords of the pancreatic epithelium and 
identify endocrine progenitor cells that give rise to the hormone-expressing cells of the 
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mature pancreas. Along with Neurog3, various other transcription factors identify a subset of 
endocrine progenitor cells, including Pax6, Nkx6-1, Nkx2-2, Insm1 and Neurod1. As the 
epithelium expands and endocrine cells become specified, the tips of the epithelial branches 
begin to commit to the acinar lineage and differentiate into pro-acinar cell clusters. Acinar 
cell commitment is dependent on the trimeric complex PTF1, which is composed of Ptf1a, a 
ubiquitously expressed class A bHLH protein, and either Rbpj or Rbpjl (Beres et al., 2006; 
Roux et al., 1989; Sommer et al., 1991). During early stages of pancreatogenesis, Ptf1a 
interacts with Rbpj and this interaction is essential for early progenitor cell specification and 
development (Masui et al., 2007). Subsequently, Rbpjl displaces Rbpj within the PTF1 
complex and promotes the specification to the acinar lineage (Masui et al., 2010).  
 
Pancreatic multipotent progenitor cells 
During the initial evagination of the foregut endoderm to form the dorsal and ventral 
pancreatic buds, the pancreatic epithelium consists of multipotent progenitor cells (MPCs) 
that give rise to all three cell types of the mature pancreas: endocrine, acinar and duct (Gu et 
al., 2002; Herrera, 2000; Kawaguchi et al., 2002; Zhou et al., 2007). While the nature of these 
pancreatic MPCs is not fully understood, it is thought that they exist within the pancreatic 
epithelium from E9.5 until approximately E12.5 (Zhou et al., 2007). A deeper understanding 
of the specification and differentiation of the pancreatic MPCs is important for multiple 
reasons. First, the number of pancreatic MPCs present early in development determines the 
final size of the pancreas (Stanger et al., 2007). Second, the formation of the mature pancreas, 
including the endocrine islets, depends upon the orderly expansion of the MPC-containing, 
pre-pancreatic epithelium. Lastly, a better understanding of the signaling pathways that 
promote progenitor cell specification and establish the genetic regulatory network in vivo will 
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be essential for learning how to mimic these processes during the directed differentiation of 
pluripotent stem cells towards pancreatic fates in vitro.  
Pdx1 and Ptf1a are both expressed in pancreatic MPCs; however while they are co-
expressed in a subpopulation of MPCs, they also have distinct spatially defined expression 
domains within the developing midgut (Figure 1.4). From E10.5 – E11.5, Pdx1 is broadly 
expressed in the epithelium of the caudal stomach, rostral duodenum, common bile duct and 
extrahepatic biliary ducts, which limits its use for exclusively identifying pancreatic MPCs 
(Burlison et al., 2008; Offield et al., 1996). Conversely, at this time within the developing 
midgut, Ptf1a is expressed exclusively within the dorsal and ventral pancreatic epithelium 
(Burlison et al., 2008; Kawaguchi et al., 2002). While both Pdx1 and Ptf1a mutant mice are 
apancreatic, Pdx1-deficient mice also have malformation of the gastro-duodenal junction, 
defects in the development of the submucosal Brunner’s glands, altered enteroendocrine cell 
numbers in the stomach and duodenum, and abnormalities in the formation of the peribilary 
glands and mucin-producing cells of the gall bladder (Burlison et al., 2008; Jonsson et al., 
1994; Kawaguchi et al., 2002; Offield et al., 1996).  
 
Genetic manipulations in mice and cells 
Genetic engineering has proven widely useful for a variety of applications in 
developmental biology. Specifically, transgenic mice have become valuable models for 
examining genetic disorders and elucidating embryonic development. Transgenic mice are 
generated via microinjection of exogenous DNA that incorporates the regulatory elements of 
a particular gene of interest driving the expression of a mutant version of the coding region 
into the pronucleus of a fertilized egg (Gordon and Ruddle, 1981; Wagner et al., 1981). 
However, advances in molecular biology and stem cell biology have permitted the generation 
of genetically engineered mice through gene targeting in mouse embryonic stem (mES) cells 
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which hold numerous advantages as compared to pronuclear injection for generating 
transgenic mice (Smithies et al., 1985; Thomas et al., 1986).  
The method of gene targeting relies on homologous recombination in ES cells. The 
technique was first developed for facilitating site-directed mutagenesis in yeast but has 
subsequently been adapted for mammalian cells. This technique relies on the generation of a 
DNA construct which incorporates several kilobases (kb) of DNA sequence homologous to 
the mouse genome thereby permitting recombination between the homologous sequences 
(Figure 1.5). The DNA construct also contains desired gene modifications, as well as 
sequences conferring drug sensitivity to permit identification of recombination events. In 
mammalian genomes, homologous recombination at the correct locus occurs at a very low 
rate, thus labeling gene targeting as a more laborious method.  
In order to accelerate the repetitive generation of mutant and/or reporter alleles for a 
given gene, strategies that utilize recombinase-mediated cassette exchange (RMCE) have 
been developed and implemented (Figure 1.5). This technique relies on the generation of a 
loxed cassette acceptor (LCA) allele in ES cells, which is achieved through standard 
homologous recombination and gene targeting. The LCA allele contains loxP or mutant loxP 
sites that facilitate the exchange of a DNA cassette containing compatible lox sites. Various 
mutant lox sites have been described and each present their own advantages and 
disadvantages, and the use of heteromeric lox sites, such as the compatible lox 66 and lox71 
sites, allow more efficient and unidirectional RMCE (Araki et al., 2002).  
The sequences removed during the generation of the LCA allele can be manipulated 
in a variety of ways, thus generating knockout alleles, knockin alleles, point mutations in the 
sequence, fluorescently-tagged alleles, or insertions of other elements, such as HA-tags for 
immunoprecipitation or Cre recombinase for lineage labeling. The modified DNA sequence 







Figure 1.5  Scheme for gene targeting and recombinase-mediated cassette exchange 
(RMCE). First, a targeting vector is generated to replace a region of interest of a wild type 
allele with a desired DNA sequence. For the generation of a loxed cassette acceptor (LCA) 
allele, this sequence typically contains a dual selection cassette consisting of a fusion of 
puromycin resistance and a mutant thymidine kinase driven by the mouse phosphoglycerol 
kinase promoter (pgk-puΔtk) and an EM7-driven kanamycin resistance (EM7-KanR) flanked 
by lox71 and lox2272 sites. To facilitate homologous recombination between the targeting 
vector and the wild type allele, long and short homologous arms are incorporated into the 
targeting vector and flank the desired DNA sequence. Additionally, the targeting vector 
contains a pgk-driven diphtheria toxin A gene (DTA) outside the long homology arm for 
negative selection following targeting. In order to generate a new allele of interest that 
contains a reporter or mutated DNA sequence, an exchange vector is generated that has lox66 
and lox2272 sites which are compatible with the lox sites present in the LCA allele. The 
exchange cassette contains an FRT-flanked pgk-HygroR cassette for positive selection of 
mES cells after RMCE. Co-electroporation of ES cells with both the exchange vector and a 
Cre-expressing vector permit the recombination of the compatible lox sites and exchange of 
the cassette into the LCA allele thereby yielding the new allele of interest.  
19 
 
present in the LCA allele. RMCE is performed by co-electroporating the exchange cassette as 
well as a Cre-expression vector into ES cells containing the LCA allele of interest. Site-
specific recombination between the compatible lox sites in the LCA allele and the exchange 
cassette is driven Cre recombinase and results in the exchange of the modified cassette into 
the LCA allele. A staggered positive-negative selection strategy permits the identification of 
properly exchanged clones (Long et al., 2004).  
While RMCE relies on the generation of an LCA allele, which requires the more 
laborious gene targeting method, the availability of a collection of LCA alleles greatly 
lessens the effort needed to generate new locus-specific alleles as compared to repetitive gene 
targeting. Indeed, once an LCA allele is generated, RMCE is significantly more efficient than 
repetitive gene targeting for the generation of modified alleles. Additionally, this technique is 
highly advantageous as it permits the insertion of different types of mutations into a precise 




The transcriptome is the complete set of all messenger RNAs (mRNAs), or 
transcripts, in a cell (Su et al., 2002). Messenger RNA is transcribed from a DNA template 
and is eventually translated into a protein product. Unlike the genome, which is encoded by 
DNA, the transcriptome can vary depending on external conditions, such as environmental 
influences and developmental timing. Since the transcriptome includes all mRNA transcripts 
in the cell, it reflects the genes being actively expressed at a given time and therefore governs 
a cell’s development. Examining the transcriptome is critical for understanding the process of 
cellular differentiation, analyzing pathways that regulate development, and interpreting the 
functional components of the genome. In addition, comparing the gene expression profiles of 
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diseased and normal cells/tissues will shed light on the pathology and development of certain 
diseases and potentially identify new targets for therapeutic intervention.  
The importance of the transcriptome has made expression profiling an active field. 
Numerous technologies have been developed to examine the expression level of mRNAs in a 
given cell, including hybridization- and sequence-based approaches. Hybridization-based 
approaches, such as microarrays, have been the most commonly used method for 
transcriptome analysis (Schena et al., 1995). These methods rely on the hybridization of short 
DNA fragments that are used as probes to fluorescently-tagged target samples, typically 
cDNA. Hybridization of the probe-target is quantified by detection of the fluorophore-labeled 
target and used to determine the relative abundance of a particular sequence. However, 
despite their common use, microarrays have a number of disadvantages that limit their 
potential, including prior knowledge of genome sequence, limited range of transcriptome 
coverage, and high background levels due to cross-hybridization (Malone and Oliver, 2011).  
In contrast, sequence-based methods directly determine the target sample sequence. 
Developed in 1991, expressed sequence tag (EST) sequencing was a valuable tool for gene 
discovery (Adams et al., 1991). EST sequencing was critical in driving the human genome 
project which produced a reference sequence for the human genome (Venter et al., 2001). 
The method relies upon Sanger sequencing of short cDNA fragments, approximately 500 – 
800 nucleotides, which can then be mapped to specific chromosome locations. While a 
valuable tool for gene discovery, the method is relatively low throughput, dependent on 
bacterial cloning constraints, not conducive to rare-transcript discovery, and requires costly 
large scale sequencing (Alba et al., 2004).  
In 1995, Velculescu et al. developed a tag-based approach for transcriptome analysis, 
termed serial analysis of gene expression (SAGE) (Velculescu et al., 1995). Numerous 
variations of this approach have been developed since its inception, including LongSAGE 
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(Saha et al., 2002), Robust-LongSAGE (RL-SAGE) (Gowda et al., 2004), SuperSAGE 
(Matsumura et al., 2005), CAGE (cap analysis of gene expression) (Kodzius et al., 2006; 
Shiraki et al., 2003), and MPSS (massively parallel signature sequencing) (Brenner et al., 
2000). While similar to EST sequencing, SAGE is dependent on generating short sequence 
“tags,” approximately 9 – 15 nucleotides (nt) in length, which are then concatenated to allow 
for efficient sequencing. Although more efficient than large-scale EST sequencing, this 
method is also laborious and dependent on a rather expensive Sanger sequencing. However, 
in comparison to hybridization approaches, sequence-based methods allow for absolute 
quantification of gene expression levels. 
 
Whole Transcriptome Profiling: RNA-Sequencing technology 
Recent advances in genome sequencing technologies have caused a new method, 
termed RNA-Seq, to propel forward. Sequencing platforms and methods developed by 
Illumina (Bennett et al., 2005), Life Science (Margulies et al., 2005), and ABI (Shendure et 
al., 2005) have numerous advantages over traditional microarrays, including independence 
from reliance on existing genomic sequence, quantitative gene expression levels, single-base 
resolution, relatively low background noise, greater dynamic range and reproducibility, low 
input RNA requirement, and an increased ability to distinguish different isoforms. Similar to 
SAGE, RNA-Seq is dependent on generating sequence “tags” that can range from 25 – 100 
nucleotides (Figure 1.6). These tagged sequences are ligated to a flow cell where clonal 
sequence clusters are generated for numerous rounds of sequencing. The sequence read is 
subsequently aligned to a genome of interest where the transcriptional profile of a tissue or 
cell can be examined. RNA-Sequencing is expected to revolutionize transcriptomics (Wang 
et al., 2009) and has already been applied to numerous species including Saccharomyces 







Figure 1.6  Scheme of Illumina RNA-Sequencing. A) cDNA (blue) is randomly 
fragmented and ligated to adaptor oligos (yellow). B) The flow cell has a dense lawn of 
oligos grafted to the surface. C) The adaptor-ligated cDNA fragments hybridize to the lawn 
of oligos. D) The bound cDNA fragments are clonally amplified through a series of 
extensions and isothermal bridge amplifications resulting in millions of unique clusters. E) 
The reverse stands are cleaved and removed. F) The clusters are sequenced simultaneously 
where four fluorescently labeled nucleotides compete to bind to the template. G) After each 
round of synthesis, the clusters are excited by a laser which excites the fluorophore. The 
emission fluorescence identifies the newly added base. H) Following sequencing, short 
fragment reads are aligned to the genome of interest and transcript expression values can be 




(Sultan et al., 2008), and mouse (Cloonan et al., 2008). While RNA-Seq is still an emerging 
technology, its advantages over previous methods are clear, and this technology is becoming 
the predominant method for transcriptional analysis of defined cellular populations.  
 
Overview and Aims of Dissertation 
To enhance cell culture based efforts that aim to generate β cells, a deeper 
understanding of the native cell types would prove beneficial. While studies of early human 
organ development would be optimal for such comparisons, these studies are typically 
limited by the ability to obtain properly staged early human fetal tissues. Although there are 
developmental differences between human and mouse, gene expression studies in mice have 
proven useful in guiding the directed differentiation of human ES cells (Bu et al., 2009; Yang 
et al., 2008). Concerning the directed differentiation of hES cells towards hormone-
expressing cells, the most promising methods have attempted to recapitulate the endogenous 
signaling pathways and transcriptional networks that guide pancreas development (discussed 
in Chapter II). Thus, it is only logical that a deeper understanding of the various 
developmental stages would serve to accelerate theefforts pertaining to the directed 
differentiation of hES cells towards β-like cells.  
To facilitate development of improved human ES cell directed pancreatic 
differentiation protocols, the research described herein represents only a portion of a larger 
scheme focused on generating and characterizing a series of high quality transcriptional 
profiles representing key stages in the generation of pancreatic endocrine cells that occur 
naturally in the mouse (Figure 1.7). By using fluorescence-activated cell sorting (FACS) to 
isolate specific pancreatic progenitor cell populations and by applying whole transcriptome 
sequencing (RNA-Seq) to these populations, we are obtaining a logical series of 








Figure 1.7  Developmental scheme of β cell development and target cell populations for 
transcriptional profiling. The graphical representation outlines the developmental pathway 
underlying β cell differentiation. The definitive endoderm gives rise to a number of organs, 
including the pancreas. Following formation of the gut tube, the pancreatic endoderm is 
specified within the posterior foregut endoderm. The early pancreatic epithelium contains 
multipotent progenitor cells (MPCs) which give rise to all three mature pancreatic cell types: 
endocrine, acinar and duct. As development continues, the MPCs give rise to endocrine 
progenitors which will eventually differentiate into one of the five hormone-expressing cell 
types: insulin-producing β cells, glucagon-producing α cells, somatostatin-producing δ cells, 
pancreatic polypeptide-producing PP cells, and ghrelin-producing ε cells. Each 
developmental intermediate can be identified by the expression of specific transcripts, and we 
are utilizing fluorescently-tagged alleles to isolate a number of these developmental stages. In 
addition to analyzing cells that express a transcript of interest, we are isolating and 
characterizing cells that are genetically deficient (denoted by X). The developmental 
intermediates and cell populations represented here will allow us to analyze the temporal 




these datasets will likely lead to the identification of signaling pathways and gene clusters 
essential for the formation of functional pancreatic β cells in the mouse, thereby stimulating 
new hypotheses for identifying pro-β cell signals necessary to direct the differentiation of 
human ES cells into pancreatic β cells.  
Our approach has many advantages over prior studies (Chiang and Melton, 2003; Gu 
et al., 2004; White et al., 2008). First, by utilizing fluorescently-tagged alleles, we are able to 
isolate genetically defined cell populations. This is a major improvement over previous 
studies that often relied solely on manual dissection of pancreatic regions and thus represent 
cell populations possibly contaminated by other non-desired cell types. Second, by utilizing 
the recently developed RNA-Sequencing approach for whole transcriptome profiling instead 
of DNA microarrays, we have obtained a less biased and more quantitative view of the gene 
regulatory changes occurring (Marioni et al., 2008; Mortazavi et al., 2008). Lastly, by 
collecting information from closely related cell types, we will be able to more accurately 
assess the spatial and temporal alteration of genetic networks that regulate the step-wise 
production of β cells, which was not achieved by previous efforts (Gu et al., 2004; White et 
al., 2008).  
To define the temporal, spatial and transcription factor-dependent gene expression of 
specific developmental intermediates, we have utilized genetically engineered mouse lines to 
obtain highly purified cell populations for deep sequencing of their transcriptomes. 
Specifically, we have sought to examine the genetic and temporal requirement of Ptf1a, a 
marker of the pancreatic MPC population and of acinar-specified cells, during pancreas 
development (discussed in Chapter III). By comparing different transcriptional profiles, we 
have been able to identify five gene clusters that demonstrate the formation of specific cell 
lineages. The datasets from these cell populations have identified of transcription factors, cell 
surface receptors, and enzymes that possibly have a role in MPC specification and pancreas 
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development. Specifically, the analysis of datasets such as these permit the identification of 
differentially expressed transcripts, such as Nephrocan (discussed in Chapter IV), an 
inhibitor of TGFβ signaling pathway, that may have a novel role in pancreatic progenitor cell 
specification or a broader role in pancreas development. Additionally, we have sought to 
generate fluorescently-tagged alleles to facilitate the combinatorial sorting of Pdx1- and 
Ptf1a-expressing cells which will permit analysis of the spatially-distinct expression domains 
of these two transcripts (discussed in Chapter V).  
We anticipate that further analysis of datasets such as these will lead to identification 
of novel transcriptional effectors which guide the sequential developmental program of β cell 
differentiation. Parallels/analogies can then be drawn for identifying and isolating human ES 
cell-derived pancreatic cells and for distinguishing different progenitor cells during the 





DIRECTED DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS AND 




Directed differentiation of human ES cells towards pancreatic fates 
In order to generate insulin-producing β-like cells via directed differentiation of 
human ES cells, it seems necessary to recapitulate, as precisely as possible, normal 
developmental processes and events. Based on knowledge obtained largely from studies 
using mice, at minimum it is necessary to sequentially induce the formation of 1) anterior 
primitive streak cells, 2) definitive endoderm, 3) primitive gut tube, 4) posterior foregut 
endoderm, 5) pancreatic endoderm and lastly 6) pancreatic β cells (Figure 1.2). These 
defined developmental stages are governed by numerous signaling pathways and molecules 
that sequentially and spatially promote, or in some cases inhibit, the differentiation of cells to 
specific fates and serve to establish critical gene regulatory networks that instruct cell 
development.  
There has been remarkable progress by numerous investigators concerning the 
directed differentiation of hES cells towards hormone-producing fates (Assady et al., 2001; 
Baharvand et al., 2006; Brolen et al., 2005; Cho et al., 2008; D'Amour et al., 2006; Jiang et 
al., 2007a; Jiang et al., 2007b; Phillips et al., 2007; Segev et al., 2004; Shim et al., 2007). 
Most notably, Baetge and colleagues reported a five-stage protocol to direct hES cells 
through a process that mimics normal pancreatic development, taking into account numerous 
years of research in vertebrate endoderm development and pancreatic organogenesis 
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(D'Amour et al., 2006). While the induction produced hormone-expressing endocrine cells, 
only seven percent of the final endocrine-specified cells expressed Insulin. Additionally, 
there are some significant deficiencies in the β-like cells including improper maturation, as 
evidenced by a number of polyhormonal cells, as well as the inability to secrete insulin in 
response to glucose. To circumvent these shortcomings, a later publication reported the 
competency of hES cell-derived pancreatic progenitors, which are formed during the fourth 
stage of differentiation, to develop in vivo into mature endocrine cells (Kroon et al., 2008). 
The gene expression pattern and functionality of the in vivo-matured insulin-producing cells 
were similar to mature, functional β cells. However, the in vivo maturation of the transplanted 
heterogeneous population, which quite possibly includes some undifferentiated pluripotent 
cells and/or cells differentiated to other lineages, resulted in teratoma formation, exposing the 
critical need for more efficient differentiation protocols and adequate purification of the 
pancreatic progenitors which are implanted.  
While these reports present compelling evidence supporting the therapeutic potential 
of ES cell research in treatments for diabetes, the ability to generate glucose-responsive 
insulin-producing cells from hES cells solely from in vitro differentiation has yet to be 
achieved. The limited success stems not only from inefficient differentiation but also from a 
lack of knowledge concerning the gene regulatory networks established as the cells transition 
through specific developmental intermediates and the three-dimensional affects leading to 
cell-to-cell signaling in vivo. Further advances could be made if we could purify hES cell-
derived developmental intermediates which then could be compared to corresponding 
authentic intermediates isolated in vivo or potentially could be transplanted into recipients 
without adverse teratoma formation. To overcome these limitations and improve hES cell 
induction protocols, the utilization of reporter alleles in human ES cells may be vital.  
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Reporter alleles in human ES cells 
The generation of hES cell lines that express reporter cDNAs, such as fluorescent 
proteins, under transcriptional control of genes that are expressed during specific stages of 
pancreas development would enable the differentiation of hES cells to be quantitatively 
monitored and permit the isolation of cell populations that mark specific developmental 
intermediates. Reporter alleles such as these would allow investigators to analyze the veracity 
of in vitro hES cell differentiation towards pancreatic fates and gain a better understanding of 
the signals that direct differentiation as well as the transcriptional networks established in 
these intermediates. To generate reporter alleles in hES cells, investigators have primarily 
utilized gene targeting (Fischer et al., 2010; Irion et al., 2007; Ruby and Zheng, 2009). 
Although this method is somewhat laborious, gene targeting eliminates positional effects 
typically seen in random transgenic insertions, and it enables accurate reporter expression as 
transcription of the reporter is controlled by endogenous regulatory sequences of the chosen 
locus.  
An alternative approach that can be utilized to generate reporter alleles in ES cells is 
recombinase-mediated cassette exchange (RMCE). Investigators have reported the generation 
of a human ROSA26 allele containing a tandem-dimer red fluorescent protein (tdRFP) 
flanked by lox sites in hES cells, thus generating an allele that can serve as a cassette 
acceptor for RMCE (Irion et al., 2007). These cells permit an exchange cassette, containing 
DNA sequences of interest flanked by compatible lox sites, to be exchanged into the ROSA26 
allele. While the generation of a reporter allele by the exchange of a DNA cassette into the 
ROSA26LCA allele is less difficult than gene targeting, it is not without certain limitations. In 
order to generate a reporter driven by the transcriptional regulatory elements of a particular 
locus rather than the regulatory elements of ROSA26, it is necessary to incorporate those 
regulatory sequences into the exchange cassette. This presents a major drawback given that 
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the promoter and enhancer sequences incorporated may not fully recapitulate endogenous 
expression. Thus, to ensure that critical regulatory regions are incorporated into the exchange 
cassette for generation of a reporter allele via this method, it is important to have a deep 
understanding of the regulatory elements driving its expression.  
The ability to insert reporters, such as fluorescent proteins, into specific loci 
revolutionized cell and molecular biology. By using a fluorescent reporter under the 
transcriptional control of a gene of interest, the developmental expression patterns for 
numerous genes were elucidated. This technology allowed for examination of temporal and 
spatial expression patterns in mouse tissues, the identification of new cell types based on 
specific expression patterns, further characterization of single cells, and transcriptional 
profiling of isolated cell populations. Similarly, gene targeting in hES cells will be critical for 
analyzing gene function in vitro and examining the function of specific genes. Not only will 
homologous recombination permit the isolation of fluorescently-tagged cells from hES cell-
derived heterogeneous populations, it will also allow for the generation of hES cell lines that 
contain specific mutations or polymorphisms that will further elucidate the pathogenesis of 
particular diseases or the physiology of tissues of interest. Regardless of its particular 
application, homologous recombination and the generation of reporter alleles in hES cells 
will promote a better understanding of specific genes and accelerate the therapeutic potential 
of human ES cells.  
 
Synopsis 
Here, we sought to determine the efficiency of the previously published five-stage 
pancreatic differentiation protocol on the federally-available WA-09 hES cells. We examined 
the gene expression pattern of the WA-09 hES cells as they transitioned through distinct 
pancreatic developmental intermediates. Given that the purification of hES cell-derived 
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developmental intermediates will prove critical for making further advances, we sought to 
generate fluorescently-tagged reporter hES cell lines through both RMCE and gene targeting. 
These reporter cell lines will enable the differentiation protocol to be quantitatively 
monitored and also permit the isolation of distinct developmental intermediates which then 
can be compared to corresponding authentic intermediates isolated in vivo (discussed further 
in Chapter III).  
 
Materials and Methods 
 
Human ES cell culture and differentiation to pancreatic fates 
WA-09 human ES cells (Thomson et al., 1998) were cultured on gelatin-coated tissue 
culture dishes on a layer of irradiated mouse embryonic fibroblasts (MEFs). Routine culture 
media consisted of DMEM-F12, 20% Knockout Serum Replacement, 1X non-essential 
amino acids, 2 mM L-glutamine, 10 ng/ml basic-FGF, 0.1 mM β-mercaptoethanol, 25 
units/ml penicillin and 25 µg/ml streptomycin (P/S) (all from Gibco/Invitrogen). Cells were 
passaged every five to seven days with 1 mg/ml collagenase (Invitrogen).  
For differentiation, cells were cultured on a layer of MEFs in 24-well plates until they 
reached approximately 70% confluency. Prior to differentiation, cells were washed briefly 
with 1X PBS with Ca2+ and Mg2+ (Gibco) and then differentiated for 15 days similar to the 
five-stage protocol described previously (Figure 2.1) (D'Amour et al., 2006). Cells were 
cultured in RPMI, DMEM, or CMRL media supplemented with varying concentrations of 
fetal bovine serum (FBS) (Hyclone) or 1% B27 supplement (Invitrogen). Cells were 
stimulated with combinations of 100 ng/ml Activin A (R&D Systems), 25 ng/ml Wnt3a 









Figure 2.1  Schematic diagram of various cell intermediates, transcripts expressed 
during development towards the endocrine lineage, and outline of differentiation 
procedure including media, growth factors and times of exposure. The differentiation 
protocol is divided into five stages that mark various developmental intermediates that 
embryonic stem (ES) cells transition through as they develop into endocrine cells, including 
definitive endoderm (DE), primitive gut tube (PG), posterior foregut (PF), pancreatic 
endoderm and endocrine precursor (PE), and hormone-expressing endocrine cell (EN). In 
stage 1, pluripotent hES cells are transitioned through the mesendoderm (ME) to a definitive 
endoderm intermediate using high concentrations of Activin A and Wnt3a. In stage 2, 
Activin A is removed and the cells are transitioned to a state resembling the primitive gut 
tube by exposure to FGF10, or FGF7, and the hedgehog-signaling inhibitor cyclopamine 
(CYC). In stage 3, the gut tube-like cells are additionally induced with retinoic acid which 
promotes the expression of posterior foregut markers. In stage 4, the cells are induced to 
pancreatic endoderm fates by exposure to a γ-secretase, Notch-pathway inhibitor (DAPT) and 
Exendin-4. During the final stage of differentiation, expression of pancreatic hormones as 
well as other markers of mature endocrine populations is evident when additionally induced 
with hepatocyte growth factor (HGF) and insulin-like growth factor (IGF1). Each 
developmental intermediate is characterized by the expression of specific transcripts; gene 
symbols are listed below each developmental stage. Figure adapted from D'Amour et al. 
(2006) by Jonathan Schug. 
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FGF7 (R&D Systems), 2 µM retinoic acid (Sigma), 1 µM DAPT (Sigma), 50 ng/ml Exendin-
4 (Sigma), 50 ng/ml IGF-1 (Sigma), and 50 ng/ml HGF (Peprotech). 
 
TaqMan Low Density Array Design 
To analyze changes in gene expression as differentiation proceeded, we utilized 
customized TaqMan low density arrays (TLDAs). These arrays allow for a high-throughput 
approach to quantitative RT-PCR by profiling up to 384 transcripts simultaneously. We 
customized a TLDA for the analysis of 48 transcripts, analyzed in technical duplicates, which 
serve as developmental markers of specific stages of endoderm and pancreas development 
(Table 2.1). Of the 48 transcripts analyzed, 18 have been characterized as part of the 
endoderm signature panel (ESP, noted in red script) (Sherwood et al., 2007) and 28 
transcripts characterize various developmental stages as cells differentiate towards the 
endocrine lineage.  
 
RNA isolation and quantitative reverse transcription PCR (qRT-PCR) 
 Total RNA was isolated from cells following each day of differentiation using 
Stratagene’s Absolutely RNA Miniprep Kit according to manufacturer’s protocol. RNA 
quality was assessed by observing the relative intensity of the 18S and 28S ribosomal RNA 
bands by electrophoresis in 0.5X TBE agarose gels. Total RNA (500 ng) was reverse-
transcribed into cDNA using the High Capacity cDNA Archive Kit (Applied Biosystems) 
according to manufacturer’s protocol. Assuming a 1:1 conversion of RNA to cDNA, a 100 µl 
volume consisting of 100 ng cDNA combined with 1X TaqMan Universal Master Mix was 
transferred into a loading port on the TLDA. The array was prepped according to 
manufacturer’s guidelines and analyzed on ABI’s 7900HT Real-Time PCR System. Relative  
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Table 2.1 Summary of transcripts profiled on human ES cell TLDA 
  GENE SYMBOL GENE NAME ASSAY ID 
1 ANXA4 Annexin A4 Hs00154040_m1 
2 BNIPL BCL2/adenovirus E1B 19kDa interacting protein 1 Hs00414503_m1 
3 CACNA1B Calcium channel, voltage-dependent, N type, alpha 1B subunit Hs00609480_m1 
4 CDCP1 CUB domain containing protein 1 Hs00224587_m1 
5 CDX1 Caudal type homeobox 1 Hs00156451_m1 
6 CER1 Cerberus 1, cysteine knot superfamily, homolog (Xenopus laevis) Hs00193796_m1 
7 CLDN8 Claudin 8 Hs00273282_s1 
8 CLIC6 Chloride intracellular channel 6 Hs00401339_m1 
9 CXCR4 Chemokine (C-X-C motif) receptor 4 Hs00607978_s1 
10 DSG2 Desmoglein 2 Hs00170071_m1 
11 EMB Embigin homolog (mouse) Hs00419017_m1 
12 EPCAM Epithelial cell adhesion molecule Hs00158980_m1 
13 ESRP1 Epithelial splicing regulatory protein 1 Hs00214472_m1 
14 FOXA1 Forkhead box A1 Hs00270129_m1 
15 FOXA2 Forkhead box A2 Hs00232764_m1 
16 FOXO1 Forkhead box O1 Hs01054576_m1 
17 GAPDH Glyceraldehyde-3-phosphate dehydrogenase Hs99999905_m1 
18 GCG Glucagon Hs00174967_m1 
19 GCK Glucokinase (hexokinase 4) Hs00175951_m1 
20 GHRL Ghrelin/obestatin prepropeptide Hs00175082_m1 
21 GSC Goosecoid homeobox Hs00418279_m1 
22 GUSB Glucuronidase, beta Hs99999908_m1 
23 HNF1B HNF1 homeobox B Hs00172123_m1 
24 HNF4A Hepatocyte nuclear factor 4, alpha Hs00230853_m1 
25 INS Insulin Hs00355773_m1 
26 MAFB V-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) Hs00534343_s1 
27 MNX1 Motor neuron and pancreas homeobox 1 Hs00232128_m1 
28 NEUROD1 Neurogenic differentiation 1 Hs00159598_m1 
29 NEUROG3 Neurogenin 3 Hs00360700_g1 
30 NKX2-2 NK2 homeobox 2 Hs00159616_m1 
31 NKX6-1 NK6 homeobox 1 Hs00232355_m1 
32 NPNT Nephronectin Hs00405900_m1 
33 ONECUT1 One cut homeobox 1 Hs00413554_m1 
34 PAX4 Paired box 4 Hs00173014_m1 
35 PAX6 Paired box 6 Hs00240871_m1 
36 PCSK1 Proprotein convertase subtilisin/kexin type 1 Hs00175619_m1 
37 PDX1 Pancreatic and duodenal homeobox 1 Hs00236830_m1 
38 POU5F1 POU class 5 homeobox 1 Hs01895061_u1 
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Table 2.1 continued 
39 PTF1A Pancreas specific transcription factor, 1a Hs00603586_g1 
40 RAB15 RAB15, member RAS onocogene family Hs00419246_m1 
41 RIPK4 Receptor-interacting serine-threonine kinase 4 Hs00221005_m1 
42 SH3GL2 SH3-domain GRB2-like 2 Hs00182352_m1 
43 SOX17 SRY (sex determining region Y)-box 17 Hs00751752_s1 
44 SPINK1 Serine peptidase inhibitor, Kazal type 1 Hs00162154_m1 
45 SST Somatostatin Hs00174949_m1 
46 ST14 Suppression of tumorigenicity 14 (colon carcinoma) Hs00222707_m1 
47 T T, brachyury homolog (mouse) Hs00610080_m1 




changes in mRNA expression were determined using the comparative Ct method (ΔΔCt). 
Gene expression profiles were displayed as a heat map and scaled as a function of the number  
of standard deviations relative to the mean of each row, where red notes the maximum fold 
increase in expression and green represents a relative decrease in gene expression (Figure 
2.2).  
 
Generation of a Pdx1-driven GFP/PuroR-expressing reporter for RMCE  
To generate a Pdx1-driven reporter in human ES cells, we obtained a basal exchange 
vector, termed pX2.PuroTK, from the laboratory of Dr. Gordon Keller (Ontario, Canada) 
(Irion et al., 2007) (Figure 2.3). The pX2.PuroTK plasmid contains one loxP site and one 
lox2272 site flanking a puromycin resistance/thymidine kinase (PuroTK) fusion gene. Unique 
ClaI and HindIII sites are present at the loxP end, as well as a unique NcoI site at the lox2272 
end. The sequences for the lox sites reported in the pX2.PuroTK plasmid are:  
loxP sequence:  ATAACTTCGTATA  ATGTATGC  TATACGAAGTTAT 
lox2272 sequence:  ATAACTTCGTATA  AGGTATCC  TATACGAAGTTAT 
As reported in Lee et al. (Lee and Saito, 1998), the sequences for lox2272 and lox2372 sites 
are: 
lox2272 sequence:  ATAACTTCGTATA  AAGTATCC  TATACGAAGTTAT 
 lox2372 sequence: ATAACTTCGTATA  AGGTATCC  TATACGAAGTTAT 
As evident by the nucleotides emphasized by underline, the lox2272 sited reported in Irion et 
al. is a lox2372 site according to the original publication by Lee et al. Therefore, attention 
needs to be taken concerning future manipulations with this plasmid given that the 
designations do not match the standard nomenclature detailed in the original publication.  
A Pdx1-containing BAC (clone 2270K21) isolated from the CTD BAC library was 
used for the construction of the pX2Pdx1-GFP/PuroR exchange cassette. The BAC DNA was 







Figure 2.2  Directed differentiation of human ES cells towards pancreatic fates. WA-09 
human ES cells were differentiated following a five-stage differentiation protocol that 
induced the cells through various intermediates towards the pancreatic endocrine lineage. 
Using a customized TaqMan Low Density Array (TLDA), the gene expression profiles of the 
cells were assayed following each day of differentiation for 15 days. The qRT-PCR results 
for each gene are displayed as a heat map to visualize the results following data analysis. Red 
notes the maximum fold increase in gene expression and green represents a relative decrease 
in gene expression. The intensity of each row is normalized separately. 
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recombination proteins exo, bet, and gam controlled by the temperature-sensitive repressor 
cI857 (Lee et al., 2001). Following electroporation, chloroamphenicol-resistant clones were 
identified by restriction analysis with EcoRI and EcoRV before proceeding to the first 
recombineering reaction. Four homologous regions (HR1, HR2, HR3, and HR4) 
approximately 500 base pairs in length were PCR amplified from the BAC DNA using the 
following primers sets:  
HR1 upper primer: 5’ CTAGCCCATGGCATGCAAAGAAATAAGTGTG,  
HR1 lower primer: 5’ CTAGCCCATGGGGGAGGCTGAGGTGGGTGGAT;  
HR2 upper primer: 5’ CTAGCATCGATACAGGATAGGAGTAAAGAGGAA,  
HR2 lower primer: 5’ CTAGCATCGATAGATGGGCGCTGAGGATT;  
HR3 upper primer: 5’ CTAGCATCGATCTCAACATGTCTCCTTGTAAACT,  
HR3 lower primer: 5’ CTAGCGGCCGGCCTGCGGCCCGGGATTGGGCACCGGGA;  
HR4 upper primer: 5’ CTAGCATGCATCCGCGGTGGCGCACCTTCACCA, 
HR4 lower primer: 5’ CTAGCGTTTAAACTCGGCTTCCTCGATGTGCACTA.  
The primers for amplification introduced appropriate restriction enzyme sites on the 5’ and 
3’-ends of the homologous regions to facilitate cloning into the appropriate insertion and 
retrieval vectors.    
A DNA fragment containing an enhanced GFP and puromycin resistance reporter 
was cloned into the PL451 plasmid which contained a pgk/EM7 promoter-driven neomycin 
resistance (NeoR) flanked by tandem FRT sites. Homologous regions 3 and 4 (HR3 and HR4) 
were cloned into this plasmid, creating the insertion plasmid. EL350 cells containing the 
BAC were electroporated (1800 V, 25 µF, 200 Ω) with insertion plasmid which was 
linearized with EcoRV and Pme1, and kanamycin-resistant clones were screened for positive 
insertions. The second recombineering step entailed the retrieval of DNA from the modified 
BAC into a basal retrieval vector. Homologous regions 1 and 2 (HR1 and HR2) were cloned 
into the pX2.PuroTK plasmid utilizing the unique NcoI and ClaI sites, thereby generating the 
retrieval plasmid. EL350 cells containing the modified BAC were electroporated (1800 V, 25 





Figure 2.3 Gene targeting of the ROSA26 locus in human ES cells. A) Schematic of 
human ROSA26 locus prior to and following targeting. The wild type hROSA26 allele is 
depicted in the upper panel. Following homologous recombination, the hROSA26 allele 
contains a viral splice acceptor (SA) followed by a loxP and lox2272 flanked tdRFP gene. 
The dashed lines indicate either predicted WT (6.0 kb) and targeted (3.5 kb) Southern band 
sizes following HindIII digestion or predicted WT (4.3 kb) and targeted (6.5 kb) Southern 
band sizes following XbaI digestion. B) Recombinase-mediated cassette exchange in the 
hROSA26tdRFP allele. The loxP and lox2272 sites allow for RMCE of an exchange cassette 
into the hROSA26tdRFP allele. A cassette containing a promoterless fusion of puromycin 
resistance and thymidine kinase (puroTK) was exchanged into the hROSA26tdRFP allele. The 
splice acceptor site allows for puromycin resistance to be driven by the hROSA26 promoter. 
Gene targeting and RMCE figures adapted from Irion et al. (2007). C) Brightfield (upper 
panel) and fluorescence (lower panel) images of hROSA26tdRFP colonies. 
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ampicillin-resistant clones were screened for positive retrievals. The placement of 
homologous regions 1 and 2 resulted in the removal of the PuroTK sequence following 
recombination.  
The pX2Pdx1-GFP/PuroR plasmid contains approximately 9.4 kb of the Pdx1 regulatory 
elements (Areas I-IV) upstream of the transcriptional start site. Following the Pdx1 5’ UTR 
are sequences containing a FLAG-tag, enhanced GFP, a 3X SV40 nuclear localization signal, 
an internal ribosome entry site (IRES2), puromycin resistance and a rabbit β-globin 
polyadenylation signal. These sequences are followed by a pgk/EM7 promoter-driven 
neomycin resistance sequence flanked by FRT sites. The pgk mammalian promoter allows 
for positive selection of correctly exchanged clones following RMCE, while the EM7 
bacterial promoter allows for positive selection during BAC recombineering. Following the 
reporter and antibiotic selection sequences are approximately 1.2 kb of Pdx1 exon 1 and 
intron sequences.  
 
Generation of a Pdx1-driven CFP-expressing reporter for RMCE  
To generate the CFP-expressing insertion plasmid, linker-primer PCR was used to 
amplify the nuclear-localized (3X SV40 NLS) Cerluean sequence, as well as the rabbit β-
globin polyadenylation sequence, which contains the splicing region and polyA sequences, 
from the Pdx1CFP exchange cassette (discussed in Chapter V) (Figure 2.4). The construct was 
cloned into the aforementioned insertion plasmid, which contained the pgk/EM7 promoter-
driven neomycin resistance flanked by tandem FRT sites as well as homologous regions 3 
and 4 (HR3 and HR4), following excision of the GFP/PuroR cassette. EL350 cells containing 
the BAC were electroporated (1800 V, 25 µF, 200 Ω) with SgrA1- and EcoRV-linearized 






Figure 2.4  Recombinase-mediated cassette exchange (RMCE) in human ES cells. A) 
The derivation of a human ES cell line (hES2) expressing a hROSA26tdRFP loxed cassette 
acceptor allele has been previously described by Irion et al. (2007). The Pdx1-CFP exchange 
vector contains approximately 9.4 kb of the Pdx1 regulatory elements containing Areas I-IV 
and the 5’UTR. Cerulean and an FRT-flanked neomycin resistance (NeoR) gene are followed 
by approximately 1.2 kb of Pdx1 exon 1 and intron sequence. Following RMCE, the final 
allele allowed for positive selection by the puroTK fusion protein. B) Representative PCR 
screen revealing exchange events on both the 5’ and 3’ ends. The four clones shown were 
among the 24 correctly exchanged clones. H9 DNA represents control DNA. C) Brightfield 
and fluorescent image of hES cell-dervied colony expressing hROSA26Pdx1-CFP allele 
following directed pancreatic differentiation. Image courtesy of Eunyoung Choi.  
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The second recombineering step entailed the retrieval of DNA from the modified 
BAC into the retrieval vector (pX2.PuroTK). Five unique restriction sites were cloned into 
the NcoI site of the basal retrieval vector, and homologous regions 1 and 2 (HR1 and HR2) 
were cloned into the modified pX2.PuroTK plasmid utilizing these unique restriction sites. 
EL350 cells containing the modified BAC were electroporated (1800 V, 25 µF, 200 Ω) with 
linearized retrieval plasmid, and ampicillin-resistant clones were screened for positive 
retrievals. The placement of homologous regions 1 and 2 resulted in the retention of the 
PuroTK sequences following recombination. 
The pX2.PuroTKPdx1-CFP plasmid contains a puromycin resistance/thymidine kinase 
(PuroTK) fusion gene to allow for positive selection following RMCE. Additionally, it 
contains approximately 9.4 kb of the Pdx1 regulatory elements (Areas I-IV) upstream of the 
transcriptional start site. Following the Pdx1 BAC 5’ UTR is a nuclear-localized Cerulean 
along with the rabbit β-globin polyadenylation sequence. These sequences are followed by a 
pgk/EM7-promoter driven neomycin resistance sequence flanked by FRT sites allowing 
positive selection following both RMCE and BAC recombineering. Following the reporter 
and antibiotic selection sequences are approximately 1.2 kb of Pdx1 exon 1 and intron 
sequence. The entire cassette is flanked by one loxP site and one lox2272/2372 site (Figure 
2.4).  
 
Generation of targeting vectors for Pdx1 gene targeting  
Utilizing both the GFP/PuroR-expressing and CFP-expressing constructs, two 
variations of a Pdx1 gene targeting vector were designed. Homologous regions 1 and 2 were 
PCR amplified from the BAC (clone 2270K21) using the following primers sets which 
contain leader sequences, necessary restriction enzyme sites and primer sequences:  
43 
 
HR1 upper primer: 5’ CTAGCACTAGTGTTTAAACCTTAAGTACCCTTGTGGAG 
CAGGTGATTA;  
HR1 lower primer: 5’ CTAGCAAGCTTATCCTCTGCTTCCGCATCCTCGGA;  
HR2 upper primer: 5’ CTAGCGTCGACGACACAGGCCGCGCCGGAACTT,  
HR2 lower primer: 5’ CTAGCATCGATCCCTCACTTCCCGCGCTTCGTTA. 
The amplified products were cloned into the basal retrieval vector (pBS.DTA) which 
contains a MC1-driven diphtheria toxin A gene (DTA). To generate the GFP/PuroR-
expressing and CFP-expressing gene targeting vectors, the aforementioned EL350 cells 
containing the modified BAC in which either the GFP/PuroR-expressing cassette or the CFP-
expressing cassette has been inserted were electroporated (1800 V, 25 µF, 200 Ω) with the 
ClaI-linearized retrieval plasmid, and ampicillin-resistant clones were screened for positive 
retrievals.  
 
Recombinase-mediated cassette exchange in human ES cells 
For DNA electroporation, hES2 cells (passage 24) that contained the tdRFP-
expressing ROSA26LCA allele (Figure 2.3) were collected by trypsinization and triturated to 
single cells. 5 x 106 cells were electroporated with 40 µg of pX2.PuroTKPdx1-CFP and 40 µg 
pBS185, a Cre expression plasmid, using a BioRad gene pulser (250 V, 500 µF). Cells were 
cultured on DR4 MEF cells, and selection with 0.5 µg/ml of puromycin began 72 hours post-
electroporation and continued for eleven days. Seventy-two colonies survived selection and 
were identified as tdRFP-negative, and 24 clones were analyzed by PCR using primers that 
spanned either the lox66/71 site on the 5’ end or the lox2272 site on the 3’ end. On the 5’ 
end, the combination of 5’ TTTGTGGGTGGGAGGCGCTT and 5’ 
CGTGGGCTTGTACTCGGTCAT primers resulted in a band size of 467 bp after RMCE and 
on the 3’ end, use of 5’ TGCGTGCGCCTGTAATCCTG and 5’ 
CCCCAGGTGAATGACTAAGCTCCA resulted in a 688 bp following RMCE. The 
resulting PCR products were visualized by electrophoresis in a 1% agarose gel and 24 out of 
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24 clones were confirmed as correctly exchanged. Clones 1A2, 1B1, 1C6 and 1D4 were 
expanded and cryopreseved for future experiments (Figure 2.4).  
 
Gene targeting in human ES cells 
 Two gene targeting experiments were performed using the GFP/PuroR-expressing 
targeting vector. For the first targeting experiment, WA-09 human ES cells (passage 36) were 
briefly cultured with media containing 10 mM of a ROCK inhibitor (Y-27632, Calbiochem) 
then collected by trypsinization. 5 x 106 cells were electroporated (250 V, 500 µF) with 40 µg 
of pBS.DTAPdx1-GFP/PuroR and cultured on DR4 MEFs in ROCK inhibitor-containing hES cell 
medium. Selection with neomycin sulfate (G418) began 48 – 72 hours post-electroporation 
and was performed in two stages: 25 µg/ml of G418 for four days followed by 50 µg/ml for 
seven days. Nine surviving clones were screened, and none displayed positive targeting. For 
the second targeting experiment, WA-09 cells (passage 32) were briefly cultured with 
medium containing 10 mM of a ROCK inhibitor then collected by trypsinization. Four 
electroporations were performed in which 40 µg of pBS.DTAPdx1-GFP/PuroR was electroporated 
into 5 x 106 WA-09 cells and cultured on DR4 MEFs in ROCK inhibitor-containing hES cell 
medium. Selection with neomycin sulfate (G418) began 48 – 72 hours post-electroporation 
and was performed in two stages. 130 clones survived selection, and 86 clones were 
screened. None displayed positive targeting. 
 Due to poor expression of the GFP/PuroR construct in mice (discussed in Chapter V), 
the human Pdx1 gene targeting vector was redesigned to incorporate a Cerulean-expressing 
construct. For electroporation, hES2 cells (passage 32) were briefly cultured with media 
containing 10 mM of a ROCK inhibitor then collected by trypsinization. 5 x 106 cells were 
electroporated with 40 µg of pBS.DTAPdx1-CFP and cultured on DR4 MEFs in ROCK 
inhibitor-containing hES cell media. Selection with neomycin sulfate (G418) began 48 – 72 
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hours post-electroporation and was performed in two stages. 94 clones survived selection, 
and 90 clones were screened. None displayed positive targeting. 
 Due to the inefficiency experienced with gene targeting for Pdx1 and to validate the 
electroporation parameters, we obtained a targeting vector for Nanog, a homeodomain 
transcription factor that is critical for maintaining stem cell pluripotency (Fischer et al., 
2010). The targeting vector consists of eGFP and neomycin resistance flanked by 12.5 kb and 
3.5 kb homology arms, and homologous recombination has been shown successful in huES-1 
and huES-3 cells (Fischer et al., 2010) (Figure 2.5). For electroporation, both WA-09 
(passage 31) and hES2 (passage 38) cells were briefly cultured with medium containing 10 
mM of a ROCK inhibitor then collected by trypsinization. 5 x 106 cells were electroporated 
with 40 µg of the targeting vector and cultured on DR4 MEFs in ROCK inhibitor-containing 
hES cell medium. Selection with neomycin sulfate (G418) began 48 – 72 hours post-
electroporation and was performed in two stages: 25 µg/ml G418 for four days followed by 
50 µg/ml for seven days. From the hES2 electroporation, 81 clones survived selection and 18 
GFP-positive clones were screened. Seven displayed positive recombination by PCR 
screening (clones 1A4, 1A5, 1B1, 1B3, 1A2, 1A3 and 1A6) and displayed GFP fluorescence 
(Figure 2.5). From the WA-09 electroporation, one clone survived selection and was 




Transition of human ES cells through definitive endoderm intermediate 
 Signaling through the TGFβ pathway is critical for the formation of the primitive 
streak, mesoderm and definitive endoderm in vertebrates (Brennan et al., 2001; Conlon et al., 






Figure 2.5  Gene targeting of Nanog in human ES cells. A) The targeting vector for 
Nanog, consisting of eGFP and a neomycin resistance gene flanked by loxP sites was 
inserted into the BAC at the Nanog start codon. Long (12.5 kb) and short (3.5 kb) homology 
arms facilitated homologous recombination resulting in the final allele which contained eGFP 
following the 5’ UTR along with a SV40-driven NeoR flanked by loxP sites. Abbreviations: 
bGL, rabbit beta-globin intron 2; eGFP, enhanced green fluorescent protein gene; LP, loxP; 
NeoR, neomycin resistance gene; pA, polyadenylation site; pSV40, SV40 promoter; Ex, 
exon; Ex1′, Ex2′, tuncated exon 1, 2. Figure from adapted from Fischer et al. (2010). B) 
Representative PCR screen revealing targeted (lane A, 5.1 kb) and wild type (lane B, 4.6 kb) 
alleles. The four clones noted in red were among the eight correctly targeted clones. C) 




Nodal, is essential for the induction of the definitive endoderm. Thus, given the critical role 
of TGFβ signaling in the specification of the definitive endoderm, the first stage of the 
directed pancreatic differentiation protocol stimulates hES cells with high levels of Activin 
A, a readily available stimulator of the TGFβ pathway that mimics Nodal activity in vitro 
(Figure 2.1). In addition to stimulating the cells with Activin A, Wnt3a improves the 
transition through the mesendoderm state. During the initial differentiation of the hES cells to 
definitive endoderm, it is critical to decrease serum supplementation. The presence of IGF or 
insulin in serum leads to elevated PI3K signaling which inhibits the differentiation of hES 
cells to DE (McLean et al., 2007).  
 The hES cell-derived definitive endoderm expresses transcripts indicative of its 
definitive endoderm like state, such as Sox17, Gsc and Cxcr4, as well as the primitive streak 
marker Mixl1 (Kanai-Azuma et al., 2002; McGrath et al., 1999; Yasunaga et al., 2005) 
(Figure 2.1 and 2.2). Furthermore, the anterior nature of the definitive endoderm was 
evident by the expression of Cer1 and Foxa2 (Figure 2.1 and 2.2) (Biben et al., 1998; Sasaki 
and Hogan, 1993). In addition to these endoderm markers, the TLDA design incorporated 19 
of the 22 endoderm signature panel genes which have been show to be preferentially 
expressed in E8.25 mouse definitive and visceral endoderm (Sherwood et al., 2007). These 
included Emb, Cacna1b, Cdcp1, Cldn8, Clic6, Npnt, Rab15, Ripk4, Spink1, Tmprss2, Foxa1, 
Tacstd1, Anxa4, Dsg2, Rbm35a, Sh3gl2, St14 and Bnipl (Table 2.1 and Figure 2.2). These 
genes were incorporated to further analyze the transition of the hES cells through the 




Transition of human ES cells through the primitive gut tube and posterior foregut 
intermediates 
During early pancreas development, it is well known that inhibition of hedgehog 
signaling is critical for the specification of gut tube endoderm (Kim and Melton, 1998; Lau et 
al., 2006). Additionally, signaling through members of the FGF family permit pancreatic 
endoderm proliferation and play a role in endoderm patterning (Bhushan et al., 2001; Hart et 
al., 2003; Jacquemin et al., 2006; Ye et al., 2005). The addition of FGF10, or FGF7, and 
cyclopamine, an inhibitor of Hedgehog signaling, induced formation of cells resembling the 
primitive gut tube endoderm and posterior foregut (Figure 2.1). The transition into a 
primitive gut tube-like state was evident by the expression of both Tcf2 (Hnf1b) and Hnf4a 
during the second stage of differentiation (Figure 2.2). During embryogenesis, the 
transcription factor Tcf2 (Hnf1b) is expressed throughout the primitive gut tube of the mouse 
at E8.0; subsequently, within 12 hours Hnf4a is similarly expressed (Barbacci et al., 1999; 
Coffinier et al., 1999; Duncan et al., 1994). This similar temporal expression pattern was seen 
during the directed differentiation of hES cells, as Hnf1b expression was evident by the fifth 
day of differentiation and Hnf4a expression peaked approximately one day later.  
In the next stage of differentiation, the gut tube endoderm-like cells are stimulated with 
retinoic acid, along with FGFs and cyclopamine, which plays a major role in formation of the 
pancreatic anlage (Stafford et al., 2004) (Figure 2.1). The exposure to retinoic acid induces 
the cells to transition into a state resembleing the posterior foregut endoderm; a number of 





Transition of human ES cells through an endocrine precursor intermediate and into 
hormone-positive cells 
 Following specification of the pancreatic endoderm from the posterior foregut 
endoderm, a subset of pancreatic endoderm cells are specified to the endocrine lineage. The 
inhibition of Notch signaling is a critical regulator of this stage and promotes the expression 
of the pre-endocrine marker Neurog3 (Wilson et al., 2003). Therefore, in the fourth stage of 
differentiation the γ-secretase inhibitor DAPT is included to inhibit signaling via the Notch 
pathway (Figure 2.1). Additionally, exendin-4, a GLP-1 agonist well known in its ability to 
stimulate insulin secretion and promote β cell replication and neogenesis, was added to 
promote the specification of the posterior foregut endoderm cells to the endocrine lineage 
(Brubaker and Drucker, 2004). The transition of the hES cells into cell resembling pancreatic 
endoderm was evident by the expression of not only Neurog3, but also Nkx2-2 (Figure 2.2).  
In the final stage of differentiation, the endocrine precursor cells are differentiated 
towards hormone-expressing fates. In addition to exendin-4, the cells are induced with IGF1 
and HGF to promote specification to hormone-expressing fates (Figure 2.1). At 
approximately 15 days of differentiation, the expression of various hormones, such as Insulin 
(Ins), Glucagon (Gcg), Ghrelin (Ghrl) and Somatostatin (Sst), became evident (Figure 2.2). 
When comparing Insulin expression from human islets to the Insulin levels seen in 
human ES cell-derived cells, we discovered that the efficiency of directed differentiation hES 
cells to Insulin-expressing cells is quite low. When compared to undifferentiated human ES 
cells, isolated human islets exhibited a 1.6x107 fold increase in Insulin expression and a 1.3 
x109 increase in Glucagon expression. Conversely, the human ES cell-derived endocrine cells 
display only a 308-fold and 55,392-fold increase in Insulin and Glucagon, respectively. 
These numbers represent only 0.0019% and 0.0042% of the Insulin and Glucagon expression 
levels, respectively, that are seen in endogenous human islets. The meager expression levels 
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induced in hES cell-derived cells further points to the need for more efficient differentiation 
protocols.  
 
Generation of a reporter allele for Pdx1 in human ES cells  
In order to effectively monitor the directed differentiation of hES cells to pancreatic 
fates, it would be advantageous to have fluorescently-tagged reporter alleles that would 
identify specific cell populations as cells transition through various developmental 
intermediates. To achieve this, we utilized hES cells that contained a loxed cassette acceptor 
(LCA) allele in the ROSA26 locus (Irion et al., 2007) (Figure 2.3). This allele contains a red 
fluorescent protein, tdRFP, flanked by loxP and lox2272/2372 sites which facilitate the 
exchange of DNA cassettes into the allele by Cre-recombinase. We generated an exchange 
vector for Pdx1 that used a 9.4 kb fragment of the upstream regulatory sequences of Pdx1, 
containing Areas I – IV and the 5’ UTR, to drive the expression of a nuclear-localized cyan 
fluorescent protein, Cerulean (Figure 2.4). A portion of the rabbit β-globin gene, containing 
both intronic and polyadenylation sequences, was placed downstream of the CFP coding 
sequences. Additionally, an FRT-flanked neomycin resistance (NeoR) gene was incorporated 
for positive selection during BAC recombineering and was followed by approximately 1.2 kb 
of Pdx1 sequences for exon 1 and intron. The exchange cassette was designed such that when 
exchanged into the ROSA26tdRFP allele the expression of the reporter would be transcribed in 
the opposite direction, thus minimizing the potential for the Pdx1CFP transgene to be 
transcribed from the ROSA26 promoter. RMCE into the ROSA26tdRFP allele was achieved by 
the co-electroporation of the exchange vector and a Cre-expression plasmid. Properly 
exchanged clones were identified through the use of a positive-negative selection strategy 
where the puroTK selection cassette permitted identification of positively exchanged clones, 
and clones not properly exchanged were excluded based on tdRFP fluorescence. 
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 The Pdx1CFP transgene permitted identification of hES cells that had differentiated 
towards posterior foregut and pancreatic endoderm-like fates. Following the directed 
differentiation ROSA26Pdx1-CFP hES cells according to a method similar to that described 
above, cyan fluorescence could be observed in the hES cell-derived pancreatic cells (Figure 
2.4). However, Pdx1CFP-expressing cells could not be isolated via fluorescence-activated cell 
sorting (FACS) due to limitations of excitation wavelengths available (discussed in Chapter 
V).  
 
Gene targeting in human ES cells 
While the ROSA26Pdx1-CFP allele permits the identification of hES cell-derived Pdx1-
expressing pancreatic progenitors, the derivation of targeted hES cell lines would be more 
advantageous than the generation of transgene reporters. The generation of a knockin allele is 
more advantageous over alternatives for generating fluorescent reporter lines, mainly because 
it more closely mimics endogenous gene expression without the confounding affects of 
random gene disruption or random integration. However, gene targeting has proven 
extremely challenging in hES cells and less robust than in mES cells. Since the initial report 
in 2003, a small number of publications have demonstrated successful gene targeting in hES 
cells (Costa et al., 2007; Davis et al., 2008; Fischer et al., 2010; Irion et al., 2007; Urbach et 
al., 2004; Zwaka and Thomson, 2003). Many limitations and obstacles prevent this method 
from fully recognizing its potential; however, improved methods and culture conditions are 
being developed and implemented. For instance, to increase the survival of dissociated hES 
cells, the addition of an inhibitor of p160-Rho-associated coiled-coil kinase (ROCK), Y-
27632, to the culture medium and has proven highly effective in reducing apoptosis and 
promoting hES cell colony survival (Watanabe et al., 2007).  
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To generate fluorescent reporter alleles in hES cells that would report the formation 
of pancreatic progenitors, we have generated a targeting vector for Pdx1. However, none of 
the targeting experiments yielded clones that underwent the desired homologous 
recombination event which may reflect chromosomal position effects (Yanez and Porter, 
2002). Due to the inefficiency experienced with gene targeting for Pdx1 and to validate the 
electroporation parameters, we obtained a targeting vector for Nanog, a homeodomain 
transcription factor that is critical for maintaining stem cell pluripotency. The NanogeGFP 
gene targeting vector contains both an eGFP reporter and selection cassette that, when 
correctly inserted into the Nanog locus by homologous recombination, will lie immediately 
5’ of the Nanog start codon (Fischer et al., 2010) (Figure 2.5). To test the hES cell targeting 
protocol, we electroporated this vector into WA-09 and hES2 human ES cells. The clones 
undergoing the desired homologous recombination event exhibited green fluorescence and 
were identified by PCR screening (Figure 2.5). We observed a targeting efficiency of 8.6%, 
which is slightly less than the reported 11.4% efficiency observed when targeting in hUES3 
cells but significantly better than the 0.6% efficiency observed when targeting in hUES1 cells 
(Fischer et al., 2010). While significant differences between mouse and human ES cells have 
limited the application of gene targeting in human ES cells, the targeting of Nanog 




 While progress has been made in understanding how to generate specific endocrine 
cell precursors, such as the definitive and foregut endoderm and pancreatic endocrine 
progenitors, the ability to differentiate hES cells to glucose-responsive insulin-producing cell 
fates, solely through in vitro differentiation, has yet to be achieved. Although insulin-
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expressing cells have been reported, the cells primarily resemble immature endocrine cells 
and respond poorly to glucose stimulation (D'Amour et al., 2006). While subsequent studies 
have shown that glucose-responsive insulin-producing cells can be generated following in 
vivo maturation of pancreatic progenitors, the cells contribute to teratoma formation, thus 
pointing out the critical need for either purification of transplantable progenitors or more 
efficient in vitro differentiation protocols (Kroon et al., 2008). To more efficiently direct the 
differentiation of hES cells towards β-like cell fates, a better understanding of the signaling 
mechanisms and the gene regulatory networks induced during in vivo pancreas development 
is needed so that it may be translated to hES cell directed pancreatic differentiation methods.  
 By applying fluorescence-activated cell sorting (FACS) and whole transcriptome 
sequencing, transcriptional profiles for hES cell-derived cell populations can be obtained and 
used to examine specific developmental stages of hES cell differentiation. These 
transcriptional profiles can also be used in combination with profiles obtained from in vivo 
isolated cell populations from the mouse (discussed in Chapter III) to determine how closely 
hES cell-derived intermediates mimic the transcriptional profiles of authentic cell 
populations. However, with comparisons such as this there are a number of concerns. First, it 
is unknown how closely the transcriptional profiles of mouse and human cells resemble one 
another. If the transcriptional profiles from in vivo isolated mouse and human cells are 
markedly different, then the comparison of in vivo isolated cells from the mouse and in vitro 
hES cell-derived cell populations will inevitably suffer from similar differences. Second, 
during in vitro differentiation, the expression profile for a given transcript can follow 
numerous patterns (i.e. expression can gradually increase followed by gradual decrease, 
expression can decrease over time, expression can increase over time and plateau, etc). Given 
this, the optimal time to isolate hES cell-derived intermediates and compare their 
transcriptional profile to in vivo isolated intermediates in the mouse is uncertain. The 
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developmental timing of hES cell differentiation protocols is still largely unknown, and most 
investigators simply transition to the next “stage” of differentiation following peak 
expression of a specific transcript, or in some cases multiple transcripts, that marks a key 
developmental stage (i.e. the peak expression of Pdx1 would indicate the end of 
differentiation to posterior foregut-like fate and the point to transition into new factors that 
promote endocrine progenitor differentiation). Thus, it is unknown if the optimal time to 
isolate specific cell populations is at the peak of a transcript’s expression or at another point 
during its expression pattern. However, regardless of the unknowns, the transcriptional 
comparison of hES cell-derived intermediates to bona fide cell populations will be critical for 
assessing the authenticity of the cellular intermediates that are generated during the directed 
differentiation of hES cells towards pancreatic fates.  
  While the study by Kroon et al. revealed the competence of hES cell-derived 
pancreatic endoderm to generate functional glucose-responsive insulin-producing cells 
following in vivo maturation, the study highlights a critical need for the purification of 
transplanted cells (Kroon et al., 2008). Although the transplanted cells primarily consisted of 
cells that resemble the pancreatic endoderm, the inefficiency of differentiation resulted in a 
heterogeneous population that gave rise to teratomas when transplanted into recipient mice. It 
is thought that purification of the hES cell-derived pancreatic endoderm-like cells will 
eliminate subsequent teratoma formation observed. Based on the gene expression profiles 
reported by Kroon et al., at the end of the fourth stage of differentiation, the point when the 
cells are isolated for transplantation, Pdx1 reaches its peak expression while Ptf1a and Nkx6-
1 are at the onset of expression (Kroon et al., 2008). Therefore, if Pdx1 is a key marker to 
identify the readiness of cells for transplant, a fluorescently-tagged Pdx1 allele would be 
useful for purifying the pancreatic endoderm-like cells following directed differentiation and 
addressing two critical issues. First, following transplantation of purified Pdx1-positive cells, 
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we would be able to assess whether or not the purification of transplantable cells eliminates 
the formation of teratomas in recipient mice. Additionally, we would be able to determine if 
Pdx1-positive cells, which represent the pancreatic endoderm-like cells, are solely 
responsible for the functional insulin-producing cells formed following in vivo maturation in 
recipient mice or if the formation is a result of other cells present in the heterogeneous 










The pancreas arises from dorsal and ventral evaginations of the foregut endoderm that 
first become evident around embryonic day (E) 9.5. These early multipotent progenitor cells 
(MPCs) can be distinguished from the surrounding mesenchyme and other foregut 
descendents by the expression of pancreas specific transcription factor 1a (Ptf1a, p48) 
(Burlison et al., 2008; Kawaguchi et al., 2002; Krapp et al., 1998; Roux et al., 1989; Zhou et 
al., 2007), a key component of both the early and late forms of the heterotrimeric PTF1 
complex. In addition to serving as a valuable lineage-specific marker, Ptf1a also plays a key 
role in pancreas development. Mice lacking Ptf1a fail to develop a mature pancreas due to the 
limited expansion of the pancreatic epithelium, thereby suggesting that Ptf1a plays an 
essential role in the proliferation and subsequent lineage specification of pancreatic MPCs to 
become endocrine, ductal, and acinar cells characterizing the mature pancreas (Kawaguchi et 
al., 2002; Krapp et al., 1998).  
Little is known about how the genetic network within pancreatic MPCs is established, 
how it changes during normal endocrine, acinar and ductal lineage specification events, and 
how it is altered in the absence critical regulatory factors, such as Ptf1a (Burlison et al., 2008; 
Kawaguchi et al., 2002; Krapp et al., 1998). An understanding of pancreatic MPC biology 
and the mechanisms that determine cell proliferation and fate specification, and particularly 
the role of Ptf1a in these processes, is important for multiple reasons. First, the number of 
pancreatic MPCs present early in development determines the final size of the pancreas 
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(Stanger et al., 2007). Second, the formation of pancreatic islets, which consist largely of 
insulin-secreting β cells, depends upon the orderly expansion of the MPC-containing, pre-
pancreatic epithelium. Indeed, while some endocrine cells are formed in the absence of Ptf1a, 
there is an insufficient mass of these cells generated to maintain glucose homeostasis in the 
adult (Fukuda et al., 2008; Kawaguchi et al., 2002). Third, an understanding of step-wise 
changes in gene expression that occur during pancreatic organogenesis is essential for 
learning how to mimic these processes during the directed differentiation of pluripotent stem 
cells to make new pancreatic β cells for therapeutic use.  
Several prior studies have explored the gene expression profile of pancreatic MPCs 
(Chiang and Melton, 2003; Gu et al., 2004; Svensson et al., 2007). These studies utilized 
early generation DNA microarrays and relied either on manual dissection methods or less 
than optimal genetic markers to obtain the target cell populations. Over recent years, 
technological advancements have occurred that enable the gene expression profiles of 
pancreatic MPCs to be more accurately determined. First, mice that express yellow 
fluorescent protein (YFP) under control of the Ptf1a gene locus were developed, thereby 
enabling fluorescence-activated cell sorting (FACS) to unambiguously isolate pancreatic 
progenitor cells (Burlison et al., 2008). Second, next-generation sequencing technologies 
have been developed that yield gene expression data based on the direct counting of 
transcripts, rather than hybridization, thereby providing results that have a far broader 
dynamic range than microarrays and allowing better detection of low abundance mRNAs 
(Marguerat and Bahler, 2010; Wang et al., 2009).  
Here, I describe my work that provides a new and highly detailed view of the gene 
expression profile of pancreatic MPCs. In these studies, we examined the effects of 
eliminating Ptf1a on gene expression during early pancreas development and have profiled 
temporal changes in gene expression as pancreatic MPCs adopt an acinar cell fate. These 
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datasets provide new insights into the dynamic alterations within pancreatic MPCs that are 
essential for several key aspects of pancreas development and provide valuable new 
molecular markers for gaining a deeper understanding of pancreatic MPCs and their biology.  
 
Materials and Methods 
 
Tissue isolation, embryonic genotyping, and flow cytometry 
Embryos were isolated from wild type CD-1 or Ptf1aYFP/+ females crossed with 
Ptf1aYFP/+ mice, where the presence of vaginal plug at noon was considered as E0.5. 
Fluorescence imaging was performed using a Leica MZ 16 FA stereoscope with a QImaging 
RETIGA 4000R camera. Heterozygous embryos were identified using a fluorescent 
microscope, and embryos obtained from heterozygous interbreeding were genotyped using 
the following two sets of custom-designed TaqMan primers and probes: 1) Ptf1aWT allele:  5’-
CGAATTGCCACGGATCACT, 5’-CCCGGAAGGACGAATGG and 6FAM-
ACAAAGCGTCACCCCGA-MGBNFQ, and 2) Ptf1aYFP allele: 5’-
GGGCACAAGCTGGAGTACAAC, 5’-TCTGCTTGTCGGCCATGA, and VIC-
ACAGCCACAACGTCT-MGBNFQ. Embryonic tissues were lysed with 10 mM Tris pH 
8.3, 100 mM KCl, 2.5 mM MgCl2, 4.5% Tween, and 0.4 mg of Proteinase K for 15 min at 
90°C. qPCR reactions used 1% of the genomic DNA per reaction with 800 nm forward and 
reverse primers and 200 nm probe in TaqMan Fast Universal PCR Mix (ABI). Analysis was 
performed using the ABI 7900HT.  
Midgut regions containing the dorsal and ventral pancreatic rudiments were dissected 
from Ptf1a+/+, Ptf1aYFP/+ or Ptf1aYFP/YFP embryos in cold phosphate buffered saline (PBS). 
Ptf1aYFP-expressing neural tubes were dissected for a FACS compensation control. Tissues 
were dissociated with Accumax (Sigma) at 37°C for up to 1.5 hours. The dissociation 
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reaction was quenched, and cells were triturated with FACS medium (L15 medium 
containing 1 mg/ml BSA, 10 mM HEPES pH 7.4, 1% penicillin/streptomycin, and 37.5 
ng/ml DNase I). Following filtration through a 35 µm cell strainer (BD Falcon) and 
centrifugation, cells were resuspended in FACS medium or FACS medium with 7-Amino-
Actinomycin D (7AAD; Invitrogen) to facilitate exclusion of nonviable cells.  
Flow cytometry experiments were performed in the VMC Flow Cytometry Shared 
Resource on a BD Aria I or II. YFP was excited with a 488 nm laser and emission detected 
with a 502LP and 530/30 bandpass filter. Gates were established using wild type midguts and 
Ptf1aYFP-expressing neural tubes. The YFP gate was set conservatively to minimize sorting 
cellular autofluorescence in the 500 – 600 nm spectral region. Experimental protocols were 
approved by the Vanderbilt Institutional Animal Care and Use Committee.  
 
RNA amplification, library construction, RNA-Sequencing and analysis  
Pools of 13, 9 or 5 pancreata were used to isolate Ptf1aYFP/+ cells at E11.5, 
Ptf1aYFP/YFP cells at E11.5 or Ptf1aYFP/+ cells at E15.5, respectively. Total RNA was isolated 
using TRIzol LS, DNase-treated, column-purified (Zymo) and assessed using an Agilent 
Bioanalyzer. RNA (0.5 – 10 ng) was amplified using the Ovation RNA-Seq system (NuGEN) 
which utilized Ribo-SPIA technology. The first step produced a cDNA/mRNA hybrid 
molecule. The mRNA within this complex is fragmented during the next step and allows for 
second strand synthesis and generation of a DNA/RNA heteroduplex double-stranded cDNA. 
Following SPIA amplification and post-SPIA modifications, the double-stranded cDNA was 
subjected to end repair using T4 DNA polymerase and Klenow polymerase. Klenow 3’ and 
5’ exopolymerase activity was used to incorporate a single ‘A’ base, followed by ligation 
with a mix of adaptor oligonucleotides using T4 DNA ligase. Size selection was performed 
on the adaptor-ligated library on a 2% agarose gel, excising the library smear of 
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approximately 200 bp. Ten to 15 cycles of ligation mediated PCR (LM-PCR) were used to 
amplify the ligated material in preparation for cluster generation. Following ligation mediated 
PCR (LM-PCR), the samples were purified and quantitated using the Agilent Bioanalyzer. 
The resulting cDNA libraries were used at a final concentration of 2 – 4 pM to achieve a 
cluster density of approximately 160,000 clusters per tile and were analyzed as 36 nucleotide 
(nt) or greater reads as single-end tags on a Solexa/Illumina Genome Analyzer II. The 
Illumina pipeline (v1.4.0) was used for image analysis and base calling. Reads were mapped 
to mm9 genome with Bowtie (v0.11.3) (Langmead et al., 2009). Expression was quantified as 
reads per kilobase of exon model per million mapped reads (RPKM) (Mortazavi et al., 2008) 
using a custom Perl script (Table 3.1). Gene Ontology analysis was performed using 
PANTHER (v6.1) (Thomas et al., 2003). Differentially expressed transcripts were identified 
as those displaying a 5-fold change in RPKM and ≥ 25 reads in one sample.  
 
Quantitative reverse transcription PCR (qRT-PCR) validation  
Customized 384- and 96-target TaqMan Low Density Arrays (TLDAs) were 
purchased from Applied Biosystems (ABI) containing the gene specific primers and probes 
listed in Table 3.2. The first phase of qRT-PCR was used as a preliminary platform to 
examine gene expression. Amplified RNA (WT-Ovation Pico, NuGEN) was analyzed as a 
single replicate from pooled embryos. 100 ng cDNA was loaded per port, and PCR 
amplification was performed using an ABI 7900HT. Transcripts for the 384-target TLDA 
were chosen based on the following criteria: 1) displayed at least a 10-fold difference in 
expression by RPKM value either between the Ptf1aYFP/+ cells at E11.5 and E15.5 or the 
Ptf1aYFP/YFP and Ptf1aYFP/+ cells at E11.5, 2) belonged to the following molecular functions: 
transcription factors, receptors, signaling molecules, proteases, protein phosphatases, or 




Table 3.1 Summary of RNA-Seq results 








Ptf1aYFP/+ 1 145,281 13,094,931 11,527,374 7,639,627 3,887,747 88.03% 
 2 166,258 15,086,822 13,728,633 8,832,758 4,895,875 91.00% 
 3 180,267 18,537,850 17,134,442 11,469,961 5,664,481 92.43% 
   46,719,603 42,390,449 27,942,346 14,448,103 90.49% 
        
E11.5 
Ptf1aYFP/YFP 1 107,399 9,668,230 8,053,904 5,434,532 2,619,372 83.30% 
 2 149,220 13,427,730 11,427,043 7,570,072 3,856,971 85.10% 
 3 156,355 15,828,875 14,109,808 9,380,331 4,729,477 89.14% 
   38,924,835 33,590,755 22,384,935 11,205,820 85.85% 
        
E15.5 
Ptf1aYFP/+ 1 121,738 11,033,718 9,584,948 5,804,116 3,780,832 86.87% 
 2 168,329 15,223,528 13,931,260 8,032,988 5,898,272 91.51% 
 3 180,626 18,309,790 17,029,893 10,189,780 6,840,113 93.01% 
   44,567,036 40,546,101 24,026,884 16,519,217 90.46% 
        




The second phase assessed expression across biological replicates (n ≥ 3), and only 
RNAs from the Ptf1aYFP/+ cells at E10.5 and Ptf1aYFP/YFP cells at E11.5 were amplified (WT-
Ovation Pico, NuGEN). Genes were selected for the second phase of qRT-PCR using the 
following criteria: 1) absolute Ct value of < 35 in at least one sample and 2) the qRT-PCR 
profiles were consistent with RNA-Seq data. Additional filtering based on hierarchical 
clustering, Gene Ontology analysis and NCBI gene reports, led to the selection of 94 genes. 
RNA was reverse transcribed using the High Capacity cDNA Archive kit (ABI).  
Genes with a Ct < 40 were normalized to Gapdh to obtain 2-ΔCt values. Values were 
set to 0 (no expression) for genes with Ct = 40. Clustering was performed with input as the 
mean expression value across biological replicates for each condition. The GenePattern 
Hierarchical Clustering module (version 2.0) was employed with Pearson correlation as 
similarity measure and average-linkage as agglomeration method. Results were visualized 
with the GenePattern Hierarchical Clustering Viewer module using the relative display mode 
where colors are scaled as a function of the number of standard deviations relative to the 
mean of each row (darkest blue = -3 and brightest red = +3). To avoid distributional 
assumptions, statistical significance was determined using a permutation test ((Ewens and 
Grant, 2004) section 3.8.1) implemented with a custom Java script. Differential expression 
analysis comparing Ptf1aYFP/YFP cells and Ptf1aYFP/+ cells at E11.5 and Ptf1aYFP/+ cells at 
E15.5 and E11.5 was performed with input as the expression values for the available 
biological replicates.  
Meta-data and processed data for both the RNA-Seq and qRT-PCR, as well as qRT-
PCR raw data are available at http://genomics.betacell.org and www.cbil.upenn.edu/RAD. 
The RNA-Seq component has been deposited at ArrayExpress (accession number E-MTAB-
449) and the Sequence Read Archive (accession number ERP000419).  
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Table 3.2 Summary of transcripts profiled on 384- and 96-format TLDAs. Transcripts 
noted in red are profiled on both the 384- and 96-format TLDA while transcripts in black are 




SYMBOL GENE NAME ASSAY ID 
1 18S Eukaryotic 18S rRNA Hs99999901_s1 
2 2210010C04Rik RIKEN cDNA 2210010C04 gene;2210010C04Rik Mm00834916_m1 
3 2310046K01Rik RIKEN cDNA 2310046K01 gene;2310046K01Rik Mm00510189_m1 
4 9630041N07Rik zinc figer protein 879 Mm00557697_m1 
5 A430110N23Rik RIKEN cDNA A430110N23 gene;A430110N23Rik Mm00557123_m1 
6 Ace2 angiotensin I converting enzyme (peptidyl-dipeptidase A) 2;Ace2 Mm01159003_m1 
7 ACTB actin, beta Mm01205647_g1 
8 Acy3 aspartoacylase (aminoacylase) 3;Acy3 Mm00503584_m1 
9 Adam33 a disintegrin and metallopeptidase domain 33;Adam33 Mm00459691_m1 
10 Adamts2 
a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin 
type 1 motif, 2;Adamts2 Mm00805170_m1 
11 Adipoq adiponectin, C1Q and collagen domain containing;Adipoq Mm00456425_m1 
12 Adora1 adenosine A1 receptor;Adora1 Mm01308023_m1 
13 Adora2a adenosine A2a receptor;Adora2a Mm00802075_m1 
14 Adra2a adrenergic receptor, alpha 2a;Adra2a Mm00845383_s1 
15 Ager advanced glycosylation end product-specific receptor;Ager Mm00545815_m1 
16 Agtr1b angiotensin II receptor, type 1b;Agtr1b Mm01701115_m1 
17 AI854703 expressed sequence AI854703;AI854703 Mm00624982_m1 
18 Amac1 acyl-malonyl condensing enzyme 1;Amac1 Mm00840143_g1 
19 Amy1 amylase 1, salivary Mm00651524_m1 
20 Amy2 amylase 2a5, pancreatic Mm02342487_g1 
21 Angptl3 angiopoietin-like 3;Angptl3 Mm00803820_m1 
22 Angptl4 angiopoietin-like 4;Angptl4 Mm00480431_m1 
23 Arhgdig Rho GDP dissociation inhibitor (GDI) gamma;Arhgdig Mm00801450_m1 
24 Arid5a AT rich interactive domain 5A (Mrf1 like);Arid5a Mm00524454_m1 
25 Arx SUMO1 activating enzyme subunit 2;Sae2 Mm00545903_m1 
26 Asgr2 asialoglycoprotein receptor 2;Asgr2 Mm00431863_m1 
27 Barhl1 BarH-like 1 (Drosophila);Barhl1 Mm00479842_m1 
28 Bgn biglycan;Bgn Mm00455918_m1 
29 Bhlhe40 basic helix-loop-helix family, member e40 Mm00478593_m1 
30 Bmp2 bone morphogenetic protein 2;Bmp2 Mm01340178_m1 
31 Bmpr1b bone morphogenetic protein receptor, type 1B;Bmpr1b Mm00432117_m1 
32 Bnc1 amiloride-sensitive cation channel 1, neuronal (degenerin);Accn1 Mm01324337_m1 
33 Calcr calcitonin receptor;Calcr Mm00432271_m1 
34 Casr calcium-sensing receptor;Casr Mm00443375_m1 
35 Cbln3 cerebellin 3 precursor protein;Cbln3 Mm00490772_g1 
36 Cck cholecystokinin;Cck Mm00446170_m1 
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37 Cckar cholecystokinin A receptor;Cckar Mm00438060_m1 
38 Ccl5 chemokine (C-C motif) ligand 5;Ccl5 Mm01302428_m1 
39 Ccl6 chemokine (C-C motif) ligand 6;Ccl6 Mm01302419_m1 
40 Ccr4 chemokine (C-C motif) receptor 4;Ccr4 Mm00438271_m1 
41 Cd180 CD180 antigen;Cd180 Mm00434804_m1 
42 Cd2 CD2 antigen;Cd2 Mm00488928_m1 
43 Cd300a CD300A antigen;Cd300a Mm00468054_m1 
44 Cd36 scavenger receptor class B, member 1;Scarb1 Mm01135198_m1 
45 Cd37 CD37 antigen;Cd37 Mm00514240_m1 
46 Cd3e CD3 antigen, epsilon polypeptide;Cd3e Mm00599683_m1 
47 Cd5 CD5 antigen;Cd5 Mm00432417_m1 
48 Cd93 CD93 antigen;Cd93 Mm00440239_g1 
49 Cdx2 caudal type homeo box 2;Cdx2 Mm00432449_m1 
50 Cela1/Ela1 elastase 1, pancreatic;Ela1 Mm00712898_m1 
51 Cela3b/Ela3b elastase 3, pancreatic;Ela3 Mm00840378_m1 
52 Chgb chromogranin B;Chgb Mm00483287_m1 
53 Chrm1 cholinergic receptor, muscarinic 1, CNS;Chrm1 Mm00432509_s1 
54 Chrna3 cholinergic receptor, nicotinic, alpha polypeptide 3;Chrna3 Mm00520145_m1 
55 Chrna9 cholinergic receptor, nicotinic, alpha polypeptide 9;Chrna9 Mm01221611_m1 
56 Chrnb1 cholinergic receptor, nicotinic, beta polypeptide 1 (muscle);Chrnb1 Mm00680412_m1 
57 Clec2d C-type lectin domain family 2, member d;Clec2d Mm00474134_m1 
58 Cnr2 protocadherin alpha 6;Pcdha6 Mm00438286_m1 
59 Cpa1 carboxypeptidase A1;Cpa1 Mm00465942_m1 
60 Cpb1 carboxypeptidase B1 (tissue);Cpb1 Mm01289391_m1 
61 Creb3 cAMP responsive element binding protein 3;Creb3 Mm00457268_m1 
62 Creb3l4 cAMP responsive element binding protein 3-like 4;Creb3l4 Mm00518698_m1 
63 Crhr2 corticotropin releasing hormone receptor 2;Crhr2 Mm00438303_m1 
64 Crlf2 cytokine receptor-like factor 3;Crlf3 Mm00497362_m1 
65 Ctgf connective tissue growth factor;Ctgf Mm01192931_g1 
66 Ctrb1 chymotrypsinogen B1;Ctrb1 Mm00481616_m1 
67 Cx3cl1 chemokine (C-X3-C motif) ligand 1;Cx3cl1 Mm00436454_m1 
68 Cx3cr1 chemokine (C-X3-C) receptor 1 Mm00438354_m1 
69 Cxcl1 chemokine (C-X-C motif) ligand 1;Cxcl1 Mm00433859_m1 
70 Cxcl16 chemokine (C-X-C motif) ligand 16;Cxcl16 Mm00469712_m1 
71 Cxcr5 Burkitt lymphoma receptor 1;Blr1 Mm00432086_m1 
72 Cxcr6 chemokine (C-X-C motif) receptor 6;Cxcr6 Mm00472858_m1 
73 Cysltr2 cysteinyl leukotriene receptor 2;Cysltr2 Mm02620584_s1 
74 Dll3 delta-like 3 (Drosophila);Dll3 Mm00432854_m1 
75 Dtx3 deltex 3 homolog (Drosophila);Dtx3 Mm00472859_m1 
76 E2f2 E2F transcription factor 2;E2f2 Mm00624964_m1 
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77 Edn3 endothelin 3;Edn3 Mm00432986_m1 
78 Ednra endothelin receptor type A;Ednra Mm01243722_m1 
79 Efna2 ephrin A2;Efna2 Mm00433011_m1 
80 Efna3 ephrin A3;Efna3 Mm01212723_g1 
81 Efna4 ephrin A4;Efna4 Mm00433013_m1 
82 Efnb3 ephrin B3 Mm00433016_m1 
83 Egfr epidermal growth factor receptor;Egfr Mm01187858_m1 
84 Ephb3 Eph receptor B3 Mm00802553_m1 
85 Ephb6 Eph receptor B6;Ephb6 Mm00432456_m1 
86 Etv4 ets variant gene 4 (E1A enhancer binding protein, E1AF);Etv4 Mm00476696_m1 
87 F12 coagulation factor XII (Hageman factor);F12 Mm00491349_m1 
88 F2rl3 coagulation factor II (thrombin) receptor-like 3;F2rl3 Mm00433161_g1 
89 Fas fatty acid synthase;Fasn Mm00433237_m1 
90 Fbln2 fibulin 2 Mm00484266_m1 
91 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide;Fcer2a Mm00442792_m1 
92 Fcgrt Fc receptor, IgG, alpha chain transporter;Fcgrt Mm00438887_m1 
93 Fcrl1 Fc receptor-like A;Fcrl Mm00462105_m1 
94 Fev FEV (ETS oncogene family);Fev Mm00462220_m1 
95 Ffar2 free fatty acid receptor 2;Ffar2 Mm01175249_g1 
96 Fga fibrinogen, alpha polypeptide;Fga Mm00802584_m1 
97 Fgb fibrinogen, B beta polypeptide;Fgb Mm00805336_m1 
98 Fgf16 fibroblast growth factor 16;Fgf16 Mm00651404_m1 
99 Fgf17 fibroblast growth factor 17;Fgf17 Mm00433282_m1 
100 Fgf23 fibroblast growth factor 23;Fgf23 Mm00445621_m1 
101 Fgg fibrinogen, gamma polypeptide;Fgg Mm00513575_m1 
102 Fhl5 Muscle development Mm00480451_m1 
103 Fosl1 fos-like antigen 1;Fosl1 Mm00487429_m1 
104 Gabra4 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 4;Gabra4 Mm00802631_m1 
105 Gabra5 gamma-aminobutyric acid (GABA-A) receptor, subunit alpha 5;Gabra5 Mm00621092_m1 
106 Gabrb3 gamma-aminobutyric acid (GABA-A) receptor, subunit beta 3;Gabrb3 Mm00433473_m1 
107 GAPDH glyceraldehyde-3-phosphate dehydrogenase Mm99999915_g1 
108 Gast gastrin;Gast Mm00772211_g1 
109 Gata1 GATA binding protein 1;Gata1 Mm01352636_m1 
110 Gata3 GATA binding protein 3;Gata3 Mm00484683_m1 
111 Gbx1 gastrulation brain homeobox 1;Gbx1 Mm00803826_m1 
112 Gcg glucagon;Gcg Mm00801714_m1 
113 Gcgr glucagon receptor;Gcgr Mm00433546_m1 
114 Gdap1 ganglioside-induced differentiation-associated-protein 1;Gdap1 Mm00494579_m1 
115 Gdap1l1 ganglioside-induced differentiation-associated protein 1-like 1;Gdap1l1 Mm00523187_m1 
116 Gdf7 growth differentiation factor 7;Gdf7 Mm00807130_m1 
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117 Gdf9 growth differentiation factor 9;Gdf9 Mm00433565_m1 
118 Gdnf glial cell line derived neurotrophic factor;Gdnf Mm00599849_m1 
119 Gfi1 growth factor independent 1;Gfi1 Mm00515855_m1 
120 Ghrh growth hormone releasing hormone;Ghrh Mm00439100_m1 
121 Gip gastric inhibitory polypeptide Mm00433601_m1 
122 Gipr gastric inhibitory polypeptide receptor;Gipr Mm01316351_g1 
123 Glra1 glycine receptor, alpha 1 subunit;Glra1 Mm00445063_m1 
124 Gnrhr gonadotropin releasing hormone receptor;Gnrhr Mm00439143_m1 
125 Gp5 glycoprotein 5 (platelet);Gp5 Mm00515021_s1 
126 Gpr1 G protein-coupled receptor 1;Gpr1 Mm00461557_m1 
127 Gpr142 G protein-coupled receptor 142;Gpr142 Mm00725194_m1 
128 Gpr157 G protein-coupled receptor 157;Gpr157 Mm00616683_m1 
129 Gpr3 G-protein coupled receptor 3;Gpr3 Mm00433719_s1 
130 Gpr37l1 G protein-coupled receptor 37-like 1;Gpr37l1 Mm00661872_m1 
131 Gpr84 G protein-coupled receptor 84;Gpr84 Mm00518921_m1 
132 Gpr98 G protein-coupled receptor 98;Gpr98 Mm00475232_m1 
133 Gria2 Gria2 glutamate receptor, ionotropic, AMPA2 (alpha 2) Mm00442822_m1 
134 Gria3 glutamate receptor, ionotropic, AMPA3 (alpha 3);Gria3 Mm00497506_m1 
135 Grin2c glutamate receptor, ionotropic, NMDA2C (epsilon 3);Grin2c Mm00439180_m1 
136 Grm2 G protein-coupled receptor, family C, group 1, member B;Grm2 Mm01235831_m1 
137 Guca2a guanylate cyclase activator 2a (guanylin);Guca2a Mm00433863_m1 
138 GUSB glucuronidase, beta Mm00446953_m1 
139 Hcrtr1 hypocretin (orexin) receptor 1;Hcrtr1 Mm01185776_m1 
140 Hes3 hairy and enhancer of split 3 (Drosophila);Hes3 Mm00468603_m1 
141 Hey1 hairy/enhancer-of-split related with YRPW motif 1;Hey1 Mm00468865_m1 
142 Heyl hairy/enhancer-of-split related with YRPW motif-like;Heyl Mm00516555_m1 
143 Hoxa1 homeo box A1;Hoxa1 Mm00439359_m1 
144 Hoxc4 homeo box C4;Hoxc4 Mm00442838_m1 
145 HPRT hypoxanthine guanine phosphoribosyl transferase 1 Mm01324427_m1 
146 Hr hairless Mm00498963_m1 
147 Hrh4 histamine H4 receptor;Hrh4 Mm00467633_m1 
148 Hsf4 heat shock transcription factor 4;Hsf4 Mm00442428_m1 
149 Icam2 intercellular adhesion molecule 2;Icam2 Mm00494862_m1 
150 Ifi204 interferon activated gene 204;Ifi204 Mm00492602_m1 
151 Igf1 insulin-like growth factor 1;Igf1 Mm00439560_m1 
152 Il17b interleukin 17B;Il17b Mm00444686_m1 
153 Il17f interleukin 17F;Il17f Mm00521423_m1 
154 Il1r2 Cytokine and chemokine mediated signaling pathway Mm00439622_m1 
155 Il22ra1 interleukin 22 receptor, alpha 1;Il22ra1 Mm00663697_m1 
156 Il27ra interleukin 27 receptor, alpha;Il27ra Mm00497259_m1 
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157 Il2rg interleukin 2 receptor, gamma chain;Il2rg Mm00442885_m1 
158 Il3ra interleukin 3 receptor, alpha chain;Il3ra Mm00434273_m1 
159 Insl6 insulin-like 6;Insl6 Mm01964671_s1 
160 Insm1 insulinoma-associated 1 Mm02581025_s1 
161 Insrr insulin receptor-related receptor;Insrr Mm00442243_m1 
162 Irf5 interferon regulatory factor 5;Irf5 Mm00496477_m1 
163 Irx1 Iroquois related homeobox 1 (Drosophila);Irx1 Mm01352526_m1 
164 Irx2 Iroquois related homeobox 2 (Drosophila);Irx2 Mm01340315_m1 
165 Isl1 ISL1 transcription factor, LIM/homeodomain;Isl1 Mm00627860_m1 
166 Isx intestine specific homeobox;Isx Mm01243745_m1 
167 Itgb8 integrin beta 8;Itgb8 Mm00623991_m1 
168 Kir3dl2 
killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 
2;Kir3dl2 Mm00844610_s1 
169 Kiss1r KISS1 receptor;Kiss1r Mm00475046_m1 
170 Klf15 Kruppel-like factor 15;Klf15 Mm00517792_m1 
171 Klf2 Kruppel-like factor 2 (lung);Klf2 Mm00500486_g1 
172 Klhdc8a kelch domain containing 8A;Klhdc8a Mm00522717_m1 
173 Klk1 kallikrein 1;Klk1 Mm00834006_g1 
174 Klk1b24 kallikrein 1-related peptidase b24;Klk1b24 Mm00658591_g1 
175 Klk1b27 kallikrein 1-related peptidase b27;Klk1b27 Mm00834759_gH 
176 Klk1b3 kallikrein 1-related peptidase b3;Klk1b3 Mm01203825_gH 
177 Klk1b5 kallikrein 1-related peptidase b5;Klk1b5 Mm00833453_g1 
178 Klk1b8 kallikrein 1-related peptidase b8;Klk1b8 Mm00776302_g1 
179 Lair1 leukocyte-associated Ig-like receptor 1;Lair1 Mm00618113_m1 
180 Ldb3 LIM domain binding 3 Mm00522021_m1 
181 Lect2 leukocyte cell-derived chemotaxin 2;Lect2 Mm00521920_m1 
182 Lgals9 lectin, galactose binding, soluble 9;Lgals9 Mm00495295_m1 
183 Lgi3 leucine-rich repeat LGI family, member 3;Lgi3 Mm00507490_m1 
184 Lhx1 LIM homeobox protein 1;Lhx1 Mm00521776_m1 
185 Lhx3 LIM homeobox protein 3;Lhx3 Mm01333633_m1 
186 Lhx4 LIM homeobox protein 4;Lhx4 Mm00521928_m1 
187 Lhx5 LIM homeobox protein 5;Lhx5 Mm00521778_m1 
188 Lilrb3 
leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM 
domains), member 3;Lilrb3 Mm01700366_m1 
189 Lin28 lin-28 homolog (C. elegans);Lin28 Mm00524077_m1 
190 Loxl2 lysyl oxidase-like 2;Loxl2 Mm00804740_m1 
191 Loxl4 lysyl oxidase-like 4;Loxl4 Mm00446385_m1 
192 Lrfn3 leucine rich repeat and fibronectin type III domain containing 3 Mm00615455_m1 
193 Lrp1 low density lipoprotein receptor-related protein 1;Lrp1 Mm00464608_m1 
194 Lrrc3b leucine rich repeat containing 3B;Lrrc3b Mm00524764_m1 
195 Lrrtm1 leucine rich repeat transmembrane neuronal 1;Lrrtm1 Mm00551337_g1 
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196 Lrrtm3 leucine rich repeat transmembrane neuronal 3;Lrrtm3 Mm00618457_m1 
197 Lsp1 lymphocyte specific 1;Lsp1 Mm00497788_m1 
198 Ltk leukocyte tyrosine kinase;Ltk Mm00434790_m1 
199 Mafb 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B 
(avian);Mafb Mm00627481_s1 
200 Mds1 myelodysplasia syndrome 1 homolog (human);Mds1 Mm00491303_m1 
201 Mef2c myocyte enhancer factor 2C;Mef2c Mm01340839_m1 
202 Meox1 mesenchyme homeobox 1;Meox1 Mm00440285_m1 
203 Mip major intrinsic protein of eye lens fiber;Mip Mm00434949_m1 
204 Mixl1 Mix1 homeobox-like 1 (Xenopus laevis);Mixl1 Mm00489085_m1 
205 Mlf1 myeloid leukemia factor 1;Mlf1 Mm00440290_m1 
206 Mmp2 matrix metallopeptidase 2;Mmp2 Mm00439506_m1 
207 Mpl myeloproliferative leukemia virus oncogene;Mpl Mm00440310_m1 
208 Msx1 homeo box, msh-like 1;Msx1 Mm00440330_m1 
209 Mt1 metallothionein 1;Mt1 Mm00496660_g1 
210 Mt2 metallothionein 2;Mt2 Mm00809556_s1 
211 Myoc myocilin;Myoc Mm00447900_m1 
212 Myt1 myelin transcription factor 1;Myt1 Mm00456190_m1 
213 Necab2 EF hand calcium binding protein 2;Efcbp2 Mm00475387_m1 
214 Nepn nephrocan;Nepn Mm00481816_m1 
215 Neurod1 neurogenic differentiation 1 Mm01280117_m1 
216 Neurog2 neurogenin 2;Neurog2 Mm00437603_g1 
217 Neurog3 neurogenin 3;Neurog3 Mm00437606_s1 
218 Nfkb2 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, 
p49/p100;Nfkb2 Mm00479807_m1 
219 Nhlh1 nescient helix loop helix 1;Nhlh1 Mm00440478_m1 
220 Nkx6-3 NK6 transcription factor related, locus 3 (Drosophila);Nkx6-3 Mm01211932_g1 
221 Nlgn3 neuroligin 3;Nlgn3 Mm00556834_m1 
222 Nodal nodal;Nodal Mm00443040_m1 
223 Notch3 Notch gene homolog 3 (Drosophila);Notch3 Mm00435270_m1 
224 Nr1h3 nuclear receptor subfamily 1, group H, member 3;Nr1h3 Mm00443454_m1 
225 Nr1h4 nuclear receptor subfamily 1, group H, member 4;Nr1h4 Mm00436419_m1 
226 Nr1h5 nuclear receptor subfamily 1, group H, member 5;Nr1h5 Mm01308716_m1 
227 Nr2e1 nuclear receptor subfamily 2, group E, member 1 Mm00455855_m1 
228 Nr2f1 nuclear receptor subfamily 2, group F, member 1;Nr2f1 Mm00657937_m1 
229 Nr4a1 nuclear receptor subfamily 4, group A, member 1;Nr4a1 Mm01300401_m1 
230 Nr4a3 nuclear receptor subfamily 4, group A, member 3;Nr4a3 Mm00450074_m1 
231 Nr5a1 nuclear receptor subfamily 5, group A, member 1;Nr5a1 Mm00446826_m1 
232 Nrl neural retina leucine zipper gene;Nrl Mm00476550_m1 
233 Nrp2 neuropilin 2;Nrp2 Mm00803099_m1 
234 Nrtn neurturin;Nrtn Mm00435387_m1 
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235 Ntf3 neurotrophin 3;Ntf3 Mm01182924_m1 
236 Ntsr2 neurotensin receptor 2;Ntsr2 Mm00435426_m1 
237 Nxph1 neurexophilin 1;Nxph1 Mm01165166_m1 
238 Nxph2 neurexophilin 2;Nxph2 Mm00801892_m1 
239 Nxph4 neurexophilin 4;Nxph4 Mm00806440_m1 
240 Olfm2 olfactomedin 2;Olfm2 Mm00620619_m1 
241 Olfml3 olfactomedin-like 3;Olfml3 Mm00513567_m1 
242 Olfr267 olfactory receptor 267;Olfr267 Mm00528927_s1 
243 Onecut2 one cut domain, family member 2;Onecut2 Mm00815708_s1 
244 Onecut3 one cut domain, family member 3;Onecut3 Mm00653012_m1 
245 Oprl1 opioid receptor-like 1;Oprl1 Mm00440563_m1 
246 P2rx1 purinergic receptor P2X, ligand-gated ion channel, 1;P2rx1 Mm00435460_m1 
247 P2ry1 purinergic receptor P2Y, G-protein coupled 1;P2ry1 Mm00435471_m1 
248 Pax2 paired box gene 2;Pax2 Mm01217939_m1 
249 Pax6 paired box gene 6;Pax6 Mm00443081_m1 
250 Pbx4 pre-B-cell leukemia transcription factor 4;Pbx4 Mm00453088_m1 
251 Pecam1 platelet/endothelial cell adhesion molecule 1;Pecam1 Mm00476702_m1 
252 Penk1 preproenkephalin 1;Penk1 Mm01212875_m1 
253 Pf4 chemokine (C-X-C motif) ligand 4;Cxcl4 Mm00451315_g1 
254 Pgp ATP-binding cassette, sub-family B (MDR/TAP), member 1A;Abcb1a Mm00546522_g1 
255 Phf1 PHD finger protein 1;Phf1 Mm00493478_m1 
256 Pira2 paired-Ig-like receptor A2;Pira2 Mm02768273_g1 
257 Pitx2 paired-like homeodomain transcription factor 2;Pitx2 Mm00440826_m1 
258 Plg plasminogen;Plg Mm00447087_m1 
259 Plxnc1 plexin C1;Plxnc1 Mm00450687_m1 
260 Plxnd1 plexin D1;Plxnd1 Mm01184367_m1 
261 Pnliprp1 pancreatic lipase related protein 1 Mm00479741_m1 
262 Podnl1 podocan-like 1;Podnl1 Mm01247693_m1 
263 Pou1f1 
POU domain, class 1, transcription factor 1 (Pit1, growth hormone factor 
1);Pou1f1 Mm00476852_m1 
264 Pou3f4 POU domain, class 3, transcription factor 4;Pou3f4 Mm00447171_s1 
265 Pou6f2 POU domain, class 6, transcription factor 2;Pou6f2 Mm00558158_m1 
266 Ppara peroxisome proliferator activated receptor alpha Mm00440939_m1 
267 Ppbp chemokine (C-X-C motif) ligand 7;Cxcl7 Mm00470163_m1 
268 Ppp1r1a protein phosphatase 1, regulatory (inhibitor) subunit 1A;Ppp1r1a Mm00451727_m1 
269 Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B;Ppp1r1b Mm00454892_m1 
270 Prdm12 PR domain containing 12;Prdm12 Mm01324476_m1 
271 Prdm14 PR domain containing 14;Prdm14 Mm01237814_m1 
272 Procr protein C receptor, endothelial;Procr Mm00440992_m1 
273 Prok1 prokineticin 2;Prok2 Mm01204733_m1 
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274 Prokr1 prokineticin receptor 1;Prokr1 Mm00517546_m1 
275 Prph2 peripherin 2;Prph2 Mm00435972_m1 
276 Prss16 protease, serine, 16 (thymus);Prss16 Mm00457601_m1 
277 Prss2 protease, serine, 2;Prss2 Mm00657001_m1 
278 Prss27 protease, serine 27;Prss27 Mm00841353_g1 
279 Psmb9 
proteosome (prosome, macropain) subunit, beta type 9 (large multifunctional 
peptidase 2);Psmb9 Mm00479004_m1 
280 Ptafr platelet-activating factor receptor;Ptafr Mm02621061_m1 
281 Ptf1a pancreas specific transcription factor, 1a Mm00479622_m1 
282 Ptger4 prostaglandin E receptor 4 (subtype EP4);Ptger4 Mm00436053_m1 
283 Ptgir prostaglandin I receptor (IP);Ptgir Mm00801939_m1 
284 Pth1r parathyroid hormone receptor 1;Pthr1 Mm00441046_m1 
285 Pyy peptide YY;Pyy Mm00520715_m1 
286 Rarg retinoic acid receptor, gamma;Rarg Mm00441091_m1 
287 Rasgrp4 RAS guanyl releasing protein 4;Rasgrp4 Mm00460898_m1 
288 Rbp1 retinol binding protein 1, cellular;Rbp1 Mm00441119_m1 
289 Rbpj recombination signal binding protein for immunoglobulin kappa J region Mm03053645_s1 
290 Rbpjl recombination signal binding protein for immunoglobulin kappa J region-like Mm00485631_m1 
291 Reep2 receptor accessory protein 2;Reep2 Mm00523031_m1 
292 Reep5 receptor accessory protein 5;Reep5 Mm00492230_m1 
293 Reg1 regenerating islet-derived 1;Reg1 Mm00485651_m1 
294 Relt tumor necrosis factor receptor superfamily, member 19-like;Tnfrsf19l Mm00723872_m1 
295 Ren1 renin 1 structural;Ren1 Mm02342889_g1 
296 Ret ret proto-oncogene;Ret Mm00436304_m1 
297 Rln1 relaxin 1;Rln1 Mm01208503_m1 
298 Rnase1 ribonuclease, RNase A family, 1 (pancreatic) Mm00726747_s1 
299 Robo2 roundabout homolog 2 (Drosophila);Robo2 Mm00620713_m1 
300 Ror1 RAR-related orphan receptor alpha;Rora Mm00443462_m1 
301 Rorc RAR-related orphan receptor gamma;Rorc Mm01261022_m1 
302 Rtn4r reticulon 4 receptor;Rtn4r Mm00452228_m1 
303 Rtn4rl2 reticulon 4 receptor-like 2;Rtn4rl2 Mm01336368_g1 
304 Rxfp4 relaxin family peptide receptor 4;Rxfp4 Mm00731536_s1 
305 Rxrg retinoid X receptor gamma;Rxrg Mm00436410_m1 
306 Sag ring finger protein 7;Rnf7 Mm00485903_m1 
307 Sall1 sal-like 1 (Drosophila);Sall1 Mm00491266_m1 
308 Sall4 sal-like 4 (Drosophila);Sall4 Mm01240680_m1 
309 Scarf1 scavenger receptor class F, member 1;Scarf1 Mm00464144_m1 
310 Scg2 secretogranin II;Scg2 Mm00843883_s1 
311 Scrt1 scratch homolog 1, zinc finger protein (Drosophila);Scrt1 Mm00459966_m1 
312 Sct secretin;Sct Mm00441235_g1 
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Table 3.2 continued 
313 Sdc3 syndecan 3;Sdc3 Mm01179832_m1 
314 Sdpr serum deprivation response Mm00507087_m1 
315 Sds serine dehydratase;Sds Mm00455126_m1 
316 Selp selectin, platelet;Selp Mm00441295_m1 
317 Selplg selectin, platelet (p-selectin) ligand;Selpl Mm01204601_m1 
318 Sema5a 
sema domain, seven thrombospondin repeats (type 1 and type 1-like), 
transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 
5A;Sema5a Mm00436500_m1 
319 Sfrp1 secreted frizzled-related sequence protein 1;Sfrp1 Mm00489161_m1 
320 Sfrp2 secreted frizzled-related protein 2;Sfrp2 Mm01213947_m1 
321 Sfrp5 secreted frizzled-related sequence protein 5;Sfrp5 Mm00490044_m1 
322 Shh sonic hedgehog;Shh Mm00436528_m1 
323 Slit1 slit homolog 1 (Drosophila);Slit1 Mm01198620_m1 
324 Sox10 SRY-box containing gene 10;Sox10 Mm01300162_m1 
325 Sox11 SRY-box containing gene 11;Sox11 Mm01281943_s1 
326 Sox5 SRY-box containing gene 5;Sox5 Mm00488381_m1 
327 Sp6 trans-acting transcription factor 6 Mm02527757_s1 
328 Spdef SAM pointed domain containing ets transcription factor;Spdef Mm00600221_m1 
329 Spib Spi-B transcription factor (Spi-1/PU.1 related);Spib Mm01719550_s1 
330 Spred3 sprouty-related, EVH1 domain containing 3;Spred3 Mm00805393_g1 
331 Sstr3 somatostatin receptor 3;Sstr3 Mm00436695_s1 
332 Stambpl1 Stam binding protein like 1;Stambpl1 Mm00472562_m1 
333 Syp Regulated exocytosis;Neurotransmitter release Mm00436850_m1 
334 Sytl1 synaptotagmin-like 1;Sytl1 Mm00473300_m1 
335 Sytl2 synaptotagmin-like 2;Sytl2 Mm00473315_m1 
336 T brachyury;T Mm01318252_m1 
337 Taf7l 
TAF7-like RNA polymerase II, TATA box binding protein (TBP)-associated 
factor;Taf7l Mm00459354_m1 
338 Tal1 T-cell acute lymphocytic leukemia 1;Tal1 Mm00441665_m1 
339 Tbx3 T-box 3;Tbx3 Mm00809779_s1 
340 Tbxa2r thromboxane A2 receptor;Tbxa2r Mm00436917_m1 
341 Tcf15 transcription factor 15;Tcf15 Mm00493442_m1 
342 Tcfl5 transcription factor-like 5 (basic helix-loop-helix);Tcfl5 Mm00626495_m1 
343 Tgfb1 transforming growth factor, beta 1;Tgfb1 Mm00441724_m1 
344 Theg testicular haploid expressed gene;Theg Mm00803557_m1 
345 Tlr13 toll-like receptor 13;Tlr13 Mm01233819_m1 
346 Tlr7 toll-like receptor 7;Tlr7 Mm00446590_m1 
347 Tmprss4 transmembrane protease, serine 4;Tmprss4 Mm00520486_m1 
348 Tmprss5 transmembrane protease, serine 5 (spinesin);Tmprss5 Mm00446105_m1 
349 Tnfrsf18 tumor necrosis factor receptor superfamily, member 18;Tnfrsf18 Mm00437136_m1 
350 Tnfrsf25 tumor necrosis factor receptor superfamily, member 25;Tnfrsf25 Mm01263821_m1 
351 Tnfsf10 tumor necrosis factor (ligand) superfamily, member 10;Tnfsf10 Mm01283606_m1 
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352 Trpm5 transient receptor potential cation channel, subfamily M, member 5;Trpm5 Mm00498453_m1 
353 Tshr thyroid stimulating hormone receptor;Tshr Mm00442027_m1 
354 Tshz3 teashirt zinc finger family member 3;Tshz3 Mm00549466_m1 
355 Tspan17 tetraspanin 17 Mm00512218_m1 
356 Tspan8 tetraspanin 8;Tspan8 Mm00524563_m1 
357 Unc13a unc-13 homolog A (C. elegans);Unc13a Mm00550016_s1 
358 Unc13c unc-13 homolog C (C. elegans);Unc13c Mm00463432_m1 
359 Unc5c unc-5 homolog C (C. elegans);Unc5c Mm00494093_m1 
360 V1rd3 vomeronasal 1 receptor, D3;V1rd3 Mm00835727_s1 
361 Vax2 ventral anterior homeobox containing gene 2;Vax2 Mm00496315_m1 
362 Vdr vitamin D receptor;Vdr Mm00437297_m1 
363 Vgll2 vestigial like 2 homolog (Drosophila);Vgll2 Mm00464115_m1 
364 Wnt11 wingless-related MMTV integration site 11;Wnt11 Mm00437328_m1 
365 Wnt16 wingless-related MMTV integration site 16;Wnt16 Mm00446420_m1 
366 Wnt3 wingless-related MMTV integration site 3;Wnt3 Mm00437336_m1 
367 Wnt4 wingless-related MMTV integration site 4;Wnt4 Mm01194003_m1 
368 Wnt5a wingless-related MMTV integration site 5A;Wnt5a Mm00437347_m1 
369 Wnt7a wingless-related MMTV integration site 7A;Wnt7a Mm00437355_m1 
370 Wnt7b wingless-related MMTV integration site 7B;Wnt7b Mm00437357_m1 
371 Wnt8a wingless-related MMTV integration site 8A;Wnt8a Mm00436822_m1 
372 Wnt9a wingless-type MMTV integration site 9A;Wnt9a Mm00460518_m1 
373 Xpnpep2 X-prolyl aminopeptidase (aminopeptidase P) 2, membrane-bound;Xpnpep2 Mm00460007_m1 
374 Zbtb7b zinc finger and BTB domain containing 7B;Zbtb7b Mm00784709_s1 
375 Zfp462 zinc finger protein 462;Zfp462 Mm00556263_m1 
376 Zfp513 zinc finger protein 513;Zfp513 Mm00614402_m1 
377 Zfp57 zinc finger protein 57;Zfp57 Mm00456405_m1 
378 Zfp811 zinc finger protein 811;Zfp811 Mm00806009_m1 
379 Zfp92 zinc finger protein 92;Zfp92 Mm00494326_m1 
380 Zp2 zona pellucida glycoprotein 2;Zp2 Mm00442173_m1 






Isolation of three distinct Ptf1aYFP-expressing cell populations 
Using FACS, we isolated three different pancreatic cell populations from mouse 
embryos that express Citrine, a yellow fluorescent protein (YFP), under control of the Ptf1a 
gene locus (Burlison et al., 2008), as illustrated in Figure 3.1. By conservatively setting the 
FACS isolation gates, the cell populations we obtained had less than one percent 
contamination as assessed by autofluorescence from wild type cells. An average of 1.06 x 
103, 4.23 x 102, and 1.42 x 104 cells were isolated per Ptf1aYFP/+ embryo at E11.5, Ptf1aYFP/YFP 
embryo at E11.5, or Ptf1aYFP/+ embryo at E15.5, respectively. RNA from these cells was then 
analyzed by RNA-Seq.  
 
Whole transcriptome profiling 
It has been suggested that the sequencing of > 40 million reads is required to detect 
and quantify RNAs from biologically relevant classes (Mortazavi 2008). For this reason, we 
performed three lanes of whole transcriptome sequencing (Illumina) on each of the three 
samples from which we obtained 38.9 to 46.7 million reads of at least 36 nucleotides (nt) for 
each of the three sample RNAs, as summarized in Table 3.1. Approximately 89% of these 
reads aligned to the mouse genome (mm9) using the short-read aligner, Bowtie (Langmead et 
al., 2009), thereby resulting in 42.4, 33.6 and 40.5 million mapped reads for the E11.5 
Ptf1aYFP/+, E11.5 Ptf1aYFP/YFP, and E15.5 Ptf1aYFP/+ cells, respectively (Table 3.1). To allow 
comparison of transcript levels between samples, transcripts were quantified in reads per 
kilobase of exon model per million mapped reads (RPKM), which normalizes the sample 
based on transcript length and the total number of mapped reads following sequencing 










Figure 3.1  Genetic and temporal comparisons of cells isolated from pancreatic MPCs, 
Ptf1a-deficient progenitor cells, and nascent acinar-specified cells. A) YFP expression 
was observed in the dorsal (DP) and ventral (VP) pancreatic buds of E11.5 Ptf1aYFP/+ 
embryos by whole mount fluorescence microscopy. Wild type embryos were used to 
establish sorting parameters (left), resulting in less than one percent contamination from 
autofluorescent cells when Ptf1aYFP-positive MPCs were isolated via FACS (right). B) In 
Ptf1aYFP/YFP mice, the expansion of the pancreatic epithelium was severely inhibited by 
E11.5, leaving only dorsal (DPR) and ventral (VPR) pancreatic remnants. The genetic 
comparison of E11.5 Ptf1aYFP/+ and Ptf1aYFP/YFP expression profiles permitted analysis of 
genes that are genetically dependent on Ptf1a. C) By E15.5, YFP expression was observed 
broadly throughout the pancreas, indicative of acinar-cell expansion. The temporal 
comparison of E11.5 and E15.5 Ptf1aYFP/+ cells enabled analysis of the changes seen as 




Ptf1a-dependent gene expression at E11.5 
1,105 genes were identified in the RNA-Seq analyses as increased in the Ptf1a-
deficient progenitors compared to Ptf1a-expressing MPCs. Among these were pre-endocrine 
and endocrine markers, such as Gcg, Mafb and Pou3f4 (Jorgensen et al., 2007), as well as 
enteroendocrine and gastrointestinal markers, such as Pyy, Sct, Cck, Gast, Syp, Prokr1 and 
Isx (Sancho et al., 2004) (Figure 3.2). The presence of pre-endocrine and gastrointestinal 
markers in the Ptf1a-deficient cells is consistent with prior results showing the existence of 
endocrine cells in the dorsal duct-like structure of E18.5 Ptf1a-null embryos and the lineage 
tracing studies that revealed the presence of morphologically-indistinguishable Ptf1a-null 
cells in the developing duodenum and common bile duct epithelia (Burlison et al., 2008; 
Kawaguchi et al., 2002). However, the detection of these markers at E11.5 suggests that the 
differentiation of Ptf1a-deficient cells towards other fates begins much earlier than was 
previously determined.  
Conversely, there were 997 genes that were more highly expressed in the Ptf1a-
expressing cells compared to the Ptf1a-null cells at E11.5. Among these were Cpa1, Gdf11, 
Nkx6-1, and Mnx1 (Hlxb9), all of which have previously been identified to be expressed 
during pancreas development (Figure 3.2). Although it has been shown that the Ptf1a-
containing PTF1 complex binds to the Pdx1 promoter (Wiebe et al., 2007), we did not see a 
significant change in Pdx1 expression between the E11.5 Ptf1a-expressing and Ptf1a-
deficient cells. Other genes that were found to be more abundant in the Ptf1a-expressing 
MPCs were transcription factors such as Scrt1, Zfp830, Tcf15, and Bhlhb2; CD antigens and 
other cell surface markers such as Cd52, Cd93, Cd4, Cxcr4, and Ager; and markers of cell 











Figure 3.2  Genetic and temporal comparisons of differentially expressed transcripts as 
determined by RNA-Seq. A and B) The genetic comparison of Ptf1a-deficient progenitors 
(light gray bars) and Ptf1a-expressing progenitors (black bars) revealed increased levels of 
enteroendocrine and gastrointestinal transcripts in Ptf1a-deficient progenitors (A) and 
transcripts upregulated by the expression of Ptf1a (B). C and D) The temporal comparison of 
acinar-specified cells (dark gray bars) and Ptf1a-expressing progenitors (black bars) revealed 
increased transcript levels of numerous enzymes in acinar-specified cells (C) and transcripts 
upregulated in the progenitors (D). Differential expression was defined as being at least a 5-
fold change in RPKM. 
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 Temporal changes as MPCs are acinar-specified 
In the temporal comparison, 657 genes were identified as upregulated at E15.5 as 
compared to E11.5 based on the RNA-Seq analyses. As expected, many different proteases, 
hydrolases and other enzymes were highly expressed in the E15.5 Ptf1a-expressing cells 
(Figure 3.2). These findings closely paralleled a prior study that examined transcript levels 
of ten digestive enzymes during pancreas development as profiled in the rat (Han et al., 
1986). Specifically, Ctrb1, Amy2 and Cpa1 were expressed at the highest levels, whereas 
Cpa2, Ela1, Rnase1, Ela2a, Cpb1 and Prss1 (Trypsin) were less abundant.  
Conversely, there were 2,136 genes identified as downregulated at E15.5 compared to 
E11.5. These genes included pancreatic markers such as Mnx1 (Hlxb9), Neurog3, Nkx6-1, 
Hnf1b, Pax6 and Isl1, as well as other factors with previously identified roles in pancreas and 
endocrine development such as Gdf11 (Harmon et al., 2004), Chgb (Obermuller et al., 2010), 
and Nnat (Chu and Tsai, 2005) (Figure 3.2). Interestingly, Sall4, which plays a crucial role in 
controlling lineage commitment of hepatoblasts and regulating stem cell pluripotency 
(Oikawa et al., 2009); Zfp57, which plays a role in imprinting and has been associated with 
transient neonatal diabetes (Mackay et al., 2008); Scrt, which is expressed in the developing 
and adult brain (Marin and Nieto, 2006); and Nepn, which is expressed in the midgut and 
hindgut endoderm (Hou et al., 2007), were also more abundant in the pancreatic MPCs 
compared to the acinar-specified cells.  
 
Validation of specific genes and temporal profiling by qRT-PCR 
Since the RNA-Seq datasets were generated from single libraries made from cells 
obtained after pooling at least five embryos, we sought to validate a subset of the transcripts 
across biological replicates by quantitative (q) RT-PCR profiling using high-throughput 
TaqMan arrays (Table 3.2). To perform this analysis, we isolated additional RNA samples 
78 
 
and used a two phase selection strategy to identify 94 genes that could be reliably detected by 
qRT-PCR under the experimental conditions of our study. In the first phase, we screened 376 
transcripts identified from the RNA-Seq dataset as differentially expressed either in a 
temporal or genetic manner. This analysis utilized seven different amplified RNA samples 
from FACS-purified Ptf1aYFP/+ cells between E10.5 and E15.5 and Ptf1aYFP/YFP cells at E11.5. 
296 of these genes (79%) exhibited an absolute Ct value < 40 in at least one sample. A 
negative correlation (-0.416 to -0.641) between the absolute Ct and RPKM values was 
observed for detectable transcripts (Figure 3.3A – C). The moderate nature of the correlation 
may reflect the number of low-abundance transcripts (< 1 RPKM) that were analyzed. An 
analysis of the detected and non-detected transcripts revealed that transcripts with an RPKM 
value of less than one were less likely to be detected by qRT-PCR (Figure 3.4). Hierarchical 
clustering allowed the transcripts to be grouped into ten primary cluster sets (data not 
shown).  
In the second phase, 94 genes were chosen for additional qRT-PCR analysis using at 
least three biological replicates for each of ten different experimental conditions. This 
included analyzing Ptf1aYFP/+ cells over a span of nine days (E10.5 – E18.5) and Ptf1a-
deficient cells (Ptf1aYFP/YFP) at E11.5. A negative correlation (-0.603 to -0.914) was again 
observed between the absolute Ct and RPKM values (Figure 3.3D – F). Hierarchical 
clustering resulted in the transcripts being grouped into five principal clusters sets based on 
their abundance in 1) Ptf1a-deficient progenitors (Ptf1aYFP/YFP at E11.5), 2) Ptf1a-deficient 
progenitors and early MPCs (Ptf1aYFP/+ at E10.5), 3) early MPCs (Ptf1aYFP/+ at E10.5 – 
E11.5), 4) early and late MPCs (Ptf1aYFP/+ at E11.5 – E13.5), and 5) acinar-specified cells 
(Ptf1aYFP/+ at E15.5 – E18.5) (Figure 3.5).  
Gene cluster one contains 26 transcripts that are most highly expressed in the Ptf1a-









Figure 3.3  Correlation of gene expression between RNA-Seq and qRT-PCR. The 
comparison of RPKM values and cycle threshold (Ct) values determined by RNA-Seq and 
qRT-PCR, respectively, was analyzed. Ct values are in logarithmic scale, thus RPKM values 
are graphed on a log2 scale. Correlations are plotted for E11.5 Ptf1aYFP/+, E11.5 Ptf1aYFP/YFP, 
and E15.5 Ptf1aYFP/+ samples following both the first phase (A – C) and the second phase (D 








Figure 3.4  Analysis of detectable transcripts by qRT-PCR relative to RPKM value. 
Transcripts profiled in the first phase of qRT-PCR were analyzed based on RPKM value and 
cycle threshold (Ct) value. Transcripts receiving a Ct value of less than 40 (A) represented 
transcripts with an RPKM > 1 (average 24.8%) and RPKM < 1 (average 75.2%). Transcripts 






Figure 3.5  Quantitative RT-PCR profiling of differentially expressed transcripts. 94 
differentially expressed transcripts were further profiled by qRT-PCR using ten different 
FACS-isolated cell samples: Ptf1aYFP/YFP cells at E11.5 and Ptf1aYFP/+ cells from E10.5 – 
E18.5. Mean pre-processed expression values across biological replicates are scaled as a 
function of the number of standard deviations relative to the mean of each row, where the 
darkest blue corresponds to -3 (less abundant) and the brightest red to +3 (more abundant). 
Hierarchical clustering permitted the identification of five main cluster sets based on 
abundance in: 1) Ptf1a-deficient progenitors (Ptf1aYFP/YFP at E11.5), 2) Ptf1a-deficient 
progenitors and early MPCs (Ptf1aYFP/+ at E10.5), 3) early MPCs (Ptf1aYFP/+ at E10.5 – 
E11.5), 4) early and late MPCs (Ptf1aYFP/+ at E11.5 – E13.5) or 5) acinar-specified cells 
(Ptf1aYFP/+ at E15.5 – E18.5). 
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gastrointestinal markers, such as Gast, Gcg, Isx, Mafb, Nxk6-3, Onecut2, Onecut3 and Sct, 
were most abundant. In addition, Cysltr2, Gria2, Hoxa1, Nxph1, Nxph2, Pbx4, Tspan8, 
Unc5c and Zfp57 follow a similar expression pattern.  
Gene cluster two contains 18 transcripts that are most highly expressed in Ptf1a-
deficient pancreatic MPCs (E11.5 Ptf1aYFP/YFP) as well as early pancreatic MPCs (E10.5 
Ptf1aYFP/+). Pre-endocrine, enteroendocrine and gastrointestinal markers, such as Insm1, Syp, 
Pax6 and Isl1, were abundant in this cluster. Other genes, such as Gpr98, Lox12, Sp6, Hey1, 
Lin28 and Nepn, were primarily expressed in the Ptf1a-deficient progenitors and early 
pancreatic MPCs, while others, such as Chgb, Lhx1, Cd300a, Xpnpep2, Etv4, Sox11, Itgb8 
and Zfp462, exhibited continued expression in later developmental stages. Analysis of the 
relative gene expression of transcripts in these two cluster sets revealed a 4.5 – 5.4 x 103 fold 
increase as compared to the Ptf1a-expressing progenitor cells at E11.5 (Figure 3.6).  
Gene cluster three contains 11 transcripts that are upregulated in the early pancreatic 
MPCs (Ptf1aYFP/+ at E10.5 – E11.5). Among the genes identified are pancreatic MPC and 
pre-endocrine markers such as Myt1, Neurog3 and Rbpj. In addition, this cluster also contains 
Fga, Nlgn3, Hoxc4, Unc13a, Meox1, Zfp92 and Unc13c. Analysis of the differential 
expression at E11.5 between the Ptf1a-expressing and Ptf1a-deficient progenitors revealed 
the abundance of Sox10, Notch3, Neurod1, Sall4, Fga, Unc13c and Arx (Figure 3.6) in the 
Ptf1a-expressing MPCs. Similarly, Cpa1, Nr4a1, Klf15 and Phf1 all showed a significant 
reduction in the E11.5 Ptf1a-deficient cells compared with the Ptf1a-expressing progenitors. 
Although it has been previously proposed that Cpa1 can be used as a marker to identify 
pancreatic MPCs at the distal tip of the branching epithelium (Zhou et al., 2007), both our 
analysis as well as a recent study (Masui et al., 2010) suggest that Cpa1 is a fortuitous marker 
of the pancreatic MPCs. Since Nr4a1, Klf15 and Phf1 are all expressed in a pattern similar to 








Figure 3.6  Genetic and temporal comparisons of differentially expressed transcripts as 
determined by qRT-PCR profiling. A) The expression levels of transcripts in Ptf1aYFP/YFP 
cells at E11.5 were analyzed by qRT-PCR and expressed relative to expression in Ptf1aYFP/+ 
cells at E11.5. B) The expression levels of transcripts in Ptf1aYFP/+ cells at E15.5 were 
analyzed by qRT-PCR and expressed relative to expression in Ptf1aYFP/+ cells at E11.5. 
Relative expression is expressed in log2 scale. Relative expression of 5 = ~35-fold change 
and 10 = ~1000-fold change. *p < 4.8x10-2, **p < 1.6x10-2, ***p < 8.0x10-3. 
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unappreciated roles in progenitor cell development and lineage specification. Additionally, 
the comparison of the progenitors at E11.5 to the acinar-specified cells at E15.5 revealed the 
upregulation of a number of transcripts including Meox1, Hey1, Sall4, Nlgn3, Tshz3, Unc13c 
and Lin28 (Figure 3.6). As expected, pancreatic MPC and pre-endocrine markers such as 
Mafb, Neurog3, Neurod1 and Arx, were more abundant in the E11.5 cells as compared to the 
acinar specified cell. An alternative display of the qRT-PCR profiling, excluding the E11.5 
Ptf1aYFP/YFP sample, allows for the temporal assessment of gene expression among only the 
Ptf1a-expressing samples (Figure 3.7).  
Gene cluster four consists of 18 genes that are most abundant as Ptf1a-expressing 
cells are becoming restricted to the developing epithelial tips (E12.5 – E13.5) (Figure 3.5). 
Interestingly, pre-endocrine markers such as Neurod1 and Arx, as well as Neurog3 and Myt1, 
which are grouped in cluster three, were also expressed in these late progenitors. The 
abundant expression of these transcripts during this developmental stage can be attributed to 
the perdurance of the YFP which was previously described to occur around E12.5 (Burlison 
et al., 2008). Several transcripts, including 9630041N07Rik, Efna4, Sall4, Fev, Sox10, Wnt4, 
Gdnf and Tshz3, were found to have a similar expression pattern to these pre-endocrine 
markers.  
Gene cluster five contains 21 genes that are most highly expressed in pre-acinar and 
acinar-committed cells. As expected, this cluster contained many digestive enzymes 
including Amy2a5, Ctrb1, Rnase1, Pnliprp1, Cela1, Cpa1, and Cpb1. Additionally, we 
observed other genes that exhibited a similar expression pattern including Egfr, Gfi1, Klf15, 
Mt1, Nr1h4, Ppp1r1b, Rbpjl, Reep5, Phf1 and Rorc. The relative gene expression of these 
transcripts between E15.5 and E11.5 Ptf1aYFP/+ revealed varying fold changes of differential 






Figure 3.7  Temporal analysis of qRT-PCR profiling of differentially expressed 
transcripts. This analysis is similar to the heat map and hierarchical clustering in Figure 3.5; 
however, the Ptf1a-deficient progenitor population (E11.5 Ptf1aYFP/YFP) is removed, thus 
displaying the expression pattern for only Ptf1aYFP/+ cells from E10.5 – E18.5. Expression 
values depicted in the heat map represent the mean 2-ΔCt and are scaled as a function of the 
number of standard deviations relative to the mean of each row, where dark blue corresponds 




Here, we utilized mice that express YFP under control of the Ptf1a gene locus to 
purify and characterize Ptf1a-expressing pancreatic cells 1) as they undergo a temporal 
transition from early MPCs to nascent acinar cells and 2) as cells lacking Ptf1a undergo a 
change in cell fate. In both cases, these studies utilized cell populations that were at least 99% 
pure. Moreover, we observed high correlations between the RPKM values obtained by RNA-
Seq and the absolute Ct values obtained by qRT-PCR (Figure 3.3). 
Due to the small number of cells isolated during early pancreas development, 
especially in the Ptf1a-null genotype, use of an RNA amplification technology was 
unavoidable. Although prior studies have shown the fidelity of mRNA expression is highly 
preserved after DNA amplification (Feldman et al., 2002), this procedure has been reported 
to affect certain GC-rich transcripts (McDowell et al., 1998). For this reason, we selected 94 
genes using a dual phase screening strategy and analyzed these genes using multiple 
biological replicates. While the number of transcripts profiled in this manner represents only 
a small fraction of the 2,793 and 2,102 genes detected in the temporal or genetic RNA-Seq 
screen, it allowed for the identification of five different gene clusters, each of which provides 
insights into the dynamics of gene expression during specific aspects of pancreas 
development.  
 
Gastrointestinal specification of pre-pancreatic endoderm occurs in the absence of Ptf1a 
Gene clusters one and two, which contain genes that are most highly expressed in 
Ptf1a-deficient cells, provide several insights into mechanisms of pancreatic cell 
specification. Prior to E9.5, posterior foregut endoderm becomes programmed in a manner to 
specify pancreas development. Although these events remain poorly understood, they lead to 
the expression of Ptf1a in both the dorsal and ventral evaginations of the pre-pancreatic 
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foregut endoderm (Krapp et al., 1998). At this developmental stage, lineage tracing 
experiments have shown that the pancreatic progenitor cells are multipotent, e.g. they go on 
to form endocrine, acinar and ductal cells that characterize the adult pancreas (Burlison et al., 
2008; Kawaguchi et al., 2002). Both the expression of Ptf1a and formation of the PTF1 
complex are clearly essential for the formation of a mature pancreas. However, exactly which 
genes are affected by PTF1 and how they are regulated has not been globally defined.  
The identification of Isx, an intestine-specific transcription factor that parallels the 
expression pattern of Cdx2 (Choi et al., 2006), Tspan8, which is expressed at high levels in 
the stomach and small intestine (Champy et al., 2010), and enteroendocrine markers such as 
gastrin, secretin and synaptophysin in the Ptf1a-null cells indicates that pancreatic MPCs, in 
the absence of Ptf1a, are being quickly redirected towards gastrointestinal fates. Indeed, 
given that the ventral pancreas is closely associated with the duodenum and previous studies 
showed that the ventral pancreas and common bile duct share a common origin (Sumazaki et 
al., 2004), cells of the ventral pancreas may be better positioned to adopt gastrointestinal 
fates. However, whether the dorsal and ventral buds are re-specified to similar or different 
fates, as well as the mechanism(s) by which this occurs, remains to be determined. 
 
Developmental arrest of pre-pancreatic endoderm occurs in the absence of Ptf1a 
The increase in pre-endocrine and endocrine specific genes in Ptf1a-deficient MPCs 
suggests that formation of early endocrine cells in the developing pancreas can occur in a 
Ptf1a-independent manner. This notion is supported by two prior observations. First, lineage 
tracing experiments have shown that approximately 50% of endocrine cells of the mature 
pancreas are derived from progenitors that do not express Ptf1a (Kawaguchi et al., 2002). 
Second, expression profiling of single cells from the dorsal pancreatic epithelium at E10.5 
has suggested the existence of six different progenitor cell types based on combinations of 
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Pdx1, Nkx2-2, Nkx6-1, Ptf1a, Neurog3, Pax6, Pax4, Isl1, Neurod1, Gcg, Ins, Sst, and Ppy 
(Chiang and Melton, 2003). Of the six types identified, only two express Ptf1a. Thus, we 
hypothesize that the Ptf1a-deficient progenitors can transition easily into other progenitor cell 
states, thereby explaining the increase in the expression of Neurog3, Pax6, Pax4, Isl1, 
Neurod1, Gcg and Ppy in the E11.5 Ptf1aYFP/YFP cells. While the notion of a metastable state 
of pancreatic MPCs is speculative, previous studies have examined dynamic states of cellular 
gene expression and how transient gene expression patterns govern cell fate decisions (Orkin 
and Zon, 2002).  
At the same time, the nature of the genes expressed in cluster two suggests that Ptf1a 
acts to prevent developmental arrest of pancreas-specified progenitor cells. The RNA-Seq 
profile of the Ptf1a-deficient cells argues against induction of apoptosis, since the majority of 
pro-apoptotic genes show little or no change. However, the profiles suggest that proliferation 
is rapidly attenuated, as is evident by the decrease in the expression of many markers of 
cellular proliferation (mKi67, Foxm1, Cenpf, Ccne1, Top2a, Ccnb1, Cdk1, Mcm4, Ccnd1 and 
Mcm3). This is consistent with the Ptf1a-containing PTF1 complex being broadly important 
for the proliferation of pancreatic MPCs. Another line of reasoning to support the notion of 
developmental arrest is the presence of Nephrocan (Nepn) (Hou et al., 2007), a definitive 
endoderm marker, Lin28, an important pluripotency factor (Zheng et al., 2009), and Hey1, a 
downstream target of Notch signaling (Ghosh and Leach, 2006), in both the E10.5 Ptf1aYFP/+ 
and E11.5 Ptf1a-deficient cells. Indeed, some of the genes expressed in early Ptf1a-
expressing MPCs and Ptf1a-deficient cells may reflect the ancestry of the cells from a 
preceding stage, e.g. E9.5 or earlier, prior to or at the earliest onset of Ptf1a expression. 
However, other possibilities are that the genes in cluster two are regulated in a Ptf1a-
independent manner or that these genes may be repressed by PTF1. In either case, these 
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results further confirm that the function of Ptf1a during early stages of pancreas development 
is to commit pre-pancreatic foregut endoderm towards pancreatic lineages.  
 
Ptf1aYFP perdurance allows for the transient isolation of MPC progeny 
Clusters three and four provide insights into events that are occurring as the cells first 
become specified to the pancreatic lineage and then begin to undergo branching 
morphogenesis, a process that is also seen during lung, kidney and mammary development 
(Affolter et al., 2009). At this stage, pancreatic progenitor cells have developed from the 
foregut, and the pre-pancreatic epithelium undergoes elongation and branching, where the 
expression of Ptf1a becomes restricted to the peripheral tips of the epithelial tree. Recently, it 
has been shown that pancreatic MPCs become restricted to the developing periphery of the 
epithelial tree, and bipotential (duct/endocrine) progeny that arise from the MPCs are located 
in the central region of the epithelial tree (Zhou et al., 2007). This central region which has 
been termed the trunk domain (Zhou et al., 2007) does not express Ptf1a. However, due to 
the perdurance of YFP (Burlison et al., 2008), some Ptf1aYFP/+ cells from E12.5 to E13.5 may 
represent cells localized to the central region of the epithelial tree. The YFP perdurance, 
while generally undesirable for a study such as this, provides further suggestive evidence that 
pre-endocrine progenitors residing in the trunk epithelium are, in fact, derived from Ptf1a-
positive ancestors.  
 Consistent with the idea that the perdurance of YFP results in isolation of endocrine 
progenitors, clusters three and four revealed increased expression of pre-endocrine markers, 
such as Neurog3, Myt1, Arx and Neurod1. While the hierarchical clustering revealed that 
some of these transcripts are most abundant by E12.5 or E13.5, an analysis of relative gene 
expression revealed that many of these transcripts are more abundant in the E11.5 Ptf1a-
expressing MPCs compared to the E15.5 acinar-specified cells (Figure 3.6). Thus, their 
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expression might begin in early pancreatic MPCs, continue as the progenitors become 
restricted to the developing peripheral tips, and further increase in the pre-endocrine 
precursors which are located in the bipotential trunk domain.  
 
Ptf1a promotes differentiation to acinar cell fates 
Finally, cluster five consists of transcripts that reflect nascent acinar cells. Consistent 
with this is the expression of many proteases, hydrolases, phosphatases and other enzymes, as 
well as the increasing expression of Rbpjl, which is consistent with previous studies (Masui 
et al., 2010). The expression profile of Rbpjl can be contrasted with Rbpj, which is most 
abundant at E10.5, where it is part of the early PTF1-J complex. While the majority of the 
transcripts in cluster five are expressed at high levels in acinar-specified cells, as displayed in 
the heat maps, some are also expressed at earlier stages of pancreas development (Figure 
3.6). For example, by expression analysis Ptf1a and Cpa1 are most abundant in the E18.5 
acinar-specified cells, yet both are expressed in the early MPC population, as previously 
shown by in situ and immunohistochemical analyses (Burlison et al., 2008; Kawaguchi et al., 
2002; Krapp et al., 1998; Zhou et al., 2007). Interestingly, the expression profiles of Klf15 
and Gfi1 closely parallel those of Ptf1a and Cpa1, suggesting that the further analysis of 
some transcripts in cluster five may reveal genes that similarly identify the MPC population 
and promote its specification towards the acinar lineage.  
 
Conclusions 
Further studies of the transcription factors, cell surface receptors and pathway-
specific genes identified from these studies will likely be useful for further characterizing the 
biology of pancreatic MPCs in vivo and for more precisely analyzing events within these 
cells as they first undergo a transition to become bipotential trunk cells and then terminally 
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differentiate to become acinar cells. While the data we obtained points to a very high degree 
of complexity in the genetic program of pancreatic MPCs, our datasets promise to provide an 
important platform for further discovery of mechanisms, pathways and factors that control 
pancreas development, especially when  compared with other pancreatic lineages, 









Nephrocan, a unique member of the SLRP family 
Nephrocan (Nepn) was first identified through a bioinformatics query examining 
proteins similar to the small leucine-rich protein (SLRP), Decorin (Mochida et al., 2006). 
SLRPs are a conserved family of proteins which contain multiple repeats of a leucine-rich 
motif (LRR) flanked by cysteine residues and can be synthesized as either glycoproteins, 
which contain N-linked oligosaccharides, or as proteoglycans, which contain 
chondroitin/dermatan or keratan sulfate chains (Hocking et al., 1998; Iozzo, 1997, 1998). 
These post-translational modifications of SLRPs are thought to modify the function of 
SLRPs, which include acting as modulators of cellular pathways and playing key roles in a 
number of biological processes, including collagen fibrillogenesis, blood vessel 
viscoelasticity, cell migration, and cell proliferation (Iozzo, 1997, 1999). Currently, SLRPs 
are classified into five classes based on several parameters, including their evolutionary 
protein conservation, the presence of a distinct cysteine-rich cluster at the N-terminus, the 
number of leucine-rich repeats, and their chromosomal organization (Schaefer and Iozzo, 
2008).  
Specifically, Decorin is grouped as a class I SLRP and is characterized by ten LRR 
motifs, N- and C-terminal cysteine clusters, N-linked glycosylation, and a 
chondroitin/dermatan sulfate side chain (Krusius and Ruoslahti, 1986; Schaefer and Iozzo, 
2008). Decorin is a small cellular matrix proteoglycan which interacts with the transforming 
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growth factor β (TGFβ) pathway, affects cell proliferation, and modifies the extracellular 
environment (Hildebrand et al., 1994; Schonherr et al., 1998; Takeuchi et al., 1994). 
Similarly, Nepn consists of multiple LRR motifs flanked by cysteine-rich clusters, as well as 
putative N-glycosylation sites; however, there are several features that suggest Nepn belongs 
to a new class of SLRPs. These distinct features include the presence of 17 LRR repeats, four 
cysteine residues in the C-terminus, and a unique polyacidic tail at the C-terminus, as well as 
the absence of a conserved propeptide domain that may function as a recognition sequence 
for xylosyltransferase (Mochida et al., 2006).  
 
Nephrocan, an inhibitor of TGFβ signaling 
Similar to Decorin, Nepn interacts with TGFβ signaling and specifically acts as an 
inhibitor of TGFβ activity (Mochida et al., 2006). The TGFβ family members include not 
only TGFβ, but also activins and bone morphogenetic proteins (BMPs) which control a 
variety of cellular processes, including proliferation, apoptosis, cellular differentiation, and 
epithelial-mesenchymal transistion (EMT), a mechanism essential for numerous 
developmental processes and characterized by loss of cell adhesion, polarity and cell-cell 
contacts, as well as increased cell mobility (Massague et al., 2000). While there are various 
routes through which the TGFβ family members can act, the Smad pathway is the canonical 
pathway through which TGFβ family members signal through (Derynck and Zhang, 1996). In 
this signaling pathway, TGFβ binds to a type II receptor dimer, subsequently recruiting and 
phosphorylating a type I receptor. A receptor-regulated Smad, such as Smad3, is 
phosphorylated by the type I receptor and binds to a co-mediator Smad protein. This 
heterodimeric Smad complex translocates into the cell nucleus where it can serve as a 
modulator of gene transcription. Studies examining the affect of Nepn on TGFβ/Smad 
signaling revealed that Nepn inhibited TGFβ activity and downregulated Smad3 
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phosphorylation, indicating that Nepn may function upstream of Smad3 to inhibit the 
TGFβ/Smad signaling pathway (Mochida et al., 2006).  
 
Role of TGFβ signaling in endoderm and pancreas development 
 The TGFβ pathway is a major regulator of pancreatic endoderm, progenitor, and 
endocrine development. During early stages of embryogenesis, the formation of definitive 
endoderm is a process dependent on the canonical TGFβ/Smad signaling pathway (Tremblay 
et al., 2000). The role of TGFβ signaling in development has become further apparent as 
recent studies have shown that TGFβ signaling molecules, such as activin, can induce human 
and mouse ES cells to differentiate into definitive endoderm-like cells (D'Amour et al., 2005; 
Kubo et al., 2004; Yasunaga et al., 2005). While TGFβ signaling promotes early endoderm 
development, it has been shown that the TGFβ pathway inhibits specification of early 
pancreatic progenitors. Utilizing embryonic explants, studies have revealed that continuous 
TGFβ signaling in the foregut endoderm limits the number of ventral pancreatic progenitors 
that become specified (Wandzioch and Zaret, 2009). As cell specification proceeds, TGFβ 
plays a critical role in regulating endocrine and exocrine cell fates in the later stages of 
pancreas development. Exposure of in vitro-cultured pancreatic rudiments to TGFβ1 
inhibited the development of acinar tissue and promoted the development of endocrine cells 
(Sanvito et al., 1994). Conversely, exposure of in vitro-cultured pancreatic rudiments to 
follistatin, an antagonist of TGFβ signaling, promoted acinar development and inhibited 
endocrine differentiation (Miralles et al., 1998).  
Collectively, these studies provide evidence for both the stimulatory and inhibitory 
affects of the TGFβ signaling pathway on pancreas development during three distinct 
temporal stages. First, during early embryogenesis, signaling by TGFβ serves to promote 
endoderm development and specification. Subsequently, pancreatic progenitor cell 
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specification is promoted only when TGFβ signaling is effectively inhibited or the cells 
spatially move outside the TGFβ signaling domain. Lastly, following specification of 
pancreatic progenitors, TGFβ signaling serves to regulate the balance between endocrine and 
exocrine cell fates.  
 
Expression of Nephrocan during mouse development 
Nepn was first identified to be predominantly expressed in kidney of adult mice and 
was such named given that the Greek word νεφρός, ‘nephros,’ means kidney (Mochida et al., 
2006). In the same study, Nepn was also detected to a lesser extent in heart, lung and skeletal 
muscle, with virtually no expression in brain, spleen, liver, or testis. Immunolabeling 
revealed the expression of Nepn extensively in the epithelial cells of distal tubules and 
collecting ducts in the kidney of adult mice and diminished labeling in the proximal epithelial 
cells. Further expression profiling at various embryonic stages revealed Nepn to be 
upregulated at E11.0, as compared to E7.0, E15.0 and E17.0, marking a critical time for cell 
specification and organogenesis. Similarly, we observed Nepn to be upregulated at E10.5 in 
Ptf1aYFP-expressing pancreatic progenitors (Figure 3.5, 3.7, and 4.1). Additionally, Nepn is 
expressed in the pylorus, the region of the caudal stomach that connects to the duodenum (Li 
et al., 2009). Microarray analysis of the transcriptome of stomach, pyloric and intestinal 
tissues from E14.5 to E16.5 revealed the enrichment of Nepn in the pylorus, and in situ 
analysis confirmed expression in the pyloric epithelium with more robust expression near the 
antral stomach. Given that Nepn is a secreted modulator of TGFβ signaling, this study was 
the first to highlight a secreted signaling protein in the pyloric epithelium.  
In addition to expression in the kidney and pylorus, Nepn, which is also known as the 









Figure 4.1  Gene expression profile of Nepn by qRT-PCR and RNA-Seq. The normalized 
expression level of Nepn is shown in Ptf1aYFP/YFP cells at E11.5 and Ptf1aYFP/+ cells from 
E10.5 to E18.5 by qRT-PCR (black) and in Ptf1aYFP/YFP cells at E11.5 and Ptf1aYFP/+ cells at 
E11.5 and E15.5 by RNA-Seq (red). Nepn is expressed in the Ptf1aYFP/YFP cells at E11.5 and 
Ptf1aYFP/+ cells at E10.5; however, Nepn expression is diminished in Ptf1a-expressing cells at 
E11.5 and barely detectable thereafter. 
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– 6 somites) of endoderm patterning and in the posterior midgut and hindgut during later 
stages (8 – 12 somites) of endoderm patterning (Hou et al., 2007). Using a serial analysis of 
gene expression (SAGE) approach, Nepn displayed a 7-fold increase in expression in the 
posterior midgut and hindgut as compared to the foregut and anterior midgut. Further 
characterization by in situ analysis showed Nepn expression as early as E7.25 in the posterior 
region of the definitive endoderm, and its expression expanded throughout the posterior 
region at E7.75. As development continues, Nepn expression extended anteriorly and was 
expressed bilaterally in the midgut region. Given the lack of definitive endoderm specific 
transcripts, the identification of Nepn as an early definitive endoderm and midgut marker will 
prove to be valuable for examining the molecular mechanisms regulating endoderm 
development.  
 
Materials and Methods 
 
Generation of a ROSA26LCA targeting vector 
The ROSA26LCA targeting vector was made by a two-step BAC recombineering 
procedure (Copeland et al., 2001). First, two inner homology regions from the ROSA26 locus 
were PCR-amplified from a mouse ROSA26 BAC (clone number: 58-D17, RPCI-22 library) 
and cloned into a plasmid (termed pLCA.71/2272) containing a dual selection cassette 
consisting of a fusion of puromycin resistance and a mutant thymidine kinase driven by the 
mouse phosphoglycerol kinase promoter (pgk-puΔtk) and an EM7-driven neomycin 
resistance (EM7-NeoR) flanked by lox71 and lox2272 sites. The resulting construct was used 
to insert the lox71, pgk-puΔtk, EM7-NeoR, and lox2272-containing cassette into the ROSA26 
BAC. Second, two outer homology regions from the ROSA26 locus were cloned into a 
diphtheria toxin A containing plasmid (termed pMCS.DT-A), and the resulting plasmid was 
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used to retrieve the lox71, pgk-puΔtk, EM7-NeoR, and lox2272 cassette along with flanking 
upstream and downstream homology arms of 8.232 kb and 3.770 kb, respectively. 
Thetargeting vector generated replaced a 5.165 kb region of the ROSA26 gene, containing 
both the regulatory sequences and first exon, with the dual pgk-puΔtk and EM7-NeoR 
selection cassette. 200 µg of the ROSA26LCA targeting vector was linearized with NotI for 
electroporation. Targeting vector construction and preparation were performed by Kathy 
Shelton.  
 
Generation of a ROSA26Nepn-Cherry exchange cassette 
The Nepn-Cherry exchange vector was made by standard BAC recombineering 
methods (Copeland et al., 2001; Lee et al., 2001). First, two inner homology regions from the 
Nepn gene locus were PCR-amplified from a BAC containing mouse Nepn (clone number: 
167-J16, RP23 library) and cloned into a plasmid containing monomeric Cherry (pmCherry-
C1; Clontech), a rabbit β-globin polyadenylation sequence containing intronic sequences to 
allow splicing (phspPolyA in pBluKS(-)), and a dual pgk/EM7-driven neomycin resistance 
sequence flanked by FRT sites (PL451 plasmid). The resulting construct was used to insert 
the Cherry-containing cassette into the Nepn BAC. Second, two outer homology regions were 
cloned into a lox66/2272-containing plasmid (termed pLS66/2272), permitting the retrieval 
of the Cherry construct flanked by 9.368 kb of 5’ Nepn sequence and 833 bp of 3’ Nepn 
sequence. The inclusion of 9.365 kb of Nepn 5’ regulatory sequences was determined by an 
analysis of homology of the Nepn locus among species (Figure 4.2). An alternative exchange 
cassette containing 12.9 kb of Nepn 3’ sequence was also constructed. The exchange 
cassettes did not reincorporate the 5.165 kb region of the ROSA26 gene which contains both 
the regulatory sequences and first exon. Exchange vector design and construction were 








Figure 4.2  VISTA plot displaying homology of Nepn locus among species. The 
conservation of the Nepn locus is shown for human, rhesus, dog, horse, rat and chicken 
relative to the mouse genome. The histograms depict sequence lengths of 100 base pairs (bp) 
with ≥ 70% sequence conservation indicated by pink shading, and exon conservation is 
indicated by purple shading. The last panel reveals the RankVISTA plot which quantitatively 
predicts conserved regions across the seven species. A 9.4 kb region upstream of Nepn exon 
1 (small purple box) was included in the Nepn-Cherry exchange cassette to incorporate 
potential upstream regulatory elements.  
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Generation of a NepnCherry targeting vector 
The NepnCherry targeting vector was made by cloning two outer homology regions 
from the mouse Nepn BAC into a diphtheria toxin A containing plasmid (termed pMCS.DT-
A). The resulting plasmid was used to retrieve a portion of the mouse Nepn BAC containing 
monomeric Cherry, the rabbit β-globin polyadenylation sequence, and the dual pgk/EM7-
driven neomycin resistance flanked by FRT sites. The Cherry cassette was flanked upstream 
and downstream by homology arms of 8.392 kb and 3.264 kb, respectively. The targeting 
vector was linearized with ClaI for electroporation. As summarized in Table 4.1, the 
screening strategy utilizes digestion with EcoRI and hybridization with a 5’ probe (wild type 
band: 14.36 kb, targeted band: 12.11 kb) and digestion with SphI and hybridization with a 3’ 
probe (wild type band: 16.7 kb, targeted band: 9.13 kb)   
 
Mouse ES cell culture and electroporation 
TL1 mouse ES cells (Labosky et al., 1994) were cultured in 0.1% gelatin-coated 
tissue culture dishes on a layer of irradiated mouse embryonic fibroblasts (MEFs) using 
complete ES cell media which consisted of DMEM (Gibco, Grand Island, NY) plus 15% 
FBS (Atlas Biologicals, Fort Collins, CO), 2 mM L-glutamine (Invitrogen, La Jolla, CA), 0.1 
mM non-essential amino acids (Invitrogen), 1,000 units/ml leukemia inhibitory factor 
(Chemicon, Temecula, CA), and 0.05 mg/ml Gentamicin (Invitrogen). MEFs were harvested 
from E13.5 antibiotic resistant (DR4) C57BL/6J embryos, expanded in vitro, and were 
mitotically inactivated by γ irradiation (137Cs). ES cells were routinely passed every two to 
three days with 0.25% trypsin, 1mM EDTA • 4Na, pH 8.  
For the generation of the ROSA26LCA allele, a total of four electroporations were 
performed in which 40 µg of the linearized ROSA26LCA targeting vector was electroporated 




Table 4.1 Southern blot hybridization probes for Nephrocan gene targeting 
5’ Hybridization 
Enzyme: EcoRI 
Wild type allele: 14.36 kb 

















Wild type allele: 16.7 kb 

















setting of 500 µFD. After selection using 1.5 µg/ml of puromycin (Sigma) for seven days, 
DNA was isolated from 270 of the 384 surviving clones for analysis by Southern blot. 
Southern probes for hybridization on the 5’ and 3’ ends were PCR-amplified from the mouse 
ROSA26 BAC (clone number: 58-D17, RPCI-22 library), and clones were screened on the 5’ 
end by digestion with SphI and hybridization with a 5’ probe (wild type band: 16.129 kb, 
targeted band: 8.116 kb) and on the 3’ end by digestion with NsiI and hybridization with a 3’ 
probe (wild type band: 19.296 kb, targeted band: 11.046 kb) (Table 4.2). Three correctly 
targeted clones were identified by Southern analysis (1H8, 2A6 and 5B9) (Figure 4.3). 
Following blastocyst injections, clones 5B9 and 2A6 both exhibited germline transmission. 
Electroporation and screening were performed by Susan Hipkens and Kathy Shelton. 
For the generation of the NepnCherry targeted allele, a total of four electroporations 
were performed in which 40 µg of the linearized NepnCherry targeting vector was used to 
electroporate 5.0 x 106 TL1 ES cells (passage 12) per electroporation at 240 V and a 
capacitance setting of 500 µFD. After selection using 200 µg/ml of G418-Geneticin 
(Invitrogen) for nine days, DNA was isolated from 366 surviving clones for analysis by 
Southern blot. Southern probes for hybridization on the 5’ and 3’ ends were PCR-amplified 
from the mouse Nepn BAC (clone number: 167-J16, RP23 library), and clones were screened 
on the 5’ end by digestion with EcoRI and hybridization with a 5’ probe (wild type band: 
14.36 kb, targeted band: 12.11 kb) and on the 3’ end by digestion with SphI and 
hybridization with a 3’ probe (wild type band: 16.70 kb, targeted band: 9.13 kb). Thirteen 
correctly targeted clones were identified by Southern analysis, and eight clones were 
expanded for karotyping (2A10, 2F5, 2H9, 4A5, 4B5, 4B8, 4C1, and 4C7). Clones 2H9 and 
4A5 exhibited the highest percentage of normality following karotyping, 75% and 65%, 
respectively, and were prepared for blastocyst injections. Electroporation and screening were 
performed by Susan Hipkens and Rama Gangula. 
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Table 4.2 Southern blot hybridization probes for ROSA26 gene targeting 
5’ Hybridization 
Enzyme: SphI 
Wild type allele: 16.129 kb 


















Wild type allele: 19.296 kb 






























Figure 4.3  Generation of a ROSA26Nepn-Cherry reporter allele by RMCE. A) Schematic 
representation of the ROSA26 locus, ROSA26LCA allele, and the ROSA26Nepn-Cherry reporter 
allele. The ROSA26LCA allele contains a pgk-driven puromycin resistance-Δthymidine kinase 
fusion gene (puΔTK) and an EM7-driven neomycin resistance (NeoR) flanked by lox71 and 
lox2272 sites (gray bars) which replace a 5.165 kb fragment containing the ROSA26 
promoter and first exon. The lox66 and lox2272-flanked Nepn-Cherry exchange cassette 
consists of a 9.365 kb fragment from the Nepn locus, Cherry coding sequence and an FRT-
flanked (black circles) dual pgk/EM7-driven NeoR cassette. RMCE was performed using a 
positive-negative selection strategy mediated by Cre. Mice containing the ROSA26Nepn-
Cherry+NeoR allele were mated to FLPe-expressing mice resulting in the final ROSA26Nepn-Cherry 
reporter allele. B) Southern analysis of three ES cell clones following gene targeting. Clones 
1H8, 2A6 and 5B9 were identified as correctly targeted. TL1 wild type DNA was used for 
representation of the non-targeted allele. C) PCR screening of ROSA26Nepn-Cherry(+NeoR) 
exchanged ESC clones using primer sets to detect wild type and exchanged alleles. Clones 
5B9/1A6, 5B9/1B2, and 5B9/1B10 were identified as properly exchanged on both the 5’ 
(lane 1, 569 bp) and 3’ end (lane 2, 1000 bp). 
105 
 
Recombinase-mediated cassette exchange 
RMCE was performed as previously described (Long et al., 2004). In brief, a total of 
two electroporations were performed in which equal amounts (40 µg) of the Nepn-Cherry 
exchange vector and pBS185, a Cre-expression vector, were used to electroporate 5.0 x 106 
mouse ES cells containing the ROSA26LCA allele, clone 5B9 (passage 24) (Chen et al., 2011). 
After a staggered positive-negative selection strategy, clones surviving exposure to both 
G418-Geneticin (88 survived) and gancyclovir (14/88 survived) were screened by PCR on 
both the 5’ and 3’ ends using the following primers sets: 5’ anlaysis: 5’-
AGACTTATCTACCTCATAGGTG and 5’-GCTATTGCGCATGCACAC; and 3’ analysis: 
5’-GCAGAATCCAGCACCTTC and 5’-TCACAAGCAATAATAACCTGTAGT. Properly 
exchanged clones yielded 569 bp and 1,000 bp bands on the 5’ and 3’ ends, respectively. 
Three clones (1A6, 1B2 and 1B10) were identified as correctly exchanged (Figure 4.3) and 
displayed 25.9%, 75.0%, and 50.0% normal karotypes, respectively. An exchange efficiency 
of 3.4% was observed for the plasmid containing the 13.8 kb insert. Conversely, the 
alternative exchange cassette, containing an additional 12.9 kb of Nepn 3’ sequence, thus 
resulting in a total insert size of 26.4 kb, yielded zero positively exchanged clones following 
two independent electroporations. Electroporation and screening were performed by Susan 
Hipkens. 
 
Blastocyst injections, mouse husbandry and genotyping 
For the ROSA26Nepn-Cherry allele, chimeric mice were generated by microinjection of 
exchanged ES cells (clones 5B9/1B2 and 5B9/1B10) into C57BL/6J blastocysts. Resulting 
chimeras were subsequently mated to C57BL/6J mice to produce mice harboring the 
ROSA26Nepn-Cherry+NeoR allele. The FRT-flanked NeoR sequence was removed by breeding with 
FLPe-expressing mice (Tg(ACTFLPe)9205Dym). The final allele, ROSA26Nepn-Cherry was 
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maintained on an outbred background by breeding to CD-1 mice. Mouse genotyping was 
performed using the same primers utilized for RMCE screening on genomic DNA isolated 
from ear punch tissue using a Puregene genomic DNA isolation kit (Gentra). Following 
removal of the FRT-flanked NeoR sequence, the FLPe transgene was removed by via 
breeding and screening for the absence of FLPe by PCR. Mice were maintained on a 12 hour 
light-dark cycle, and all experimental protocols were approved by the Vanderbilt Institutional 
Animal Care and Use Committee. Blastocyst injections were performed by the Vanderbilt 
Transgenic Mouse/ES Cell Shared Resource.  
 
Immunolabeling 
For immunodetection, dissected tissues were fixed in 4% paraformaldehyde in 1X 
PBS for at least one hour at 4°C, saturated with 30% sucrose at 4°C, embedded in Tissue-Tek 
Optimal Cutting Temperature (OCT) compound (Sakura), and frozen on dry ice. Sections (7-
10 µm) were thawed at room temperature for 5-10 minutes, permeablized with 0.2% 
TritonX-100 in 1X PBS for 20 minutes, and washed in 1X PBS. Non-specific binding was 
blocked by incubating slides with 5% normal donkey serum (NDS; Jackson 
Immunoresearch) in 1X PBS. Primary antibodies were used at the following dilutions in 1X 
PBS with 1% BSA (Sigma): goat anti-Pdx1 (C.V.E. Wright), 1:5000; guinea pig anti-Insulin 
(Linco), 1:1000; guinea pig anti-Glucagon (Linco), 1:1000; rabbit anti-RFP (Rockland), 
1:800. Tissue sections were incubated with primary antibodies overnight at 4°C in a 
humidified chamber and then washed with 1X PBS. Secondary antibodies were diluted in 1X 
PBS with 1% BSA as follows: Alexa Fluor 488 donkey anti-goat IgG (Invitrogen), 1:1000; 
Alexa Fluor 555 donkey anti-rabbit IgG (Invitrogen), 1:1000; donkey anti-guinea pig IgG 
conjugated to Cy5 (Jackson Immuno Research), 1:500. Sections were incubated with 
secondary antibodies for 1-2 hours at room temperature in a humidified chamber and then 
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washed with 1X PBS. Coverslips were mounted with Prolong Gold with DAPI (Invitrogen). 
Imaging was performed using an Axioplan2 microscope (Zeiss) with a QImaging RETIGA 
EXi camera. 
 
Fluorescence-activated cell sorting  
Embryos were isolated from wild type CD-1 or Ptf1aYFP/+ females crossed with 
ROSA26Nepn-Cherry mice, where the presence of vaginal plug the following day was considered 
E0.5. Embryo genotypes were identified using a fluorescent microscope, and fluorescence 
imaging was performed using a Leica MZ 16 FA stereoscope with a QImaging RETIGA 
4000R camera. Midgut regions containing the posterior stomach, dorsal and ventral 
pancreatic buds, and anterior intestine were dissected from wild type, Ptf1aYFP/+, ROSA26Nepn-
Cherry, and ROSA26Nepn-Cherry; Ptf1aYFP/+ embryos in cold 1X PBS. Tissues were dissociated 
with Accumax (Sigma) at 37°C for up to 1.5 hours with repetitive trituration. The 
dissociation was quenched with FACS medium (L15 medium containing 1 mg/ml BSA, 10 
mM HEPES pH 7.4, 1% penicillin/streptomycin, and 37.5 ng/ml DNase I), and cells were 
filtered through a 35 µm cell strainer (BD Falcon). Following centrifugation, cells were 
resuspended in FACS medium or FACS medium with DAPI. Flow cytometry experiments 
were performed by the VMC Flow Cytometry Shared Resource on a BD Aria III. YFP was 
excited with a 488 nm laser and emission detected with a 502LP and 530/30 bandpass filter. 
Cherry was excited with a 561 nm laser and emission detected with a 600LP and 610/20 
bandpass filter. Compensation and gates were established using wild type midguts, Ptf1aYFP-





Whole mount in situ hybridization 
For generation of Nepn in situ hybridization probes, RNA was isolated from E8.5 
embryos, cDNA was transcribed, and a 659 bp fragment of Nepn sequence was amplified 
using the following primers: 5’ CTAGCAAGCTTGCATTCCTTCCACCACCAAGAG and 
5’ CTAGCGAATTCTGACAGGTAAAGATGGGACAGGTTC. The PCR-amplified 
fragment was cloned into the pLitmus28i vector. The antisense RNA probe was generated 
using T7 RNA Polymerase and HindIII-digested plasmid DNA, while the sense RNA probe 
was generated using T7 RNA Polymerase and XhoI-digested plasmid DNA. Probes were 
labeled with digoxigenin-UTP (DIG-UTP) using the DIG RNA Labeling Kit (Roche).  
Embryos were fixed with 4% formaldehyde, 2 mM EGTA (pH 7.0), and 3 mM 
NaOH in 1X PBS for at least one hour, dehydrated in a methanol gradient and stored at  
-20°C. Embryos were rehydrated through a methanol gradient, treated with proteinase K, and 
post-fixed in 4% formaldehyde and 0.1% glutaraldehyde. Embryos were pre-hybridized for 
one hour at 65°C in Hybridization Solution (50% Formamide, 1.3X SSC pH 5.0, 5 mM 
EDTA pH 8.0, 50 µg/ml yeast tRNA, 0.2% Tween-20, 0.5% CHAPS and 100 µg/ml 
heparin), followed by hybridization overnight at 65°C with an appropriate dilution of each 
probe in Hybridization Solution. Embryos were subsequently washed repeatedly with 
Hybridization Solution, followed by washes with TBS-T (1X TBS with 0.1% Tween-20). 
Embryos were blocked in 2% blocking reagent (Roche) and 20% sheep serum for at least 2 
hours and incubated with anti-DIG primary antibody (Roche) for at least 4 hours. Following 
a series of washes with TBS-T and NTMT (100 mM Tris-HCl pH 9.5, 100 mM NaCl, 50 mM 
MgCl2, 1% Tween-20), embryos were exposed to NBT/BCIP precipitating substrate (Roche). 
Following visualization of precipitate, embryos were fixed in 4% formaldehyde and 0.1% 





 Embryos were dissected in cold 1X PBS, and midguts were cultured in chamber 
slides (Nunc) at 37°C for 24 hours in DMEM containing 10% calf serum (Hyclone; not heat-
inactivated). As indicated, culture medium was supplemented with either recombinant human 
TGFβ2 (R&D Systems) in 4 mM HCl and 0.1% BSA, or an ALK4,5,7 inhibitor, SB431542 
hydrate (Sigma) in DMSO. Fluorescence imaging was performed using a Leica MZ 16 FA 




Expression pattern of Nepn in Ptf1aYFP-expressing cells 
In the RNA-Seq datasets for Ptf1aYFP-expressing cells, an analysis of the RPKM 
values for Nepn reveals a meager 1.4-fold increase in expression in Ptf1a-deficient cells at 
E11.5 as compared to Ptf1a-expressing MPCs (Figure 4.1). Conversely, Nepn is upregulated 
86.5-fold in Ptf1a-expressing MPCs as compared to acinar-specified cells at E15.5. The 
expression pattern of Nepn was further examined in the qRT-PCR profiling of Ptf1aYFP-
expressing and Ptf1a-deficient cells. In the temporal and genetic analysis, several genes were 
identified as highly expressed in both early-stage pancreatic MPCs at E10.5and in Ptf1a-null 
cells at E11.5 (Figure 3.5). Closer examination indicated that Nepn is expressed in Ptf1a-
expressing pancreatic MPCs until E11.5 but virtually absent by E12.5 and later as Ptf1a-
expressing cells are differentiating into acinar cells (Figure 4.1). By qRT-PCR, Nepn is 50.5-
fold more abundant in Ptf1a-deficient cells compared to Ptf1a-expressing cells at E11.5 and 
35.5-fold more abundant in Ptf1a-expressing cells at E11.5 compared to E15.5. While the 
range of expression differs between the RNA-Seq and qRT-PCR analysis, both datasets show 
that Nepn is most abundant in Ptf1a-deficient cells at E11.5 and is expressed in early (E10.5 
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– E11.5) pancreatic progenitors, while its expression is virtually absent as the Ptf1a-
expressing cells become specified to the acinar lineage. 
 
Generation of a ROSA26Nepn-Cherry reporter allele 
To further explore the expression pattern of Nepn during embryogenesis, a three-step 
procedure was utilized to generate mice containing a Nepn reporter in the ROSA26 locus 
(Figure 4.3) (Zambrowicz et al., 1997). First, a ROSA26 loxed cassette acceptor (LCA) allele 
was generated. Gene targeting of the ROSA26 locus was performed to replace a 5.165 kb 
region, containing both the promoter and first exon of ROSA26, with a lox71/lox2272-
flanked dual selection cassette consisting of a fusion of puromycin resistance and a mutant 
thymidine kinase driven by the mouse phosphoglycerol kinase promoter (pgk-puΔtk) and an 
EM7-driven neomycin resistance (EM7-NeoR) (Chen et al., 2011). Three clones were 
identified by Southern analysis as correctly targeted (Figure 4.3). Second, a lox61/lox2272-
flanked exchange cassette containing an FRT-flanked pgk/EM7-NeoR selection cassette and a 
fusion gene consisting of 9.365 kb of Nepn 5’-regulatory sequences (Figure 4.3) driving the 
expression of a monomeric red fluorescent protein, mCherry (Shaner et al., 2004), was 
generated. The inclusion of 9.365 kb of Nepn 5’ regulatory sequences was determined by an 
analysis of homology of the Nepn locus among species (Figure 4.2). Utilizing RMCE, the 
Nepn reporter cassette was exchanged into the ROSA26LCA allele and resulted in three 
correctly exchanged clones (Figure 4.3). Lastly, mice containing the ROSA26Nepn-Cherry+NeoR 
allele were bred with FLPe-expressing transgenic mice (Rodriguez et al., 2000) to remove the 





Expression of ROSA26Nepn-Cherry transgene 
 Expression of the Nepn-Cherry transgene was first assessed in embryos by whole 
mount fluorescence microscopy (Figure 4.4). Cherry expression was observed in a punctate 
pattern throughout the midgut and hindgut region of E8.5 (7 – 8 somites) embryos, and the 
punctate pattern was maintained throughout the midgut region at E9.5. By E10.5, the 
expression domain of the Nepn-Cherry transgene was more clearly defined with stronger 
expression observed in the dorsal and ventral pancreatic buds and weaker expression present 
in the caudal stomach, pyloric antrum, duodenum and intestine. A similar pattern was seen at 
E11.5, with strongest expression present in the dorsal and ventral pancreatic buds. From 
E10.5 to E11.5, expression of the ROSA26Nepn-Cherry allele is strikingly similar to the spatial 
profile of Pdx1 in the developing midgut (Offield et al., 1996). As development proceeds, 
Cherry expression is diminished in the pancreas with virtually no expression observed in the 
pancreas after E15.5. Conversely, as the expression of ROSA26Nepn-Cherry is diminished in the 
pancreas, its expression becomes more evident in the embryonic kidneys (data not shown).  
To further examine expression of the ROSA26Nepn-Cherry allele, we performed 
immunolabeling to identify the population of cells in the developing pancreatic buds that 
expressed the transgene (Figure 4.5). This analysis revealed the co-localization of Cherry 
with a subpopulation of Pdx1-positive pancreatic progenitor cells from E10.5 – E11.5. 
Additionally, weak Cherry immunolabeling was observed in the caudal stomach, pyloric 
antrum, and small intestine in a subpopulation of Pdx1-positive cells at E10.5 with stronger 
Cherry immunolabeling observed in the pyloric antrum at E11.5. Interestingly, ROSA26Nepn-
Cherry expression was greatly reduced as cells differentiated towards specific lineages, as 
evident by the exclusion of Cherry expression in the early insulin- and glucagon-positive 
cells (Figure 4.5). Similarly, as observed in the RNA-Seq and qRT-PCR datasets, the 






Figure 4.4  Brightfield and fluorescent imaging of ROSA26Nepn-Cherry embryos. A) At 
E8.5, ROSA26Nepn-Cherry expression is observed in a punctate pattern throughout the 
developing gut tube endoderm. B) At E9.5, ROSA26Nepn-Cherry expression can be seen in both 
the dorsal and ventral endoderm as well as in the posterior endoderm. C) At E10.5, the dorsal 
and ventral pancreatic buds display higher levels of ROSA26Nepn-Cherry expression while the 
antral stomach and duodenum have a punctate expression pattern. D) At E11.5, Cherry 
expression is more visible in the dorsal and ventral pancreatic buds with continued 







Figure 4.5  Immunolabeling of ROSA26Nepn-Cherry embryos. A) Immunofluorescent analysis 
of Pdx1 and Cherry expression at E10.5 reveal the co-expression of Pdx1 and Cherry in the 
dorsal and ventral pancreatic epithelium while lower expression levels of Cherry are 
observed in the caudal stomach and duodenum. B) Immunofluorescent analysis of Pdx1 and 
Cherry expression at E11.5 indicates ROSA26Nepn-Cherry expression in a subpopulation of 
Pdx1-expressing MPCs in the pancreatic epithelium. C and D) Both glucagon and insulin-
expressing endocrine cells are present in the pancreatic epithelium at E11.5 and do not co-
express ROSA26Nepn-Cherry.  
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acinar lineage (Figure 4.1). Based on the temporal pattern of Nepn expression during 
pancreas development, we speculate that Nepn plays a role during pancreatic progenitor cell 
development.  
 
 FACS analysis of ROSA26Nepn-Cherry cells  
To further analyze the ROSA26Nepn-Cherry cells during development, we crossed mice 
bearing the ROSA26Nepn-Cherry allele with Ptf1aYFP/+ mice. At E10.5 and E11.5, whole mount 
imaging revealed fluorescence of both Cherry and YFP in the dorsal and ventral pancreatic 
buds with Cherry expression also present in the caudal stomach, pyloric antrum and 
duodenum (Figure 4.6 and data not shown). To examine the population of cells which co-
express Ptf1aYFP and ROSA26Nepn-Cherry, we performed fluorescence-activated cell sorting 
(FACS). While the optimal excitation wavelengths for Cherry and YFP are 587 nm and 516 
nm (Griesbeck et al., 2001; Shaner et al., 2004), the 561 nm and 488 nm lasers were utilized 
due to instrument configuration limitations. 
Consistent with the expression pattern observed by immunolabeling, FACS analysis 
of ROSA26Nepn-Cherry; Ptf1aYFP/+ embryos revealed that a subpopulation of the Ptf1aYFP-
expressing MPCs is positive for Nepn-Cherry (Figure 4.6). While we observed a population 
of Cherry single-positive cells, which would represent the Cherry-positive cells in the caudal 
stomach and intestine or other Cherry-single positive cells, we observed a significant Cherry-
positive population in wild type embryos. While these wild type embryos are not Cherry-
positive by whole mount microscopy or genotyping, the dissected tissues exhibited 
fluorescence in the Cherry parameters by FACS. This undesirable fluorescence presents a 
limitation when analyzing and attempting to isolate Cherry single-positive cell populations; 






Figure 4.6  FACS analysis of ROSA26Nepn-Cherry/+; Ptf1aYFP/+ embryos. A – D) At E11.5, 
ROSA26Nepn-Cherry expression is observed in the caudal stomach, intestine and the dorsal and 
ventral pancreatic buds (B) while Ptf1aYFP expression is restricted to the pancreatic buds in 
the developing midgut (C). Overlay displays the co-incidence of Ptf1aYFP and ROSA26Nepn-
Cherry in the pancreatic buds (D). Dorsal pancreas (dp), ventral pancreas (vp), stomach (sto), 
and duodenum (duo). E) FACS analysis of wild type embryos revealed non-specific 
fluorescence in the Cherry single-positive gate. F) Analysis of ROSA26Nepn-Cherry/+; Ptf1aYFP/+ 
embryos reveals that Ptf1a-expressing MPCs can be divided into two populations: Ptf1aYFP-
positive (YFP) and ROSA26Nepn-Cherry; Ptf1aYFP double-positive cells (Cherry/YFP). 
Additionally, Cherry single-positive cells are identified which represent either non-specific 
fluorescence or ROSA26Nepn-Cherry positive cells in the caudal stomach and intestine.  
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tagged allele, such as Ptf1aYFP, then dual-positive cells are able to be distinguished and 
isolated without significant contamination.  
 
Analysis of Nephrocan expression by in situ hybridization  
To assess endogenous expression of Nepn during embryogenesis, we performed in 
situ hybridization on E11.5 embryos (Figure 4.7). Given that Nepn expression was detected 
in pancreatic progenitor cells by both RNA-Sequencing and qRT-PCR, we anticipated that 
Nepn would be detected in the pancreatic epithelium by in situ hybridization. However, when 
hybridized with an RNA probe for Nepn, expression was only visualized in the pyloric 
epithelium, consistent with previous reports (Li et al., 2009). Similar to the expression pattern 
previously observed, Nepn exhibited expression predominantly in the anterior portion of the 
pylorus; however, there is no clear boundary of expression across the pylorus. Although the 
in situ hybridization did not reveal expression of Nepn in the pancreatic epithelium, it is 
possible that the transcript level of Nepn in the pancreatic epithelium is below detection 
threshold for this assay. 
 
Analysis of TGFβ signaling in embryos  
Given that Nepn is a secreted modulator of TGFβ signaling, we sought to further 
assess the role of TGFβ signaling during the development and differentiation of early 
pancreatic progenitor cells. To examine the impact of both stimulation and inhibition of 
TGFβ signaling, we utilized embryos at E9.5 from a fluorescently-tagged Pdx1 reporter allele 
(discussed in Chapter V) (Potter et al., 2011). Tissue explants containing the pancreatic 
epithelium were cultured with either TGFβ2 or SB431542, an inhibitor of the TGFβ receptors 
(ALK4, 5, and 7). The expression of Pdx1 was assessed by whole mount fluorescence 











Figure 4.7  In situ analysis of endogenous Nephrocan. A – B) Dorsal and ventral views 
following in situ hybridization with an anti-sense probe for Nepn at E11.5. Expression was 
predominantly detected at the pylorus with expression evident in the caudal stomach and 
duodenum. Endogenous Nepn expression was not observed in the pancreatic epithelium by 
the whole mount in situ hybridization; however, the expression level of Nepn in the 
developing pancreatic buds may be below the detection threshold of this assay. C – D) Dorsal 










Figure 4.8  Embryo explants to study TGFβ signaling in specification of progenitor 
cells. Midgut regions containing both the dorsal and ventral endoderm were isolated from 
Pdx1CFP/+ embryos and imaged by fluorescent microscopy. Explants were cultured for 24 
hours with either a stimulant, TGFβ2, or an inhibitor of the TGFβ signaling pathway, 
SB43154I, (A and C) as well as corresponding control conditions (B and D). Following 24 
hours of culture, explants were imaged by fluorescent microscopy. The maintained 
fluorescence in the SB431542I-treated Pdx1CFP explants suggests that TGFβ inhibition 
promotes Pdx1 expression in the dorsal and ventral endoderm at this developmental stage.  
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hours of culture, treatment of the tissue explants with TGFβ2 showed little alteration in the 
induction of the early pancreatic epithelium marker Pdx1, whereas exposure to the TGFβ 
inhibitor slightly enhanced induction of Pdx1 as demonstrated by the increased fluorescence 




Generation of a reporter allele for Nephrocan by RMCE 
 Given that there are few studies concerning the expression pattern of Nepn and a 
reporter allele has not been documented, we sought to generate a fluorescent reporter mouse 
line to enable the identification of Nepn-expressing cells. To achieve this, we utilized RMCE 
to insert a single copy of a Nepn-Cherry transgene into a transcriptionally-disabled ROSA26 
locus. This method was advantageous specifically for two reasons. First, RMCE is more 
efficient than traditional gene targeting. In RMCE, a DNA cassette can be exchanged rapidly 
into an acceptor allele and simply screened via PCR, eliminating the need to screen by 
Southern analysis which is more laborious. Second, this method allowed for a single-copy 
insertion of the Nepn-Cherry transgene into a specified locus, ROSA26, which presents 
advantages over standard BAC transgenic mice which can exhibit multiple insertions and 
transgene silencing.  
Although the method employed to generate the ROSA26Nepn-Cherry allele has certain 
advantages, our approach is not without certain disadvantages. First, ROSA26 is known to be 
ubiquitously expressed, thus insertion into this locus could result in a ubiquitously expressed 
transgene. However, given that the design of the ROSA26LCA allele resulted in the removal of 
both the promoter region and exon 1 of ROSA26, the potential for ubiquitious expression of 
an inserted transgene is small. Second, while our Nepn-Cherry reporter incorporated 9.365 kb 
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of sequence upstream and 833 bp downstream, the proximal and distal regulatory elements 
driving Nepn transcription are unknown. Thus, it is possible that the ROSA26Nepn-Cherry 
reporter allele does not accurately mimic Nepn expression or the allele may display 
variegation. However, the construct incorporated all the 5’ sequence up to the next gene 
located upstream (Figure 4.2) and the expression pattern seen by whole mount imaging 
during early endoderm development was similar to previous reports (Figure 4.4). 
 While the maximum size of an exchange cassette for RMCE has not been fully 
elucidated, the Nepn-Cherry exchange cassette was one of the largest cassette exchanges we 
have performed. The exchange cassette was 13.8 kb in size and resulted in 3.4% exchange 
efficiency, a percentage lower than what we typically observe for RMCE. In addition to this 
exchange cassette, an alternative exchange cassette that was 26.4 kb in size, containing an 
additional 12.9 kb of Nepn 3’ sequence, yielded zero positively exchanged clones from two 
separate electroporations.  
 
ROSA26Nepn-Cherry is expressed in a subset of pancreatic MPCs  
Our analyses indicate that Nepn is variably expressed in a subpopulation of pancreatic 
MPCs from E10.5 to E11.5, with a subset of Pdx1-expressing MPCs co-expressing Nepn as 
observed by immunolabeling, and a subpopulation of Ptf1a-expressing MPCs expressing 
Nepn as observed by FACS analysis. The generation of a fluorescently-tagged reporter allele 
for Nepn permits isolation of two subpopulations of pancreatic MPCs by FACS: 1) MPCs co-
expressing both Ptf1aYFP and ROSA26Nepn-Cherry and 2) MPCs expressing only Ptf1aYFP 
(Figure 4.6). Using these cells, we will be able to examine and characterize potential 
differences and similarities between the two cell populations. We speculate that MPCs co-
expressing both Ptf1aYFP and ROSA26Nepn-Cherry represent cells in an earlier progenitor cell 
state, while MPCs expressing only Ptf1aYFP represent cells in a more transitional phase of 
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differentiation and specification. This hypothesis is based on a previous report utilizing 
single-cell profiling of E10.5 dorsal pancreatic epithelium which identified at least six types 
of progenitor cells based on combinations of Pdx1, Nkx2-2, Nkx6-1, Ptf1a, Neurog3, Pax6, 
Pax4, Isl1, Neurod1, Gcg, Ins, Sst and Ppy expression (Chiang and Melton, 2003). Of the six 
progenitor cell types identified, two types (32/60 cells) expressed Ptf1a and were subdivided 
based on expression of Neurog3. Given the two different Ptf1a-expressing populations 
classified in that study, we speculate that the MPCs expressing only Ptf1aYFP may represent 
cells that have become further specified and have activated transcription for specific pre-
endocrine progenitor markers, such as Neurog3, while MPCs co-expressing both Ptf1aYFP 
and ROSA26Nepn-Cherry may represent earlier progenitor cells that express markers such as 
Pdx1, Nkx2-2, and Nkx6-1.  
While Nepn is expressed in a population of Ptf1a-expressing cells, it is unlikely Nepn 
itself is regulated by Ptf1a given that it is also very highly expressed in Ptf1a-null cells at 
E11.5 (Figure 4.1). Given that Nepn is also expressed in other posterior foregut derivatives, 
the increased expression of Nepn in Ptf1a-null cells may also reflect reprogramming of the 
cells to alternative posterior foregut fates. Interestingly, Nepn has also been found to be 
upregulated in Nkx2-2-null embryos (Anderson et al., 2009), an observation that may reflect 
developmental arrest of Nkx2-2-deficient cells at a pancreatic MPC state. In this study, the 
expression of Nepn was most abundant in E12.5 and E13.5 Nkx2-2-mutant embryos with 
significant downregulation by E15.5. Thus, it is plausible that at later stages of development 
when the requirement for Nkx2-2 is the greatest, the Nkx2-2-mutant cells are “held” in a 




ROSA26Nepn-Cherry expression is downregulated as MPCs differentiate 
The possible requirement for Nepn in regulating pancreas development is likely to be 
temporally-dependent as evident by its diminished expression as MPCs become further 
specified. This was first observed in the RNA-Seq datasets when the expression of Nepn in 
Ptf1a-expressing cells was downregulated over 86-fold from E11.5 to E15.5 (Figure 4.1). 
Similarly, in the qRT-PCR datasets, the expression of Nepn is downregulated over 35-fold 
from E11.5 to E15.5 and 12,000-fold from E10.5 to E18.5 (Figure 4.1). In addition, by 
immunohistochemical analysis at E11.5, the expression of the NepnCherry transgene is 
virtually absent in the first-wave hormone-positive cells as they are specified from early 
progenitors (Figure 4.5). 
 
ROSA26Nepn-Cherry future directions 
In addition to analyzing Nepn-expressing pancreatic progenitor cells in combination 
with the Ptf1aYFP allele, the ROSA26Nepn-Cherry reporter is advantageous for use in two other 
studies. First, given that the NepnCherry transgene is expressed in a punctate pattern throughout 
the midgut and hindgut endoderm, the ROSA26Nepn-Cherry reporter mice can be used in 
combination with mice containing a Sox17GFP-Cre allele (unpublished). The fluorescently-
tagged Sox17 allele allows for the identification of the definitive endoderm during early 
embryogenesis, as well as the foregut, midgut and hindgut at E8.5. The analysis of mice 
bearing both ROSA26Nepn-Cherry and Sox17GFP-Cre will allow for the identification of NepnCherry-
expressing cells within the Sox17-expressing endoderm. The isolation of these cells and their 
characterization by RNA-Sequencing would allow us to examine the difference between 
endodermal cells that express both NepnCherry and Sox17GFP or simply Sox17GFP. This 
comparison, as well as further analyses by immunolabeling and utilizing embryo explants, 
will help us examine if Nepn plays a role in endoderm patterning through the inhibition of 
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TGFβ signaling. Additionally, given that the Nepn transgene is expressed in a pattern 
strikingly similar to Pdx1, the ROSA26Nepn-Cherry reporter mice could be used in combination 
with mice containing a fluorescently-tagged Pdx1 allele (see Chapter V), which would 
facilitate examination of similarities and differences in their expression patterns as well as 
permit the isolation and characterization of dual-positive cells in the pancreas, caudal 
stomach and duodenum. 
 
Potential role of Nephrocan in pancreatic progenitor development 
Given that TGFβ signaling inhibits specification of ventral pancreatic progenitors 
(Wandzioch and Zaret, 2009), Nepn functions to inhibit TGFβ signaling (Mochida et al., 
2006), and the NepnCherry transgene is expressed in some, but not all, pancreatic MPCs 
(Figure 4.5 and 4.6), we speculate that Nepn plays a role in early pancreas specification 
(Figure 4.9). Similar to other signaling pathways during embryogenesis, the requirement for 
TGFβ signaling is likely to be both temporally and spatially defined. While the inhibition of 
TGFβ signaling may promote progenitor cell specification, TGFβ signaling is critical for 
endocrine cell specification (Miralles et al., 1998; Sanvito et al., 1994). Consistent with this 
temporal role is our findings. First, we observed by RNA-Seq that Nepn is expressed during 
early progenitor cell development, thus possibly inhibiting TGFβ signaling in these cells and 
thus promoting progenitor specification. Using the ROSA26Nepn-Cherry reporter, we were also 
able to observe expression of the NepnCherry transgene in a subset of the pancreatic MPCs. 
Second, we observed that Nepn expression decreased as Ptf1aYFP-expressing cells were 
committed to the acinar lineage. Similarly, we observed that the expression of the NepnCherry 
transgene was diminished as MPCs began to differentiate towards specific lineages, including 







Figure 4.9  Model of potential role of Nepn in pancreas development. A) During 
pancreatic progenitor cell specification, TGFβ signaling inhibits specification of MPCs. 
Given that Nepn is expressed in a subset of pancreatic MPCs and that Nepn inhibits TGFβ 
signaling, we speculate that Nepn plays a role in the specification of pancreatic MPCs. 
Green: pancreatic MPCs; Grey: mesenchyme. B) During later development, TGFβ signaling 
is critical for endocrine cell specification. We observed a downregulation in Nepn expression 
as MPCs differentiate to both the endocrine and acinar cell lineages. Thus, we speculate that 
the downregulation of Nepn in these lineages relieves the inhibition of TGFβ signaling and 
thereby promotes mature cell specification. Orange: acinar cells; blue: biopotential 
(endocrine/duct) progenitor cells; cluster: Islet of Langerhans.  
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To more fully elucidate the plausible role of Nepn in pancreatic progenitor cell 
development, it would be advantageous to generate a knockout allele (described in Materials 
and Methods). However, seeing that Nepn is expressed in definitive and midgut endoderm, it 
is possible that global knockout mice would cease development shortly after endoderm 
specification. Thus, it would be more advantageous to generate a conditional knockout where  
the coding sequence for Nepn is flanked by lox sites. Using this approach, mice containing 
the Nepnflox/flox allele can be mated to Cre-expressing mice to conditionally eliminate Nepn at 
specific temporal stages during development, such as in early endoderm or pancreatic 
progenitors using Foxa2-Cre or Pdx1-Cre. These studies would allow for a better assessment 
of the temporal requirement for Nepn in the developing endoderm and permit further 





FLUORESCENT PROTEIN REPORTER ALLELES FOR PDX1 
 
Introduction 
Numerous studies have revealed the importance of pancreatic and duodenal 
homeobox 1 (Pdx1) in the specification and subsequent development of the pancreas (Gu et 
al., 2002; Jonsson et al., 1994; Offield et al., 1996; Stoffers et al., 1997a; Stoffers et al., 
1997b). Prior to its analysis in mammalian model organisms, it was identified first in 
Xenopus laevis as a homeobox gene, XlHbox8, which was expressed in the epithelial cells of 
the pancreatic anlagen and duodenum (Wright et al., 1989). Within mammalian model 
organisms, Pdx1 has a number of aliases including somatostatin-transactivating factor 1 (Stf-
1) (Leonard et al., 1993), islet/duodenum homeobox 1 (Idx-1) (Miller et al., 1994), insulin 
promoter factor 1 (Ipf-1) (Jonsson et al., 1994; Ohlsson et al., 1991), and maturity onset 
diabetes of the young 4 (MODY4) (Stoffers et al., 1997a).  
Mammalian Pdx1 was first identified as a transcription factor that regulates the 
transcription of insulin and somatostatin (Leonard et al., 1993; Ohlsson et al., 1993). At the 
developmental level, Pdx1 displays restricted expression in the posterior foregut beginning at 
E8.0, is expressed throughout the pancreatic epithelium at E9.5, and later in development, 
high levels of Pdx1 expression are evident primarily in the β cells (Ohlsson et al., 1993). The 
temporal expression pattern of Pdx1 highlights two distinct functional roles, first as a critical 
regulator of pancreas development where its early expression is thought to initiate a complex 
transcriptional network that leads to the formation of the mature pancreas, and second as a 
regulator of glucose-induced gene expression (Melloul et al., 1993). The critical role of Pdx1 
in pancreas development is further made evident by Pdx1-null mutations which result in 
127 
 
pancreatic agenesis in both mouse and human (Jonsson et al., 1994; Offield et al., 1996; 
Stoffers et al., 1997b). Additionally, Pdx1 haploinsufficiency results in impaired glucose 
tolerance and early onset diabetes which led to the identification of Pdx1 as a genetic locus of 
early-onset diabetes, known as MODY4 (Ahlgren et al., 1998; Stoffers et al., 1997a). 
Within the developing foregut, Pdx1 expression begins at E8.0 (approximately 7 
somites) in a small population of ventral foregut endothelial cells on the left side of the 
anterior intestinal portal (AIP). By E8.5, expression is observed on both the left and right 
sides of the AIP, and by E9.0, expression in the dorsal endoderm is observed (Gannon et al., 
2000). At E11.5, the broad foregut expression pattern of Pdx1 is evident by its expression in 
the dorsal and ventral pancreatic epithelium, as well as expression in the epithelium of the 
duodenum, cystic duct, common bile duct and antral stomach (Offield et al., 1996). Lineage 
tracing results using a Cre/loxP system have shown that Pdx1-expressing progenitors can 
give rise to all three lineages of the mature pancreas (Gu et al., 2002; Herrera, 2000). 
Notably, it has been suggested that the coinciding expression of Pdx1 and Ptf1a in the 
pancreatic epithelium from E9.5 to E11.5 demarcates the pancreatic MPC population which 
gives rise to all cells types of the mature pancreas (Burlison et al., 2008; Zhou et al., 2007).  
Numerous lines of mice expressing green fluorescent protein (GFP) (Chalfie et al., 
1994; Heim et al., 1995; Shimomura et al., 1962) under control of a variety of gene loci, 
including Pdx1 (Micallef et al., 2005), have been reported. However, the utility of some of 
these reporter alleles, including that of the Pdx1GFP allele, is limited by a single spectral 
profile which prevents their combinatorial use. Indeed, the isolation of many distinct cell 
populations by fluorescence-activated cell sorting (FACS) requires the simultaneous use of 
two or more FPs with spectrally distinct excitation and emission profiles (Heikal et al., 2000; 
Nagai et al., 2002; Rizzo et al., 2004; Shaner et al., 2004). Given the differing expression 
patterns of Pdx1 and Ptf1a within the foregut endoderm, comparisons of the different cell  
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populations will help to define the genetic pathways and transcriptional networks that 
regulate the development of spatially-defined tissues. In order to achieve these comparisons, 
it is pertinent to obtain a fluorescently-tagged Pdx1 allele that can be used in combinatorial 
fluorescence-activated cell sorting together with GFP- or YFP-expressing reporter alleles.  
 
Materials and Methods 
 
Generation of a loxed cassette acceptor allele for Pdx1 
A gene targeting vector for Pdx1 was constructed using BAC recombineering and 
utilized the Cre/lox system for future manipulations by recombinase-mediated cassette 
exchange (RMCE). The long and short homology arms for Pdx1, 8.128 kb and 3.584 kb, 
respectively, were derived from an RP22 BAC (clone 228-B22). The targeting replaced an 
8.6 kb region of the Pdx1 gene, spanning from -6586 to +2024 bp, with a mouse 
phosphoglycerol kinase promoter (pgk) driving expression of a puromycin resistance-
Δthymidine kinase fusion gene (puΔTK) and a bacterial EM7 promoter driving expression of 
a kanamycin resistance gene (EM7-KanR). Both selectable markers were flanked with 
tandemly-oriented lox71 and lox2272 sites. An MC1-driven diphtheria toxin A gene (DTA) 
was placed outside the long homology arm to select against nonrecombinant clones (Figure 
5.1).  
The targeting vector was linearized with NotI prior to electroporation into TL1 mouse 
ES cells. Four electroporations were performed in which 40 µg of the linearized targeting 
vector was electroporated into 5.6 x 106 TL1 mES cells (passage 13) and cultured with 
puromycin (1.5 µg/ml) to select for positive insertions. After selection, 192 surviving clones 
were picked for further expansion and screening. Clones that had undergone the desired 







Figure 5.1  Generation of a Pdx1 loxed cassette acceptor (LCA) allele. A) Schematic 
representation of the Pdx1 locus, targeting vector, and Pdx1LCA allele. An 8.6 kb region 
containing the enhancer elements (Areas I-IV) and exon 1 was replaced by a floxed 
puΔTK/EM7-KanR sequence flanked by minimal (34 bp) tandemly oriented lox71 and 
lox2272 sites. The targeting vector also contains a mouse pgk-driven diphtheria toxin A gene 
(DTA) outside the long homology arm for negative selection following targeting. Restriction 
endonucleases (X: XmaI, S: SphI) and probes for Southern hybridization are noted. B) 
Southern analysis of four ES cell clones following gene targeting. Clones 2F11, 2G9, 3B3, 
and 3E6 were identified as correctly targeted by a 9.0 kb band following hybridization with a 
5’ probe and a 4.7 kb band following hybridization with a 3’ probe.  
130 
 
XmaI (wild type band: 15.5 kb) and hybridization with a 5’ probe and a band of 4.7 kb after 
digestion with SphI (wild type band: 8.8 kb) and hybridization with a 3’ probe (Table 5.1 and 
data not shown). Clone 1H5 showed correct targeting at both the 5’ and 3’ ends of the Pdx1 
allele and was injected into blastocysts. Although clone 1H5 displayed germline competence, 
subsequent use in RMCE experiments has proven unsuccessful.  
Due to the germline incompetence of clone 1H5 in subsequent RMCE experiments, 
gene targeting was performed for a second time at the Vanderbilt Transgenic Mouse/ESC 
Shared Resource (TMESCSR). In brief, 200 µg of the linearized targeting vector was 
electroporated into 35 x 106 TL1 mES cells (passage 13) and cultured with puromycin (1.5 
µg/ml) to select for positive insertions. After selection, 269 surviving clones were picked for 
further expansion and screening. DNA was extracted from 172 clones and screened by 
Southern hybridization as noted above. Clones 2F11, 2G9, 3B3, and 3E6 all displayed correct 
targeting at both the 5’ and 3’ ends of the Pdx1 allele (Figure 5.1).  
 
Generation of a GFP/PuroR-expressing reporter for RMCE  
A basal exchange vector for Pdx1 (termed pPdx1.Ex1) was constructed to facilitate 
genetic manipulation of the locus and subsequent insertion by RMCE into mES cells 
containing the Pdx1LCA targeted locus. This basal exchange vector includes lox66 and 
lox2272 sites flanking the 8.6 kb DNA sequence, containing Areas I-IV and exon 1 of the 
Pdx1 locus, removed during gene targeting. A fragment from pPdx1.Ex1, obtained by 
digestion with BglII, was cloned into a modified pGL2 vector (Promega) for construction of 
the Pdx1GFP/PuroR exchange cassette. The EagI to MluI fragment of the Pdx1 basal exchange 
vector was PCR amplified to introduce FseI and MluI sites, and kinased oligos containing 
sequences for a FLAG-tag and multiple cloning sites (NheI, NdeI, XhoI) were cloned into the 





Table 5.1 Southern blot hybridization probes for Pdx1 gene targeting 
5’ Hybridization 
Enzyme: XmaI 
Wild type allele: 15.5 kb 











Wild type allele: 8.8 kb 
















nuclear localization signal (3X SV40 NLS), an internal ribosome entry site (IRES2), and 
puromycin resistance (PuroR) were PCR amplified and cloned into the modified BglII 
fragment. The final fragment was extracted via BglII digestion and cloned into the basal 
exchange vector (pPdx1.Ex1). A pgk-driven hygromycin resistance (HygroR) sequence, 
flanked by tandem flippase recognition target (FRT) sites, was cloned into a NotI site at the 
5’ end of the exchange vector (Figure 5.2).  
To validate the GFP/PuroR-expressing reporter, the FseI to MluI fragment, containing 
the FLAG-tagged GFP/PuroR reporter, was cloned into a cytomegalovirus (CMV) promoter-
driven plasmid. The CMV-driven GFP/PuroR construct was transfected into COS7 cells using 
SuperFect (Qiagen). Nuclear-localized eGFP was examined by fluorescence microscopy 
(Figure 5.3A). Immunocytochemistry was used to detect the FLAG-tag using a mouse anti-
flag primary antibody and a donkey anti-mouse Cy3 secondary antibody (Figure 5.3B). 
Puromycin resistance was tested by subjecting cells to 1.5 ug/ml puromycin for three weeks 
(Figure 5.3C and D).  
 
Generation of a CFP-expressing reporter for RMCE 
To generate a Pdx1 reporter expressing a cyan fluorescent protein (CFP), the 
Pdx1GFP/PuroR exchange vector was digested with FseI and MluI to remove the GFP/PuroR 
sequences, and an oligo containing restriction sites FseI, PacI, BbvCI, PmeI, and MluI was 
inserted to introduce multiple cloning sites. A cyan fluorescent protein, Cerulean, along with 
a 3X SV40 nuclear localization signal (NLS) was PCR-amplified and cloned into the 
modified  exchange vector. In addition, the rabbit β-globin polyadenylation sequence, 
containing the splicing region and polyadenylation sequences, was cloned into the plasmid 
downstream of the nuclear-localized Cerulean. The exchange cassette retained the FRT-





Figure 5.2  Insertion of GFP/PuroR into a Pdx1 loxed cassette acceptor (LCA) allele by 
RMCE. A) Schematic representation of the Pdx1LCA allele, GFP/PuroR exchange vector, and 
Pdx1GFP/PuroR allele. Part of the 8.6 kb endogenous Pdx1 allele, containing the enhancer 
elements (Areas I-IV) and exon 1, removed in the Pdx1LCA allele was incorporated in the 
GFP/PuroR exchange vector. The exchange vector included the sequences for enhanced GFP, 
a three-repeat of a SV40 nuclear localization signal, an internal ribosome entry site, and 
puromycin resistance (PuroR), as well as a pgk-driven hygromycin resistance (HygroR) 
sequence, flanked by tandem flippase recognition target (FRT) sites, for positive selection 
following RMCE. Lox66 and lox2272 sites were included to allow recombination with the 
lox71 and lox2272 sites in the Pdx1LCA allele. B) PCR analysis of five exchanged ES cell 
clones following RMCE with targeted clone 1H5. Screening of the 5’ and 3’ ends reveal all 
five clones are correctly exchanged by the prescence of 660 bp and 481 bp bands; however, 
the internal screen revealed 1H5/1C4 was a mosaic clone. C) PCR analysis of six exchanged 
ES cell clones following RMCE with either targeted clone 2G9 or 3E6. Screening of the 5’ 








Figure 5.3  Validation of the GFP/PuroR-expressing construct in COS7 cells. The 
GFP/PuroR-expressing construct containing a FLAG-tag, enhanced GFP, and puromycin 
resistance was transcfected into COS7 cells. Nuclear-localized eGFP was observed by 
fluorescent microscopy (A). Presence of the FLAG-tag was determined by 
immunocytochemistry (B). To assess resistance to puromycin, transfected COS7 cells were 
subjected to puromycin for three weeks and fluorescent microscopy revealed eGFP 








Figure 5.4  Insertion of CFP into a Pdx1 loxed cassette acceptor (LCA) allele by RMCE. 
A) Diagram of the Pdx1LCA allele, exchange vector, Pdx1CFP+HygroR allele, and 
Pdx1CFPallele. The exchange vector contained lox66 (red triangle) and lox2272 (black 
triangle) sites flanking a nuclear-localized CFP sequence followed by a rabbit β-globin 
polyadenylation sequence. A pgk-driven hygromycin resistance (HygroR) cassette flanked 
by FRT sites (open circles) was used as a positive selectable marker during RMCE. Mice 
containing the Pdx1CFP+HygroR allele were bred with FLPe-expressing transgenic mice to 
remove the FRT-flanked HygroR cassette. Restriction sites: XmaI (X) and SphI (S). 
Primer locations: p1, p2, p3 and p4. B) PCR analysis on both the 5’ (lane A, p1 and p2) 
and 3’ (lane B, p3 and p4) ends of three Pdx1CFP+HygroR exchanged clones. Properly 




Recombinase-mediated cassette exchange for Pdx1 
To generate the Pdx1GFP/PuroR reporter, two electroporations were performed in which 
40 µg of Pdx1GFP/PuroR and 40 µg pBS185, a Cre recombinase expression plasmid, were co-
electroporated into 5.0 x 106 TL1 mES cells that contained the Pdx1LCA allele (clone 1H5). 
Selection with 200 µg/ml hygromycin B (Invitrogen) began 48 hours post-electroporation 
and continued for seven days. 107 surviving colonies were isolated, grown on MEFs in 96-
well gelatinized tissue culture plates, and fed complete ES cell medium without hygromycin 
B for 4-5 days. Cells were then split to two 96-well plates: one for a master plate, which was 
frozen 3 days later, and one for negative selection using 8 µM gancyclovir (Sigma, St. Louis, 
MO) for 3-4 days. Following gancyclovir selection, 25 surviving clones were expanded for 
DNA isolation using proteinaseK (1mg/ml) incubation and phenol/chloroform extraction. 
DNA was precipitated using 0.3 M sodium acetate in ethanol, and clones surviving selection 
with both hygromycin and gancyclovir were analyzed for cassette exchange by PCR using 
primers that spanned either the lox66/71 site on the 5’ end or the lox2272 site on the 3’ end. 
On the 5’ end, the combination of 5’-TGAGATTGTATATTGCGGTGCA and 5’-
ACGAGACTAGTGAGACGTGCTACT primers resulted in a band size of 660 bp after 
RMCE and on the 3’ end, use of 5’-TGAGCAATTCCAAGCAGCTGGA and 5’-
ACCTTGCAGTCCTTCTGAAGT primers resulted in a 481 bp band for the exchanged allele 
and a 426 bp band in the wild type allele. Seventeen clones were properly exchanged, and 
four clones (1H5/3A2, 1H5/1B6, 1H5/1F2, and 1H5/2G5) were expanded (Figure 5.2). 
Clones 1H5/3A2 and 1H5/1F2 were injected into blastocysts but did not display germline 
competence. 
Recombinase-mediated cassette exchange was repeated to generate the Pdx1GFP/PuroR 
reporter using Pdx1LCA clones obtained from the second targeting experiment. For the first 
repeat, parental clone 3E6 was used and 40 µg of Pdx1GFP/PuroR and 40 µg pBS185 were co-
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electroporated into 5.0 x 106 mES cells. A staggered positive-negative selection strategy 
using hygromycin B (200 µg/ml) then gancyclovir (8 µM) identified 48 hygromycin-resistant 
and 12 gancyclovir-resistanct clones. DNA was extracted from six clones and PCR screening 
was performed to identify positive exchanges. All six clones were properly exchanged, and 
three clones (3E6/2A2, 3E6/2B5 and 3E6/2C12) were expanded (Figure 5.2, C). All three 
clones were injected into blastocysts with only 3E6/2A2 displaying germline competence. In 
parallel, a second repeat was performed where parental clone 2G9 was used and 40 µg of 
Pdx1GFP/PuroR and 40 µg pBS185 were co-electroporated into 5.0 x 106 mES cells (passage 
24). A staggered positive-negative selection strategy identified 60 hygromycin-resistant and 
18 gancyclovir-resistanct clones. DNA was extracted from six clones and PCR screening was 
performed to identify positive exchanges. All six clones were properly exchanged, and three 
clones (2G9/1A4, 2G9/1B8 and 2G9/1D9) were expanded (Figure 5.2C). Clone 2G9/1A4 
was injected into blastocysts but did not display germline competence. 
For the generation of a CFP-expressing reporter for Pdx1, RMCE was performed 
using clone 2F11 from the second targeting experiment, and 40 µg of Pdx1CFP and 40 µg 
pBS185 were co-electroporated into 5.0 x 106 mES cells (passage 24). A staggered positive-
negative selection strategy identified 35 hygromycin-resistant and 8gancyclovir-resistant 
clones. DNA was extracted from six clones and PCR screening was performed to identify 
positive exchanges. All six clones were properly exchanged, and three clones (2F11/1A6, 
2F11/1B1 and 2F11/1B3) were expanded (Figure 5.4). Karyotyping was performed for 
2F11/1B1 and 2F11/1A6 and revealed they were 71% and 68% normal, respectively. Clones 
2F11/1B1 and 2F11/1A6 were injected into E3.5 C57BL/6 blastocysts and both displayed 
germline competence. The FRT-flanked HygroR sequence was removed by inbreeding with 
Tg(ACTFLPe)9205Dym mice, and the resulting Pdx1CFP allele was maintained on an outbred 
background. Embryos were isolated from wild type CD-1 females crossed with Pdx1CFP/+ 
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mice where the presence of vaginal plug at noon was considered E0.5. Experimental 
protocols were approved by the Vanderbilt Institutional Animal Care and Use Committee. 
 
Immunolabeling and imaging 
Immunolabeling was performed as previously reported (Burlison et al., 2008). 
Primary antibodies were diluted in 1% BSA in 1X PBS as follows: guinea pig anti-Pdx1 
(C.V.E. Wright), 1:2500; chicken anti-GFP (Invitrogen), 1:1000; goat anti-amylase (Santa 
Cruz Biotechnology), 1:1000; guinea pig anti-insulin (Linco), 1:1000. Secondary antibodies 
were diluted in 1% BSA in 1X PBS as follows: donkey anti-chicken DyLight 488 (Jackson 
ImmunoResearch), 1:500; donkey anti-guinea pig Cy3 (Jackson ImmunoResearch), 1:1000; 
donkey anti-goat Alexa Fluor 647 (Invitrogen), 1:1000. Sections were counterstained with 
DAPI and cover slips mounted using Aqua/Poly Mount (Polysciences, Inc.). Images were 
acquired using an Axioplan2 microscope (Zeiss) with a QImaging RETIGA EXi camera. 
Whole mount imaging of Pdx1CFP embryos was performed using a Leica MZ 16 FA 
stereoscope with a QImaging RETIGA 4000R camera.  
 
Fluorescence-activated cell sorting 
Pdx1CFP/+ embryos were identified by direct fluorescence and dissected tissues were 
dissociated using Accumax (Sigma). Following filtration through a 35 µm cell strainer (BD 
Biosciences) and centrifugation, cells were resuspended in FACS medium [L15 medium 
(Invitrogen) containing 1 mg/ml BSA, 10 mM HEPES pH 7.4, 1% penicillin/streptomycin, 
and 37.5 ng/ml DNase I] or FACS medium with 7AAD (Invitrogen). Cells were analyzed and 
isolated using an Aria III (BD Biosciences). CFP was excited using either a 405 nm or 445 




RNA Isolation and semi-quantitative RT-PCR 
Total RNA was isolated using TRIzol LS (Invitrogen), DNase-treated (Ambion), and 
column-purified (Zymo Research). Total RNA was reverse transcribed (High Capacity 
cDNA Archive kit; ABI), and PCR was performed using 1 ng of cDNA template. Ptf1a was 
detected using the following primers: 5’-CGAATTGCCACGGATCACT and 5’-
CCCGGAAGGACGAATGG. Insulin was detected using the following primers: 5’-




Generation of a Pdx1LCA allele 
BAC recombineering and gene targeting were used to generate mES cells with a 
Pdx1LCA allele, as shown in Figure 5.1. In this allele, an 8.6 kb region of the Pdx1 locus, 
containing four previously characterized conserved regulatory regions termed Areas I – IV 
(Gittes, 2009; Pan and Wright, 2011), as well as exon 1, was replaced with a dual positive-
negative selection cassette flanked by lox71 and lox2272 sites (Araki et al., 2002; Chen et al., 
2011). Southern blot analysis using probes on both the 5’ and 3’ ends of the Pdx1 locus 
confirmed the desired homologous recombination events (Figure 5.1).  
 
Derivation of a Pdx1GFP/PuroR allele by RMCE 
To validate the functionality of the Pdx1LCA allele and generate a Pdx1 reporter allele, 
we next made an exchange vector that replaced Pdx1 coding sequences in exon one with a 
bicistronic cassette containing a FLAG-tagged and a nuclear-localized enhanced GFP (eGFP) 
(Rizzo et al., 2004) followed by an internal ribosome entry site (IRES) to initiate translation 
of puromycin resistance, thereby generating a Pdx1-null allele (Figure 5.2). In addition, the 
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exchange vector contains a pgk-driven hygromycin resistance (HygroR) cassette, flanked by 
tandem flippase recognition target (FRT) sites. Prior to RMCE, the GFP/PuroR-expressing 
reporter was validated by cloning the FLAG-tagged GFP/PuroR reporter into a 
cytomegalovirus (CMV) promoter-driven plasmid. Following transfection into COS7 cells, 
nuclear-localized eGFP was detected by fluorescence microscopy (Figure 5.3, A), and the 
cells exhibited immunolabeling with an anti-FLAG antibody (Figure 5.3, B). Additionally, 
cells survived culture with puromycin and exhibited GFP fluorescence (Figure 5.3, C and 
D). Taken together, these results confirmed the functionality of the cassette. 
RMCE of the GFP/PuroR-expressing reporter into the Pdx1LCA was achieved through 
the use of a staggered positive-negative selection strategy (Long et al., 2004) after co-
electroporation of the exchange vector and a Cre-expression plasmid. Chimeric mice were 
generated by injection of an exchanged clone (Figure 5.2) into E3.5 mouse blastocysts. After 
germline transmission, mice containing the Pdx1GFP/PuroR+HygroR allele were bred with FLPe-
expressing transgenic mice to remove the FRT-flanked HygroR cassette, thereby generating 
the Pdx1GFP/PuroR allele. Although the preliminary data suggested that the GFP/PuroR-
expressing reporter was functional, the targeted mice did not exhibit GFP fluorescence in the 
expected Pdx1 expression domains (data not shown). While the exact cause for the lack of 
GFP fluorescence is unknown, we suspect that the IRES sequence resulted in the 
destabilization of the protein and diminished fluorescence (Mizuguchi et al., 2000). 
 
Derivation of a Pdx1CFP allele by RMCE 
Given the lack of fluorescence observed from the Pdx1GFP/PuroR allele, we sought to 
generate another Pdx1 fluorescent reporter allele. We generated an exchange vector that 
replaced coding sequences in exon one of the Pdx1 gene with a nuclear-localized CFP 
(Cerulean) (Rizzo et al., 2004), thereby generating a Pdx1-null allele (Figure 5.4). A portion 
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of the rabbit β-globin gene, containing both intronic and polyadenylation sequences, was 
placed downstream of the CFP coding sequences (Chen et al., 2011; Westwood et al., 1993). 
In addition, the exchange vector contains a pgk-hygromycin resistance (HygroR) cassette,  
 flanked by tandem flippase recognition target (FRT) sites. RMCE into the Pdx1LCA was  
achieved and chimeric mice were generated similar to the methods describe above. After 
germline transmission, mice containing the Pdx1CFP+HygroR allele were bred with FLPe-
expressing transgenic mice to remove the FRT-flanked HygroR cassette, thereby generating 
the Pdx1CFP allele. While similar in nature to the Pdx1GFP/PuroR allele, the Pdx1CFP allele is 
more advantageous because the excitation and emission profiles for CFP are spectrally 
distinct from both GFP and YFP, thus permitting the combinatorial use of this allele with 
GFP- and YFP-expressing reporter alleles.  
 
Expression pattern of Pdx1CFP by whole mount fluorescence microscopy 
To analyze expression of CFP, we first utilized whole mount fluorescence 
microscopy (Figure 5.5). In Pdx1CFP/+ embryos, CFP expression was easily observable 
beginning at E9.5 in both the dorsal and ventral endoderm, consistent with the pattern 
previously determined from a Pdx1lacZ insertion allele (Offield et al., 1996). Between E10.5 
to E11.5, CFP expression in both the dorsal and ventral pancreatic buds was brighter than 
that of the caudal stomach and duodenum, normal domains of Pdx1 expression. During this 
developmental stage, the expression domain of Pdx1 contains a subpopulation of pancreatic 
MPCs (Gu et al., 2002; Pan and Wright, 2011). As development proceeds, CFP expression 
persisted at a high level in the pancreatic epithelium and at a lower level in the caudal 







Figure 5.5  Cerulean fluorescence in Pdx1CFP/+ embryos. CFP fluorescence was observed 
in dissected Pdx1CFP/+ embryos as early as E9.5 in the dorsal and ventral endoderm, 
consistent with previous reports detailing the expression pattern of Pdx1. From E10.5 to 
E11.5, CFP expression was detected in the dorsal and ventral pancreatic buds at a higher 
intensity as compared to the expression visualized in the caudal stomach and duodenum. 
Throughout development, CFP expression persisted at higher levels in the pancreatic 
epithelium than in the caudal stomach and duodenum. Scale bar = 250 µm unless otherwise 
noted. Dorsal pancreas (dp), ventral pancreas (vp), stomach (sto), duodenum (duo), anterior 




Expression pattern of Pdx1CFP by immunohistochemical analysis 
To determine whether CFP and Pdx1 were co-expressed, we performed 
immunohistochemical analysis using tissues from multiple developmental stages (Figure 5.6 
and data not shown). Both Pdx1 and CFP were detected in the dorsal and ventral endodermal 
evaginations of the posterior foregut at E9.5. From E10.5 to E11.5, Pdx1 and CFP were 
detected throughout the pancreatic epithelium, and expression was also observed in the 
stomach and duodenum. From E12.5 – E14.5, CFP immunofluorescence co-localized with 
Pdx1 throughout the branching epithelium, and by E15.5, high levels of Pdx1 and CFP 
expression were evident in periodic clusters throughout the epithelium with lower levels 
throughout the epithelium. At E18.5, high levels of Pdx1CFP expression were restricted 
primarily to the developing β cells as evident by the co-localization with insulin-expressing 
cells (Figure 5.6B). Additionally, lower levels of CFP expression were co-localized with 
amylase, indicative of Pdx1 expression in the acinar cells, again in accordance with previous 
reports (Figure 5.6B) (Guz et al., 1995; Wu et al., 1997). At each developmental stage, 
expression the Pdx1CFP allele paralleled that of endogenous Pdx1 expression, consistent with 
the Pdx1CFP allele faithfully recapitulating expression of Pdx1 (Guz et al., 1995; Leonard et 
al., 1993; Miller et al., 1994; Offield et al., 1996; Ohlsson et al., 1993). While perdurance of 
certain FP reporter alleles has been reported (Burlison et al., 2008; Viotti et al., 2011), this 
was not observed at any of the time points examined in this study which may simply reflect 
the maintained expression of Pdx1 in numerous cell types of the pancreatic epithelium.  
 
FACS analysis of Pdx1CFP cells 
Given that the optimal excitation wavelength for Cerulean is 433 nm (Rizzo et al., 
2004), we determined the effect of using either a 405 nm or 445 nm laser, both of which are 






Figure 5.6  Immunolabeling in Pdx1CFP/+ embryos. A) Co-expression of Pdx1 and CFP at 
E9.5 throughout the dorsal and ventral endoderm. At E10.5, Pdx1 and CFP expression are co-
localized in the pancreatic epithelium with expression also observed in other posterior foregut 
derivatives, such as the stomach. By E15.5, high levels of Pdx1 and CFP were evident in 
scattered clusters (arrows) throughout the epithelium with lower levels throughout the 
epithelium. At E18.5, Pdx1 and CFP are co-localized in cells displaying both high and low 
levels of expression. Stomach (sto), dorsal pancreas (dp). DAPI: nuclear counterstain. B) At 
E18.5, Pdx1CFP expression is restricted primarily to developing β cells, as indicated by co-
expression with insulin, with lower levels of CFP expression observed in the acinar cells, as 






5.7  FACS analysis of Pdx1CFP/+ embryos. The emission intensity of CFP following 
excitation with either 405 nm or 445 nm was compared. E11.5 embryos (A) and E18.5 
embryos (B) were used to isolate CFP-positive cells. The fluorescence intensity observed 
following excitation with 405 nm laser (top panels) is minimally distinguishable above 
cellular autofluorescence seen in the wild type embryos (left panels); whereas a 445 nm laser 
(bottom panels) provided more optimal excitation of CFP. Both high- and low-expressing 
cells, indicated by red and green boxes, respectively, were isolated from both E11.5 embryos 
(A) and E18.5 embryos (B). (C) A higher level of Ptf1a gene expression was detected in cells 
showing high- versus low-intensity CFP fluorescence consistent with their origin in the 
pancreatic epithelium. (D) Similarly, a higher level of Insulin gene expression was observed  
in high- versus low-intensity CFP fluorescence cells at E18.5 consistent with them being 
pancreatic β cells. 
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445 nm laser resulted in a broader range of emission intensity using embryonic tissues at 
E11.5 and E18.5. Cyan fluorescence observed using the 405 nm laser was minimally 
distinguishable above cellular autofluorescence in wild type embryos. However, CFP-
expressing cells excited by the 445 nm laser displayed approximately 50-fold higher  
fluorescence intensity. At E11.5, both high- and low-intensity CFP fluorescence was 
observed by FACS (Figure 5.7A), which is similar to the high- and low-expression patterns 
evident by immunolabeling in the pancreatic epithelium and the stomach/duodenal 
epithelium, respectively. Cells exhibiting higher levels of CFP fluorescence primarily 
represented cells of the pancreatic epithelium as indicated by Ptf1a expression (Figure 5.7C). 
In addition, high- and low-intensity CFP fluorescence was observed at E18.5 (Figure 5.7B). 
An analysis of Insulin expression revealed that cells displaying high levels of CFP 
fluorescence at E18.5 were predominantly pancreatic β cells (Figure 5.7D). 
 
Discussion 
 An analysis of purified native cell populations from the various intermediates 
transitioned through during pancreas development (e.g. definitive endoderm, posterior 
foregut, pancreatic MPC, endocrine progenitor, etc.) may help to identify transcriptional 
networks and signaling mechanisms that are critical for the growth and maturation of the 
final organ. Similar to the isolation and transcriptional profiling of Ptf1a-expressing cells 
(discussed in Chapter III), by utilizing the Pdx1CFP-expressing mice, we are poised to isolate 
specific cell populations, such as the posterior foregut endoderm, that will be useful for 
further understanding specific developmental stages within the context of the β cell 
developmental pathway. While valuable in and of itself, the transcriptional profile is most 
useful when assessed within the context of the sequential development of the pancreatic β 
cell (Figure 1.7). When analyzed within the context of numerous developmental 
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intermediates, the expression profile of the single cell population becomes much more 
valuable and will provide a context in which to discover transcripts and mechanisms that may 
be critical during numerous steps of β cell development (discussed further in Chapter VI).  
In addition to identifying and isolating cell populations based on the expression of a 
single transcriptional marker, the use of combinatorial cell sorting will prove useful for 
identifying and isolating specific subsets of cells or cells that are spatially-defined. These 
combinatorial comparisons will allow for the identification of transcripts whose expression is 
restricted spatially or more precisely defines specific cell populations. By utilizing the 
Pdx1CFP and Ptf1aYFP alleles, we will be able to specifically discriminate between pancreatic 
and non-pancreatic foregut endothelial cells which will enable us to identify transcripts that 
are specifically expressed within the developing pancreatic MPCs (discussed further in 
Chapter VI). Furthermore, it will allow for the identification of signaling pathways that 
promote the growth and maturation of the pancreatic progenitors explicitly. The identification 
of such signaling mechanisms will help to further focus hES cell directed differentiation 
efforts in directing the differentiation of the posterior foregut endoderm-like cells specifically 





CONCLUSIONS AND FUTURE DIRECTIONS 
 
Synopsis 
Progress in learning how to direct the differentiation of hES cells to pancreatic fates 
rests upon a foundation of knowledge gained over the past two decades concerning the 
mechanisms of pancreas development, and most of this information has been gained from 
studies in mice. However, as our understanding of pancreas development in the mouse has 
expanded, it has become apparent that greater efforts must be made to translate this 
information into new human therapies. 
Numerous prior studies have shown the central importance of Pdx1 and Ptf1a in 
pancreas development (Jonsson et al., 1994; Kawaguchi et al., 2002; Krapp et al., 1998; 
Offield et al., 1996). Specifically, Ptf1a is a valuable marker of the pancreatic multipotent 
progenitor cell population within the pancreatic epithelium, and thus many studies have 
sought to understand how Ptf1a functions during development. During early organogenesis, 
PTF1 is required for the growth and branching of the epithelium and is composed of Ptf1a, a 
class A bHLH protein and Rbpj (PTF1-J) (Rose et al., 2001; Roux et al., 1989). At the 
secondary transition, Ptf1a becomes restricted to the MPCs in the branching tips, and its 
continued expression is required for the further development of the late multipotent 
progenitor cells (MPCs). At approximately E13, Rbpl replaces Rbpj in the PTF1 complex 
(Beres et al., 2006) of pancreatic MPCs that commit to acinar cell fate. This transition to a 
PTF1-L complex completes acinar differentiation and maintains the acinar phenotype in adult 
pancreas (Masui et al., 2010).  
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To explore changes in the gene expression profile of Ptf1a-expressing cells, we 
performed RNA-Seq using a temporal and genetic approach enabled by FACS isolation of 
three distinct cell populations marked by the Ptf1aYFP allele (Burlison et al., 2008). To 
analyze the temporal changes that occur as the Ptf1a-expressing pancreatic MPCs transition 
to a unipotent, committed acinar cell fate, the transcriptional profiles of Ptf1aYFP/+ cells at 
E11.5 and E15.5 were compared. Additionally, to examine the genetic changes between 
Ptf1a-expressing MPCs and Ptf1a-deficient progenitor cells, Ptf1aYFP/YFP cells, which lack 
Ptf1a, and Ptf1aYFP/+ cells were profiled at E11.5 (Figure 3.1). These specific developmental 
timepoints were chosen because at E11.5 Ptf1a is broadly expressed throughout the 
expanding dorsal and ventral pancreatic epithelium marking the MPC population, while at 
E15.5 Ptf1a expression has become restricted to the acinar lineage (Burlison et al., 2008; 
Masui et al., 2007). A temporal comparison of the E11.5 Ptf1aYFP/+ and E15.5 Ptf1aYFP/+ 
profiles identified 2,136 genes whose expression was increased at least 5-fold and another 
657 genes that were decreased by a similar amount. Among the upregulated genes were 
amylase 2a5 (Amy2a5), chymotrypsin-like elastase family, member 1 (Cela1/Ela1), 
chymotrypsinogen B (Ctrb), and carboxypeptidase A1 (Cpa1), all of which are known targets 
for PTF1-L (Beres et al., 2006). Conversely, neurogenin 3 (Neurog3), insulinoma 1 (Insm1), 
and glucagon (Gcg) were expressed in the Ptf1a-expressing MPCs at E11.5 but not detected 
in Ptf1a-expressing cells at E15.5. Similarly, by comparing the transcriptional profile of the 
Ptf1a-expressing MPCs at E11.5 with those from the Ptf1a-null embryos of the same age, we 
found 997 genes that were expressed at levels exceeding 5-fold in cells in Ptf1a-expressing 
MPCs at E11.5 and 1,105 genes that had the opposite pattern. Interestingly, the expression of 
genes such as glucagon (Gcg), secretin (Sct), v-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein B (Mafb), and synaptophysin (Syp) were more strongly expressed in 
the Ptf1a-deficient progenitor cells, a result that agrees with publications suggesting that 
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Ptf1a acts to prevent the premature differentiation of pancreatic MPCs towards endocrine or 
intestinal cell fates (Kawaguchi et al., 2002).  
Following transcriptional profiling, a deeper analysis of the expression datasets from 
the various developmental intermediates proves useful for identifying transcription factors 
and signaling pathways that have undiscovered roles in pancreas progenitor cell specification 
and pancreatic organogenesis. An analysis of the transcriptional profiles for Ptf1aYFP-
expressing cells as determined by RNA-Seq and qRT-PCR revealed an upregulation of Nepn 
in Ptf1a-expressing MPCs at E10.5 and E11.5 as compared to acinar-specified cells at E15.5 
and later (Figure 4.1). Given these results, we sought to further explore the expression 
pattern of Nepn during embryogenesis, and thus generated mice containing a Nepn-Cherry 
reporter in the ROSA26 locus which revealed the expression of ROSA26Nepn-Cherry in a 
subpopulation of pancreatic MPCs from E10.5 to E11.5 (Figure 4.5 and 4.6). Given these 
results and that Nepn fuctions to inhibit TGFβ signaling (Mochida et al., 2006), further 
studies using either a global or conditional gene knockout would allow for a better 
assessment of the temporal requirement for Nepn in the developing endoderm and permit 
further elucidation of the potential role of Nepn in pancreatic progenitor cell specification.  
In order to generate new reporter alleles, our preference is to perform gene targeting 
since this method inherently assures that necessary regulatory sequences for proper 
expression of a fluorescent protein reporter are utilized. This may be important since it is 
likely that the enhancer sequences for certain genes have not been identified, as is the case 
with Nepn. However, we are also acutely aware that the gene targeting approach is time 
consuming, especially as it pertains to gene targeting in hES cells, which has proven more 
difficult than targeting in mES cells. For this reason, generating an optimal reporter line may 
not always be worth the time or effort, especially when one considers that FP reporter lines 
generated in this manner are typically rendered haploinsufficient at the locus used to drive 
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reporter expression. For this reason, our second choice has been to utilize RMCE to place FP 
reporters driven by 8 – 12 kb fragments of upstream regulatory sequence into the mouse or 
human ROSA26 gene locus, as has been done for the generation of the Nepn-Cherry 
transgene (Figure 4.3) and the Pdx1-CFP reporter human ES cell line (Figure 2.4). While 
not without certain limitations, these reporter transgenes permit identification of genetically-
tagged cells. For instance, hES cells containing the Pdx1-CFP transgene were used during 
directed pancreatic differentiation in vitro, and expression of the reporter gene can be 
observed as hES cells differentiated into posterior foregut and pancreatic endoderm-like cell 
fates (Figure 2.4) which provides compelling preliminary data that it will be possible to 
isolate pancreatic MPCs that have been induced to express Pdx1 and thus may represent early 
pancreatic endoderm.  
One objective of our future studies is to utilize hES cell lines in which key 
developmental regulatory genes are marked by distinct FP reporters to generate 
transcriptional profiles that can be compared to the profiles established for in vivo isolated 
cell populations during mouse development, similar to the studies discussed in Chapter III. 
However, while the availability of such hES cell lines will enable purification and 
characterization of specific cellular populations from impure populations and facilitate the 
development of more robust directed differentiation protocols capable of generating 
functional human β cells, the generation of reporter alleles via RMCE into the ROSA26LCA is 
not currently feasible. In response to Executive Order 13505, issued on March 9, 2009, the 
NIH established new guidelines under which they will fund research pertaining to the area of 
hES cells. Based on these guidelines, each hES cell line must adhere to the new policy 
standards and only eligible hES cell lines may be used for NIH-supported research. The hES2 
hES cell line, which is currently the only cell line in which the targeted ROSA26LCA allele 
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exists, has not been federally approved based on these new guidelines; therefore NIH-
supported research using these cells is not permitted.  
 
Transcriptional profiling of pancreatic developmental intermediates 
During mouse development, endocrine cells form as the result of a sequential process 
that is best distinguished by a combination of marker genes that are direct transcriptional 
effectors of the developmental program. The transcriptional profiling of the Ptf1a-expressing 
cells documented here represents only a small portion of a larger developmental scheme. We 
have critically assessed and identified cell populations that are likely to yield the greatest 
understanding of the lineage from definitive endoderm to mature β cells, which in turn will 
be used to mirror the cellular stages through which hES cells must transit to become β cells. 
As shown in Figure 1.7, these populations span a developmental window ranging from E8.0 
(definitive endoderm) to P60 (mature pancreatic β cells), but primarily consist of pancreatic 
progenitor cell populations that will be isolated from dissected mouse embryonic tissues. To 
characterize these developmental intermediates, we are using specific combinations of 
fluorescently-tagged mouse alleles to obtain highly defined FACS-purified cell populations. 
Similar to the profiling performed for the Ptf1a-expressing cells, we will obtain a detailed 
RNA expression profile for each specific purified cell population through RNA-Sequencing, 
as well as transcription factor-promoter binding data through ChIP-Seq. These data will be 
used to precisely ascertain changes in gene expression at different times and in very discrete 
populations of cells in the developing mouse pancreas, including those formed in mutant 
backgrounds, such as the Ptf1aYFP/YFP progenitor cells reported here. By comparing different 
RNA profiles using RNA-Seq and protein/DNA interactions using ChIP-Seq, we hope to 
identify gene clusters essential for the formation of pancreatic β cells from normal and 
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genetically modified pathways. Identification of transcription factors and cell surface 
receptors in these cell populations will be useful for further dissecting the subpopulations of 
pancreatic MPCs in vivo. Parallels and analogies can then be drawn for identifying and 
isolating human MPC-like cells and for distinguishing different progenitor cells during the 
appropriate and inappropriate directed differentiation of hES cells towards a β cell fate.  
Our approach to obtain the transcriptional profiles of these developmental 
intermediates has many advantages over prior studies (Chiang and Melton, 2003; Gu et al., 
2004; White et al., 2008). First, by utilizing fluorescently-tagged alleles, we are able to 
isolate genetically defined cell populations. This is a major improvement upon previous 
studies that often relied on manual dissection of pancreatic regions resulting in populations 
that are inescapably contaminated by other cell types. While numerous researchers have 
sought to characterize the transcriptome of specific cell populations present during pancreatic 
organogenesis during mouse development, one of the major drawbacks has been the inability 
to identify precisely and isolate, with minimal contamination, distinct cell populations 
marking specific developmental intermediates. The method of manually dissecting desired 
tissues has been one of the major contributors to contamination by other cell types, such as 
the mesoderm or mesenchyme. Therefore, the use of fluorescently-tagged reporter alleles 
permits the isolation of a cell population of interest by FACS without risking contamination 
of the cell population by undesired tissues. However, one consideration to take into account 
with fluorescently-tagged alleles is fluorescent protein perdurance. For example, the 
perdurance of a Neurog3-eGFP transgene led to the labeling of both Neurog3-positive 
endocrine progenitors and their hormone-positive progeny (Sugiyama et al., 2007). 
Therefore, when identifying a cell population to isolate, it is pertinent to examine whether the 
fluorescent reporter faithfully mimics the gene’s endogenous expression. Second, by utilizing 
the recently developed RNA-Sequencing approach for whole transcriptome profiling, instead 
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of DNA microarrays, we obtain a less biased and more quantitative view of the gene 
regulatory changes occurring (Marioni et al., 2008; Mortazavi et al., 2008). Third, by 
collecting information from closely related cell types, we will be able to more accurately 
assess the spatial and temporal alteration of genetic networks that regulate the step-wise 
production of β cells, which was not achieved by previous efforts (Gu et al., 2004; White et 
al., 2008). Finally, as part of the future directions for the transcriptional profiling of the 
various developmental intermediates, we plan to utilize ChIP-Seq to directly define binding 
of transcription factors, such as Neurog3, Nkx2-2, and Pax4, to regulatory sites in chromatin, 
which will reveal how these factors regulate gene expression in cell type specific manners for 
proper cell differentiation and function.  
In addition to analyzing the transcriptional profile of these developmental 
intermediates, the fluorescently-tagged reporter alleles permit FACS isolation of distinct cell 
populations which can then be used in cell transplantation assays to assess the lineage 
potential of specific purified progenitor cell populations. Previously, it has been shown that 
the injection of mouse Pdx1-positive progenitor cells into E12.5 dorsal mouse pancreas, and 
subsequent culturing of these cells in vitro, results in proliferation and differentiation of the 
cells into endocrine cells, including those of the β cell lineage (Xu et al., 2008). Similarly, 
studies have demonstrated that hES cell-derived unpurified pancreatic progenitors can be 
differentiated into β cell clusters when transplanted into an E12.5 mouse dorsal pancreas 
(Brolen et al., 2005). Based on these results, we hypothesize that hES cell-derived Pdx1-
positive progenitors will respond to signals within the in vitro developing dorsal pancreas by 
differentiating into insulin-positive β cells and other pancreatic cell types. To test this 
directly, hES cell-derived Pdx1-positive cells can be isolated by FACS and injected into the 
dorsal pancreas from E12.5 Neurog3-/- embryos, which lack the ability to generate 
endogenous endocrine cells. Subsequently, explants can be analyzed by both immunolabeling 
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and RT-PCR for markers characteristic of human cells and mature functional endocrine and 
exocrine cells. This analysis will reveal if these hES cell-derived progenitors are, in fact, 
bona fide β cell progenitors and competent to mature in vivo without the undesired teratoma 
formation evident in previous studies (Kroon et al., 2008).  
 
Examining complex gene regulatory networks and elucidating signaling pathways 
through transcriptional profiling of developmental intermediates 
As transcriptional profiles are obtained, we expect to identify transcripts that are not 
previously known to be expressed in each cell population, including components of growth 
factor pathways, juxtacrine or intercellular signaling pathways, transcription factors, 
structural proteins, channels, and other necessary proteins for hormone production, transport, 
and secretion. Thus, we will seek to identify a signature group of transcripts that define each 
intermediate cell type and then examine whether specific hES cell differentiation methods 
favor the derivation of each cell type from hES cells. However, while experiments using 
RNA-Seq will reveal transcriptional profiles for a number of critical cell populations, they do 
not directly reveal how these profiles are established. Such knowledge can be obtained only 
by identifying transcription factor binding sites. Thus, to facilitate identification of critical 
regulatory molecules for each stage of pancreas development process, it would be 
advantageous to determine the direct transcriptional targets of factors whose function is well 
established for pancreatic cell differentiation. While such studies can be performed using 
antibody-based ChIP analysis, antibodies that are suitable for this purpose are sometimes 
unavailable. Therefore, mouse lines in which a gene of interest has been epitope-tagged may 
be necessary to further examine the complex regulatory networks that underlie each 
developmental intermediate.  
The RNA-Seq datasets provide a significant amount of information pertaining to each 
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cellular population analyzed, and these datasets are rich for downstream analyses of specific 
transcription factors with novel roles in pancreatic organogenesis, for elucidating gene 
regulatory networks that promote cell specification, and for examining signaling pathways 
that direct cell differentiation. By performing pair-wise analyses of the datasets, differentially 
expressed transcripts can be identified. Performing such a comparison, the analysis of 
Ptf1aYFP expressing MPCs and Ptf1aYFP-expressing acinar specified cells led to the 
identification of Nepn, an inhibitor of TGFβ signaling, as a potential novel marker of the 
pancreatic MPCs (Figure 4.1). While the role of Nepn in pancreas development and MPC 
specification still remains unclear, the use of a ROSA26Nepn-Cherry transgene permitted the 
identification of Nepn-expressing cells during embryogenesis (Figure 4.4). However, the 
ROSA26Nepn-Cherry transgene has certain drawbacks, therefore generating a targeted reporter 
allele for Nepn will be essential for more accurately assessing its expression pattern during 
development and for identifying and isolating Nepn-expressing cells.  
While a targeted reporter allele for Nepn will permit the identification and isolation of 
Nepn-expressing cells during development and elucidate the developmental role of Nepn in 
the context of a null background, the current design of the targeted allele will not permit the 
generation of a conditional knockout using spatiotemporally restricted Cre expression. Given 
that we would like to analyze the role of Nepn in pancreatic MPC development, if the global 
null allele displays a phenotype much earlier during development than pancreatic progenitor 
specification it may be necessary to generate a conditional floxed allele. Taking this into 
consideration, as investigators move forward analyzing the RNA-Seq datasets, identifying 
differentially expressed transcripts, and selecting transcripts of interest, the generation of a 
conditional allele may be more advantageous than simply a reporter allele for its analysis at 
certain developmental timepoints.  
In addition to identifying transcription factors with potential novel roles in pancreas 
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development, the RNA-Seq datasets hold the possibility of uncovering signaling pathways 
critical for endoderm, MPC, and/or endocrine progenitor specification. Signaling pathways 
are the main foundation upon which a cell becomes specified, and these pathways activate 
and/or repress certain transcriptional regulatory networks, thus governing the differentiation 
of cells. Therefore, an analysis of which receptors and signaling molecules are differentially 
expressed between two various timepoints will elucidate which signaling pathways may be 
upregulated or downregulated at a particular stage and thus be critical for the specification of 
a certain developmental intermediate.  
 
Analysis of cell populations using combinatorial sorting 
In addition to obtaining transcriptional profiles for Ptf1aYFP-expressing cells, the 
generation of a new fluorescently-tagged Pdx1 reporter permits isolation of additional 
distinct developmental intermediates. Although Pdx1 is expressed in other early endoderm 
populations such as the epithelium of the duodenum, cystic duct, common bile duct and 
antral stomach, it is a valuable marker of the pancreatic MPCs and will facilitate isolation of 
spatially-defined progenitor cells within the developing foregut. When used in combination 
with other fluorescently-tagged alleles, Pdx1CFP allows for the isolation of cell populations 
that will provide important comparisons following transcriptional profiling of the cells. For 
example, when used in combination with Ptf1aYFP, Pdx1CFP allows for the isolation of two 
critical populations: 1) non-pancreatic foregut cells (Pdx1CFP/+ cells minus Ptf1aYFP/+ cells at 
E11.5) and 2) late pancreatic MPCs (Ptf1aYFP/+; Pdx1CFP/+ double-positive cells at E12.5).  
During early stages of development (E10.5 – E11.5), Pdx1 is broadly expressed 
throughout the posterior foregut endoderm, serving to mark the dorsal and ventral pancreatic 
epithelium and the antral stomach, common bile duct, and duodenum (Figure 6.1). 
Conversely, Ptf1a is primarily restricted to the dorsal and ventral pancreatic epithelium 
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within the posterior foregut (Figure 6.1). Thus, by isolating Pdx1CFP/+ single-positive cells 
and comparing them with Ptf1aYFP/+; Pdx1CFP/+ double-positive cells, we will be able to 
examine the transcriptional differences between cells that adopt a gastrointestinal or 
pancreatic fate (Figure 6.1). Indeed, given the differing expression patterns of Pdx1 and 
Ptf1a within the foregut endoderm, this combinatorial comparison will allow for the 
identification of signaling pathways that promote the growth and maturation of the pancreatic 
progenitors explicitly and can in turn be used to enhance hES cell directed differentiation 
efforts whereby posterior foregut endoderm-like cells are specifically differentiated towards 
pancreatic fates and not other foregut derivatives. 
After E11.5, the pancreatic epithelium undergoes extensive proliferation and 
branching leading to the formation of an epithelial ductal tree. Ptf1a is predominantly 
expressed in the periphery of the epithelial tree (termed the “tip” cells) and restricted from 
the central domain of the epithelial tree (termed the “trunk” domain) (Zhou et al., 2007). 
Conversely, Pdx1 expression is evident in both the periphery and central domain of the 
epithelial tree. Importantly, the periphery of the epithelial tree is thought to maintain the 
pancreatic MPC population for a period of time, while the central domain contains a 
bipotential cell population that arose from the MPCs and can subsequently give rise to 
endocrine and ductal cells (Gu et al., 2002; Zhou et al., 2007). Thus, Pdx1 and Ptf1a can be 
used in combination to distinguish the late pancreatic MPCs in the periphery of the 
epithelium (Ptf1aYFP/+; Pdx1CFP/+ double-positive cells) and the bipotential progeny of the 
central domain (Pdx1CFP/+ single-positive cells). 
However, the full utility of reporter alleles in combination is only realized when the 
FPs have spectrally distinct excitation and emission profiles (Heikal et al., 2000; Nagai et al., 









Figure 6.1  Combinatorial analysis of Ptf1aYFP/+; Pdx1CFP/+ embryos by fluorescence-
activated cell sorting (FACS). A) Whole mount fluorescent imaging of an E11.5 Ptf1aYFP/+ 
dissected embryo which displays fluorescence in the dorsal and ventral pancreatic buds. B) 
Conversely, Pdx1CFP/+ dissected embryos display expression in the caudal stomach, common 
bile duct, and duodenum in addition to the dorsal and ventral pancreatic epithelium. C) 
Merged fluorescence revealing co-expression of Ptf1aYFP and Pdx1CFP in the dorsal and 
ventral pancreatic buds. D) When used in combination Pdx1CFP and Ptf1aYFP permit the 
isolation of Ptf1aYFP/+; Pdx1CFP/+ double-positive pancreatic MPCs (gate 1) and Pdx1CFP/+ 
single-positive non-pancreatic foregut cells (gate 2); however the latter contains significant 
contamination due to cellular autofluorescence. 
160 
 
combination, it is important to assess both the wavelength at which they are optimally excited 
and the range of emission wavelengths they exhibit. An analysis of the spectral profiles for  
cyan, green, yellow and red fluorescent protein variants is critical for assessing which 
combinations of fluorescent reporters can be discriminated by FACS (Figure 6.2). Although 
CFP can be excited with the 405 nm laser, this suboptimal excitation resulted in the inability 
to distinguish between CFP-expressing cells and the cellular auto-fluorescence seen in wild 
type cells (Figure 5.7). While the use of the 445 nm laser alleviated this problem, currently it 
is not possible to utilize both the 445 nm and 488 nm lasers simultaneously, thus not 
permitting concurrent sorting of CFP and YFP. However, one alternative approach is to 
utilize a recently generated Ptf1atdTomato-expressing mouse (unpublished). The tandem dimer 
red fluorescent protein, tdTomato, is optimally excited at 554 nm (Shaner et al., 2004). Thus, 
it is possible to utilize the 561 nm laser, for tdTomato excitation, in combination with the 445 
nm laser, for Cerulean excitation, to perform combinatorial cell sorting and obtain the desired 
double-positive and single-positive cell populations.  
 
Improving the directed pancreatic differentiation of human ES cells 
How can you know you are on the right track if you do not even know where you 
want to end up? While philosophical in nature, that question holds true even for the directed 
differentiation of hES cells to pancreatic fates. An understanding of the fundamental 
characteristics of authentic, in vivo-isolated mature pancreatic β cells will certainly provide a 
“landmark” to strive towards as we attempt to produce cells that resemble certain cellular 
intermediates. In support of this theory, the transcriptional analyses of FACS-purified 
hematopoietic progenitor cells have accelerated the attempts to generate these cells from hES 
cells (Bu et al., 2009; Yang et al., 2008). Seeing that the premise underlying in vitro 















Figure 6.2  Spectral profile for cyan fluorescent protein (ECFP), green fluorescent 
protein (EGFP), yellow fluorescent protein (EYFP) and red fluorescent protein 
(DsRED). Excitation (dashed lines) and emission (filled peaks) profiles are shown for ECFP 
(dark blue dashed line/blue filled emission peak), EGFP (light blue/green), EYFP (dark 
green/light green) and DsRED (light green/yellow). Excitation wavelengths at 405 nm, 445 
nm, 488 nm, and 561 nm are noted. The spectral profiles for ECFP, EYFP and dsRED are 
similar to the profiles for Cerulean, Citrine and tdTomato, respectively. By using different 
fluorescently-tagged alleles in the mouse, we are able to isolate by fluorescence activated cell 
sorting (FACS) various cell populations marked by specific genetic reporters. However, 
when determining fluorescently-tagged alleles to use in combination, it is critical to examine 
the spectral overlap displayed by the excitation and emission profiles.  
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signaling mechanisms for cell specification and establish the proper gene regulatory networks 
at each developmental stage, a deeper understanding of the signaling pathways and 
transcriptional networks established at each developmental stage will further accelerate how 
functional β cells can be replicated in cultured cells. While progress has been made in 
learning how to generate specific β cell forebearers such as definitive, foregut and pancreatic 
endoderm, the differentiation towards these intermediates still results in a heterogeneous 
population of cells. The contributions of said heterogeneity is debatable with a number of 
investigators recognizing that the undesired cell populations provide signals to instruct the 
other cells towards pancreatic fates while other investigators feel that the heterogeneity 
simply decreases the overall efficiency and any potential signals provided by these undesired 
cells should be elucidated to achieve more robust differentiation. Recognizing this problem, 
we assert that the best path forward is to 1) isolate and characterize specific pancreatic 
progenitor cell populations, 2) profile gene expression changes at the level of the entire 
transcriptome, and 3) learn how to translate this information into better protocols for the 
directed differentiation of hES cells into hormone-producing cells. Thus, the transcriptional 
profiling reported in this dissertation is only one of the high quality datasets that will be 
obtained from defined pancreatic progenitor cell populations and subsequently used to 
develop new bioinformatics strategies that will enable the discovery of pro-β cell signals in 
the mouse and other key information for guiding improvements of protocols for the directed 
differentiation of hES cells into β cells.  
While the genes and developmental pathways are likely to be highly conserved 
between mice and humans, we recognize that they are unlikely to be identical. Thus, there are 
major challenges for performing meaningful comparisons of gene expression profiles in a 
setting that is highly dynamic and temporally-specific. For this reason further strategies need 
to be developed for 1) distinguishing natural species-related differences in development 
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between mouse and human and 2) distinguishing the differences in gene expression profiles 
that arise in vivo with those that are the result of ex vivo manipulations. Finally, even when 
cross-species differences can be interpreted and managed, we will need to determine what 
extra- and intracellular signals invoke the expression of specific gene networks and clusters. 
However, in spite of the limitations, a deeper understanding of the transcriptional networks 
established at each developmental intermediate is likely to guide the directed differentiation 
efforts concerning the differentiation of hES cells to pancreatic fates and thus, in turn, 
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